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SUMMARY
MECHANISMS AND TREATMENT OF WEIGHT LOSS IN CANCER
Weight loss and the development of cancer cachexia are well known 
to contribute to the morbidity and mortality of cancer patients. Loss 
of body mass is most commonly due to an imbalance between energy intake 
and energy expenditure. The aim of this study was to examine the 
nature of the negative energy balance in cancer patients and evaluate 
several new approaches to redress the host-tumour imbalance in cancer 
cachexia.
Clearly an investigation of weight loss must first determine 
which compartments of the body are affected. Therefore, a study of the 
body composition of a group of cachectic lung cancer patients was 
undertaken. In this group of patients an 86% reduction of body fat 
and a 20% reduction of body protein was demonstrated. The loss of body 
protein was almost entirely due to severe depletion of skeletal muscle; 
non-muscle protein mass being preserved. Thus not only does cachexia 
lead to an overall reduction of body mass, but specific body 
compartments are affected by the disease.
These changes in body composition might, in part, be due to 
starvation. This hypothesis is supported by the observation that the 
food intake of the cachectic cancer patients was markedly reduced. 
However, it could not be determined whether a reduced food intake was 
present throughout the period of the patients' weight loss.
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An alternative explanation for weight loss could be that the 
energy expenditure of cancer patients is increased. It has been 
proposed that an elevated energy expenditure in cancer patients might 
be due to the energy cost of an accelerated rate of whole body protein 
turnover. However, although patients with either lung or colon cancer 
had rates of whole body protein turnover which were 50 - 70% greater
than weight-stable controls, this was not associated with an increased 
resting energy expenditure and was not necessarily associated with 
weight loss.
It was apparent that the relationship between energy expenditure, 
energy intake and weight loss might be better studied with an animal 
model of cancer cachexia. Total energy expenditure could be determined, 
food intake might be more accurately measured and interindividual 
variation reduced.
The mechanisms of weight loss were studied in two animal models 
of cancer cachexia. These were rats bearing the Walker 256 and mice 
bearing the MAC-16 tumour. The weight and protein loss of rats bearing 
the Walker tumour was shown to be equivalent to the weight and protein 
content of the tumour. In contrast, the tumour mass itself could not 
account for host weight loss in mice bearing the MAC-16 tumour.
When mice bearing the MAC-16 tumour had become cachectic weight 
loss was associated with a reduced food intake with no compensatory 
reduction in energy expenditure. However, the cause of the energy 
deficit during the early phase of weight loss could not be determined. 
As with studies on humans this might be explained by substantial 
interindividual variation, the errors of the methods available for the
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measurement of food intake and energy expenditure and, the relatively 
small size of the changes in either variable necessary to account for 
host weight loss. The pattern of alterations in the food intake, 
energy expenditure and protein metabolism of mice bearing the MAC-16 
tumour were markedly different from those observed in other murine 
models of cancer cachexia. This suggests that the mechanism of weight 
loss in cachexia may depend on the particular model studied.
Several methods of treating cachexia were evaluated. It has been 
proposed that many tumours are dependent on glucose as an energy 
source. In order to maintain a glucose supply to the tumour, host
muscle protein is broken- down to supply amino acids for an increased 
de novo synthesis of glucose in the liver. Ketone bodies are 
fat-derived energy substrates which may act to reduce gluconeogenesis 
by inhibiting muscle protein degradation. Thus the induction of 
systemic ketosis might be a method of selectively feeding the host 
whilst reducing the supply of glucose to the tumour. However, systemic 
ketosis had no effect on host nitrogen losses in either humans with 
cancer cachexia or rats bearing the Walker 256 tumour. Moreover, 
although blood glucose was slightly reduced in humans with cancer fed a 
ketogenic diet, this effect of the diet was not observed in rats 
bearing the Walker 256 tumour and there was no reduction in tumour 
growth rate. Taken together these results indicate that systemic 
ketosis is unlikely to improve the host-tumour imbalance of cachexia.
Clearly the best way to cure cachexia is to cure the cancer. 
Unfortunately, for the majority of solid epithelial malignancies 
systemic anticancer therapy is largely ineffective and may actually 
worsen the nutritional status of the host. In an attempt to develop a
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non-toxic method of controlling tumour growth within the cachectic 
host, a novel approach based on potential differences between host and 
tumour energy metabolism was evaluated. Many tumours are known to be 
glucose dependent and have mitochondria which are reduced in number and 
abnormal in morphology and enzyme content. Thus, in tumour cells there 
may be abnormalities of both of the major sources of intracellular ATP. 
The simultaneous manipulation of glycolysis and oxidative phosphory­
lation by administration of the mitochondrial inhibitor Rhodamine 6G 
during a period of hypoglycaemia was shown to have a synergistic 
antitumour effect in rats bearing the Walker 256 tumour. The treatment 
was non-toxic and might well form the basis of future therapy in 
patients with disseminated malignancy and weight loss.
In conclusion, a reduced food intake is probably the main cause 
of continuing weight loss in the cachectic cancer host. The incidence 
and mechanisms of an increased energy expenditure remain uncertain and 
may be different for each group of cancer patients examined. Selective 
manipulation of tumour energy metabolism may be one method of 
inhibiting tumour growth, thereby allowing reversal of the cachectic 
state.
CHAPTER 1 
Introduction to the Thesis
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Starvation and the metabolism of the cachectic cancer host
The majority of patients with malignant disease lose weight 
(Nixon et al.r 1980) and a proportion become emaciated to the point 
where they appear to die of starvation (Warren, 1932; Inagaki, 
Rodriguez and Bodey, 1974)• This syndrome is known as cancer cachexia. 
The term cachexia is derived from the Greek words kakos meaning bad and 
hexis meaning condition. The patient with cachexia is characterised by 
severe weight loss, lethargy, anorexia, early satiety and anaemia 
(Caiman, 1982). In addition, numerous studies have documented 
abnormalities of host metabolism which together indicate that cancer 
cachexia is not the same as simple starvation (Brennan, 1977).
In order to understand the problem of cancer cachexia it is 
necessary first to understand both the normal mechanism of energy 
balance in the body and the changes involved during adaptation to 
starvation.
The body requires energy and this is obtained either from food or 
from body fuel stores. During a prolonged period without food the 
energy and amino acids which are normally provided by the diet have to 
be obtained by the breakdown of body tissues and it is this process 
which leads to the emaciation characteristic of starvation. Fat is the 
major energy reserve in the body and loss of adipose tissue during 
starvation is well tolerated. However, there is no specific store of 
/ protein in the body and daily amino acids requirements have to be met 
by the breakdown of structural and functional proteins. Clearly vital
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organs such as the heart need to be preserved for as long as possible. 
Therefore, during prolonged starvation the body first mobilizes protein 
from low priority tissues such as skeletal muscle. Thus, the tissues 
most affected by starvation are adipose tissue and skeletal muscle. 
However, the selectivity of wasting is not absolute and visceral 
protein is also lost.
One factor which contributes to protein loss in early starvation 
is the inability of the brain to use free fatty acids as substrates for 
energy production. Glucose is the preferred fuel and this is obtained 
by the release of amino acids from skeletal muscle which are then 
converted into glucose by the liver and kidney (Owen et al., 1969). 
Thus during early starvation the body excretes about 12g of nitrogen 
per day principally as a result of muscle proteolysis. If this process 
continued unabated the duration of survival would be limited due to a 
rapid loss of lean tissue. However, in response to starvation, ketone 
bodies are generated in the liver from free fatty acids and these 
replace glucose as the main substrates for cerebral energy metabolism 
(Robinson and Williamson, 1980) . Thus the need for amino acids for 
gluconeogenesis is greatly reduced, the rate of muscle proteolysis is 
decreased, and the rate of nitrogen excretion in compensated starvation 
is only about 2g of nitrogen per day (Cahill, 1970).
This ordered pattern of metabolic adaptation would appear to be 
disrupted by the presence of the tumour. Although anorexia is often 
present in cancer patients, weight loss frequently exceeds that 
expected from a reduced food intake alone (Costa et al., 1981). In 
contrast with compensated starvation the rate of gluconeogenesis from 
alanine (Waterhouse, Jeanpetre and Keilson, 1979), lactate (Waterhouse, 
1974? Holroyde, Gabuzda and Putnam, 1975) and glycerol (Lundholm et
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al., 1981) has been shown to be increased in various groups of cancer 
patients. The mechanism of this accelerated gluconeogenesis is not 
clearly established. In 1930 Warburg observed that tumours metabolise 
glucose via glycolysis at a high rate, whilst in normal cells this 
pathway is usually reserved for anaerobic conditions. Subsequently, 
several studies demonstrated a high rate of glycolysis in tumours and a 
dependence on glucose as an energy source (Gold, 1966? Shapot and 
Blinov, 1974; Demetrakopoulos, Linn and Amos, 1982). Gold (1968) 
proposed that this high glucose demand by the tumour is an important 
factor in the development of cachexia. He suggested that body fat and 
protein reserves are depleted in order to provide substrates for gluco­
neogenesis. The glucose so produced is metabolised by the tumour which 
releases lactate into the blood stream. The lactate is then transported 
to the host1s liver where it is converted back to glucose. The cycle 
from glucose to lactate and back to glucose is known as the Cori cycle 
and a 2 - 3 fold increase in the activity of this cycle has been 
reported in cachectic cancer patients (Waterhouse, 1974). Since the 
anaerobic breakdown of glucose to lactic acid yields only two molecules 
of ATP and the resynthesis of glucose from lactate requires six mole­
cules of ATP this cycle is very wasteful of energy compared with the 
potential 36 molecules of ATP via the aerobic oxidation of glucose. 
However, since cachexia can develop in the presence of a very small 
tumour burden (Gosta, 1977) and since some tumours that produce 
cachexia do not have increased rates of glycolysis (Weinhouse, 1982) 
the suggestion that cachexia is caused by the high glucose demand of 
the tumour does not seem generally applicable.
Protein metabolism in the tumour bearing host also appears to be 
different from that of uncomplicated starvation. Lundholm and co­
workers (1976) demonstrated a decreased rate of protein synthesis and
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an increased rate of protein degradation in muscle biopsies from 
cachectic cancer patients. This observation would account for a net 
protein mobilization. Moreover the reduced protein synthesis rate is 
consistant with the pattern observed in starvation (McNurlan, Pain and 
Garlick, 1980). However, in contrast to the overall depletion of muscle 
protein, a marked increase in liver mass accompanies the growth of 
several tumours (Stewart and Begg, 1953; Lundholm et al., 1979; 
Heymsfield and McManus, 1985). Unlike the changes observed in 
starvation, the liver seems to be protected from the net negative 
nitrogen balance in the tumour bearing host such that an increased rate 
of hepatic protein synthesis has been described (Lundholm et al., 1979; 
Emery, Lovell and Rennie, 1984). An increased rate of protein 
synthesis in the liver and a decreased rate in skeletal muscle together 
with the additional protein synthesis occuring in the tumour is thought 
to result in an apparently normal to increased rate of protein 
synthesis and turnover in the whole body (Jeevanadam et al., 1984; Eden 
et al., 1984). This is in sharp contrast to the decreased rates of 
whole body protein turnover and synthesis seen during uncomplicated 
starvation (Rennie et al., 1982).
Fat metabolism in the cancer bearing host is also abnormal. Fat 
is mobilized as the major energy reserve during starvation; the free 
fatty acids released are oxidized to provide energy and the glycerol 
backbone is converted to glucose via gluconeogenesis. Administration 
of glucose during starvation reduces both free fatty acid oxidation and 
gluconeogenesis and it is thought that this effect is mediated by 
insulin (Butcher, 1968). In contrast, free fatty acid oxidation 
continues in the presence of administered glucose in cachectic cancer 
patients (Waterhouse and Kemperman, 1971).
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Although these observations support the suggestion that cancer 
cachexia may not be entirely consistant with semistarvation the 
question remains as to which metabolic abnormalities are significant 
and how do they induce weight loss?
Mechanisms of weight loss in cancer
In order to determine possible mechanisms of weight loss in 
cancer patients it is necessary to consider the factors which keep the 
body weight stable in normal individuals. When the energy lost as 
mechanical work or as heat is balanced by the energy obtained from food 
in the diet the body weight remains stable. Therefore, loss or gain of 
body mass is due to an imbalance between energy intake and energy 
expenditure. A number of studies have looked for an imbalance in this 
relationship in cachexia. Walsh and coworkers (1983) and Cohn and 
colleagues (1981b) both demonstrated a marked reduction of food intake 
in cancer patients who had become. severely cachectic. However , in 
contrast, when cancer patients were studied during the early phase of 
weight loss a reduction in food intake was not observed (Costa et al., 
1981).
Whether or not food intake is reduced, an increased energy
expenditure might account for the rapid weight loss and other symptoms 
of cachexia in cancer patients. When an individual is at rest and is 
not performing any mechanical work energy expenditure is equal to the 
amount of heat transferred from the body to the atmosphere. This 
resting energy expenditure can be determined by measuring the amount of 
heat given off by the body and this technique is known as direct
calorimetry. However, in clinical medicine direct calorimetry is
rarely employed to determine heat loss or heat production; rather
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indirect calorimetry is the preferred method. This method relies upon 
the direct relationship between the rate of release of energy from the 
body and the rate of oxygen consumption and carbon dioxide production.
Numerous investigators have used indirect calorimetry to 
determine whether the resting energy expenditure of patients with 
cancer is elevated. Lindmark and coworkers (1984) and McFie and
colleagues (1982) both demonstrated that the resting energy expenditure 
of patients with disseminated malingancy is increased by 5 - 20% when
i
compared with controls. In contrast, Hansell and coworkers (1986) 
showed that there was no difference between the resting energy 
expenditure of large groups of patients with either lung, colon or 
gastric cancer and that of non-cancer controls. In another study 
(Dempsy et al., 1984) it was shown that approximately one third of 
cancer patients were hypermetabolic r one third were normal and one 
third were hypometabolic. However, even a 'normal* rate of energy 
expenditure would be inappropriate in the semistarving cancer host 
since the normal adaptive response to a reduction in energy intake is a 
decrease in energy expenditure.
The mechanisms whereby the energy expenditure of some cancer 
patients is increased or at least fails to adapt to the semistarving 
state are unknown. One proposal is that energy dependent metabolic 
cycles such as protein turnover or the glucose-lactate cycle (Cori 
cycle) are increased. However, the relation between these abnormalities 
and the metabolic rate, increased or otherwise, is not clear. 
Although some investigators have found a correlation between an 
increased Cori cycle activity and weight loss (Holroyde et al., 1975), 
other workers have failed to do so (Kokal et al., 1983). Similarly, 
whole body protein turnover has been shown to be elevated in some
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groups of malnourished cancer patients (Jeevanandam et al., 1984? Eden 
et -al., 1984) but not in others (Glass et al., 1983). Thus, as yet it 
is unclear whether the weight loss of cancer patients is primarily due 
to a reduced food intake, an increased energy expenditure or a 
combination of the two. Moreover, the mechanism of any proposed 
elevation of energy expenditure is not established.
Clearly in order to discriminate between these possibilities it 
is first necessary to determine which of the body compartments are 
reduced in cancer cachexia. Thus one of the primary aims of this study 
was to characterise the body composition changes that occur during the 
development of cachexia. And, secondly, to determine whether weight 
loss is caused primarily by a reduced food intake. This study is 
described in Chapter 5.
The possibility that host energy expenditure is increased by the 
presence of the tumour causing an increased rate of protein turnover in 
the host is considered in a study described in Chapter 6. A similar 
study, based on a novel animal model of cancer cachexia is described in 
Chapter 7.
The reasons for abnormalities of protein, fat, carbohydrate and 
energy metabolism which have been documented in the cancer host are 
unknown. Indeed, it is not even clear if the observed changes form a 
consistent pattern such that all cases of cancer cachexia can be 
classed as a single syndrome. Cachexia can arise in humans when a 
tumour is less than 0.01% of host weight (Morrison, 1976) yet some 
patients with very large tumours show no sign of cachexia (Stein,
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1978). Thus it is unlikely that the metabolic demands of the tumour 
constitute a significant drain on host metabolism. An alternative 
theory is that tumours produce small molecular weight peptides which 
are capable of altering the activity of various host enzymes. Because 
this occurs in a random manner, a state of metabolic chaos is produced 
(Theologides, 1977). However, although human tumours are known to be 
capable of both exocrine (Coombes, 1982) and autocrine (Sporn and 
Todaro, 1980) secretion of polypeptides, no tumour specific product has 
yet been shown to be responsbile for the metabolic defects which are 
thought to contribute to cachexia.
It has also been suggested that some of the metabolic 
abnormalities in cancer cachexia are similar to those observed in 
trauma and sepsis (Brennan, 1977). The loss of body fat and protein in 
patients with trauma or sepsis is thought to result from a combination 
of altered hormone profiles superimposed on semistarvation (Wilmore, 
1983). Many of the metabolic events of trauma or sepsis (e.g. hyper- 
glycaemia, increased nitrogen loss) can be reproduced by a combined 
infusion of glucagon, cortisol and adrenalin (Bessey et al., 1984). 
However, several aspects such as fever and production of acute phase 
proteins are not observed folowing such an infusion. The latter 
phenomena may be due to peptide lymphokines (e.g. Interleukin I and 
tumour necrosis factor) which are produced by inflammatory cells in 
response to injury and infection (Dinarello, 1985). Moreover, these 
mediators may enhance net triglyceride mobilization from adipose tissue 
(Beutler et al., 1985 a and b) and amino acid release from skeletal 
muscle (Baracos et al., 1983). Thus, the inflammatory response and the 
release of these mediators may be a key component in the events leading 
to body wasting associated with disease. In humans with cancer, tumour
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necrosis, destruction of normal tissue and infection are just some of 
the factors independent of tumour type that could elicit such an 
inflammatory response. The hypothesis that the metabolic abnormalities 
observed in cancer cachexia are due to mediators of the inflammatory 
response is examined further in Chapter 6 with particular reference to 
protein turnover.
Treatment of cancer cachexia
Clearly, the best way to resolve the nutritional and metabolic 
abnormalities resulting from the growth of a tumour is the removal of 
the tumour (Caiman, 1982). However, for the majority of solid 
epithelial malignancies, once the tumour has spread beyond the organ of 
origin, chemotherapy, radiotherapy or surgery will not effect a cure 
and may even worsen the nutritional deficit of the patient (Ohnuma and 
Holland, 1977? Kokal, 1985). Thus, whilst the search continues for 
more effective antineoplastic therapy, attention has been focused on 
supportive measures to reduce the morbidity and mortality which result 
from the nutritional problems associated with progressive tumour growth 
(Copeland, Daly and Dudrick, 1977). However, it is not known whether 
the nutritional state of cancer patients is an independent determinant 
of survival (Van Eys, 1982). Recent studies have suggested that when 
there is a good response to antineoplastic therapy the nutritional 
status of the patient will return to normal (McR. Russel et al., 1984). 
In contrast, with progressive tumour growth there is a partial block to 
the repletion of lean tissue (Nixon et al., 1981? Cohn et al., 1982) 
and nutritional support will neither lengthen survival nor improve the 
efficacy or tolerance of antineoplastic therapy (Brennan, 1981). This
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lack of benefit from conventional nutritional support has emphasised 
the need for an understanding of the basic mechanisms of weight loss in 
in cancer patients. Moreover, the demand for alternative approaches to 
the treatment of cachexia has become all the more acute.
Selective feeding of the cancer host
Stimulation of tumour growth rate may be one explanation for the 
failure of nutritional support to improve the survival of wasted cancer 
patients. Hyperalimentation has been shown to increase tumour growth 
rates in a number of tumour bearing animals (Popp, Morrison and 
Brennan, 1981? Cameron, 1981), but the effects in humans are unclear 
(Brennan, 1981). A possible strategy to overcome this problem may be 
to refeed the wasted cancer patients with an energy substrate that 
could be used by the host but not by the tumour (Magee et al., 1979? 
Tisdale and Brennan, 1983) • This approach is based on the fact that 
many tumours are dependent on glucose (Gold, 1966; Gullino, Grantham 
and Courtney, 1967) rather than fat or ketone bodies for energy 
production (Cederbaum and Rubin, 1976; Tisdale and Brennan, 1983)• In 
contrast, most host tissues can use lipid substrate or glucose equally 
well for energy metabolism. The use of lipid substrates to control 
cachexia and tumour growth in an animal model of cachexia is discussed 
in Chapter 8. A similar study in cancer patients is described in 
Chapter 9. However, in the latter study the effect of systemic ketosis 
on tumour growth rate is not assessed.
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Selective inhibition of the tumour
Current cancer chemotherapy is only curative for a small minority 
of cancer patients with disseminated disease (Frei, 1985). This 
systemic form of therapy involves the use of cytotoxic agents to 
inhibit cell division within the tumour. These agents are non-selective 
since they also inhibit cell division within the tissues of the host. 
Their use is based on the assumption that the rate of cell division 
within the tumour is greater than that of the majority of host tissues. 
Clearly this is not always a valid assumption and such treatment is 
often limited by host toxicity. Thus, cancer chemotherapy is often only 
partially effective and may, in fact, exacerbate the nutritional 
consequences of progressive tumour growth (Donaldson and Lenon, 1979; 
Kokal, 1985). An alternative approach would be to evolve a more 
selective therapy based on the differences in energy metabolism between 
normal and malignant cells. Several tumours have been shown to have an 
abnormally high rate of anaerobic glycolysis (Warburg, 1930) and to be 
dependent on glucose as a major energy substrate (Gold, 1965? Shapot 
and Blinov, 1974? Demetrakopoulos, 1978). Furthermore, many tumours are 
known to have few mitochondria which are abnormal in morphology and 
enzyme content (Pedersen, 1978). Since glycolysis and oxidative 
phosphorylation are the two major pathways of energy production within 
the cell, these observations suggest that there are major differences 
between the energy metabolism of normal and of tumour cells. Thus, 
chapter 10 describes an attempt to inhibit tumour growth by selective 
inhibition of tumour energy metabolism.
Aims of the study 39
The principle aims of this study can be summarised thus:
1) To characterise the nature and rate of tissue loss in patients
with cancer cachexia.
2) To establish whether the rate of whole body protein turnover is
increased in patients with cancer, and if so, whether this is 
associated with an increased resting energy expenditure and hence 
with weight loss.
3) To establish a representative animal model of human cachexia and
to use this model to determine whether there is a metabolic 
component to weight loss.
4) To investigate in an animal system whether a host specific energy
substrate might be used to inhibit both the development of 
cachexia and the growth of the tumour.
5) To investigate the effect of a host specific energy source on
substrate levels and protein metabolism in cachectic cancer 
patients.
6) TO investigate the possible use of tumour energy metabolism as a
novel target for systemic antineoplastic therapy.
Layout of thesis
Each chapter begins with a self contained introduction and therefore
details of the rationale behind the various stages of the work are not 
discussed here.
In order to determine the rate of whole body protein turnover in 
patients with cancer it was necessary to have a method which was both 
reproducible and easily performed in the clinical situation. Two
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methods were available. One involved the administration of an amino
acid labelled with a stable isotope of nitrogen and the other an amino
acid labelled with a stable isotope of carbon. A primed, constant, 24h 
. . 15infusion of N-glycine was chosen because it was the cheaper of the 
two methods and involved less disturbance of the patients. Ibis method 
is described in Chapter 2.
The influence of protein turnover on host energy expenditure was 
also studied. Energy expenditure can be measured either by direct or 
indirect calorimetry. Indirect calorimetry, was the method more easily 
adapted to the clinical situation and is described in detail in Chapter 
3. Protein metabolism and energy expenditure were studied in greater 
detail in a new murine model of cancer cachexia and the methods which 
were used are described at the end of Chapters 2 and 3 respectively.
Clearly, destructive chemical composition analysis of humans is 
not feasible and therefore a method was sought which would allow 
accurate determination of body composition in vivo. The technique of 
neutron activation analysis and whole body gamma spectrometry was 
chosen since not only did this allow accurate determination of chemical 
body composition in vivo but also enabled the division of the lean body 
mass into protein, water and mineral compartments. The details of this 
method are described in Chapter 4.
The nature and quantity of tissue loss in a group of cachectic 
lung cancer patients are described in Chapter 5. Patients who had lost 
approximately 30 per cent of their pre-illness weight underwent neutron 
activation body composition analysis. The results from these patients 
were compared with those from healthy controls who were matched for the 
age, sex and pre-illness stable weight of the cancer patients.
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One possible mechanism for loss of weight was investigated in 
patients with either lung or colon cancer (Chapter 6). It had been 
suggested that whole body protein turnover might be elevated in the 
cancer host and that the energy cost of this might lead to a rise in 
host energy expenditure and thus initiate or worsen a negative energy 
balance. This hypothesis was investigated by measuring whole body 
protein turnover and resting energy expenditure simultaneously in both 
cancer and non-cancer patients with or without weight loss.
The nature and cause of the negative energy balance of the 
weight-losing cancer host was further investigated in Chapter 7. Body 
composition analysis was used to determine the nature of tissue loss in 
mice bearing the MAC-16 adenocarcinoma. Furthermore, food intake, 
energy expenditure and rates of protein synthesis were determined in 
the tumour bearing mice.
In addition to these studies of the mechanisms of weight loss in 
the cancer host, two new methods of treating the host tumour imbalance 
of cancer cachexia were evaluated. In the first, the use of systemic 
ketosis as a method of selectively feeding the host whilst reducing 
tumour glucose supply was appraised. The effect of a ketogenic diet on 
tumour growth rate and the development of host wasting was determined 
in rats bearing the Walker 256 tumour (Chapter 8) . In Chapter 9 the 
effects of systemic ketosis on host nitrogen metabolism and blood 
susbstrate concentrations were determined in a group of cachectic 
cancer patients. However, the effect of ketosis on tumour growth 
rate was not determined in the latter study.
A more direct attempt to inhibit tumour growth rate is described 
in Chapter 10. This study involved the use of tumour energy metabolism
42
as a novel target for systemic anticancer therapy. Rats bearing the 
Walker 256 tumour were rendered hypoglycaemic by inhibition of 
gluconeogensis and at the same time an inhibitor of oxidative phos­
phorylation (Rhodamide 6G) was administered systemically. The effect 
on tumour growth rate of this simultaneous manipulation of both 
glycolysis and oxidative phosphorylation was then determined.
The results of each of these individual studies and the 
conclusions which can be reached with respect to the mechanisms and 
treatment of cancer cachexia are discussed in Chapter 11.
CHAPTER 2 43
Measurement of protein synthesis and turnover in vivo
Introduction
Proteins play a crucial role in virtually all biological
processes (Stryer, 1975) and are continually broken down and
resynthesised within the body (Golden, Waterlow and Picou, 1977).
Protein synthesis is a process which requires energy and some energy
may be used in the hydrolysis of peptide bonds when protein is broken
down (Water low, Gar lick and Millward, 1978). A method was required to
measure the rate of protein turnover in cancer patients and to
determine the effect of such turnover on energy expenditure and energy
balance. This chapter describes the principal features of the model
used to study whole body protein turnover, synthesis and degradation in
vivo. The two techniques that can be used to measure whole body protein
turnover, and the reasons for selection of a primed, continuous 24h 
15infusion of N-glycine as the method of choice are discussed. The 
latter method is then detailed along with an assessment of its 
reproducibility in a young male volunteer. The technique used to 
measure protein synthesis rates in the tissues of a murine model of 
cancer cachexia is also outlined.
Model used to evaluate whole body protein turnover in vivo
The concept of a measurement which represents protein turnover in 
the whole body comes from the techniques which have been used to 
investigate protein metabolism in man. These techniques can be divided 
into precursor and end product methods. Both rely upon a basic two pool
44
/
model (Figure 2.1) where protein turnover is estimated from the flux of 
labelled amino acids into protein and into excretory pathways (Shipley 
and Clark, 1972). The label enters a single homogen&ras free amino acid 
pool (the metabolic pool) from which it can either be oxidized, giving 
rise to CX^ and urinary N, or it can be incorporated into protein. 
The protein of the body is regarded as a single pool which is 
continually recycling amino acids back into the metabolic pool, but 
because of its large size, acts as a sink for label entering it. 
Therefore, recycling of label is assumed not to occur. Thus, under 
steady state conditions, when the free amino acid pool is a constant 
size, the flux (Q) into the metabolic pool (from food intake, (I) and 
protein breakdown, (B) must equal the flux out of the metabolic pool 
(via protein synthesis, (S), and amino acid oxidation, (E). Thus:
Q = S + E = I + B.
It is therefore possible to calculate rates of whole body protein 
synthesis (S) and breakdown (B) by measuring flux (Q) and establishing 
the rate of nitrogen intake (I) and excretion (E). The end-product 
method and precursor method (representative amino acid method) are the 
two techniques which can be used to estimate Q.
End-product method
. 1 5This approach has been used mainly with N-labelled glycine. It is
15assumed that the labelled glycine donates N via transamination to
15other ammo acids and thus the N acts as a label for the total free 
amino nitrogen pool. Since the urinary end-products of nitrogen 
metabolism (urea and ammonia) are derived solely from the free amino N 
pool their labelling can be taken as representative of that pool.
Precursor
M ethods
m  I Dietary  
u; Amino 
X  Acids
FREE 
AMINO ACID 
POOL
Oxidation
... JN Excretion C O - 
M ethod 1CNH3 and urea)
Synthesis
(S)
Breakdown
(B)
Figure 2.1 Two pool model of whole body protein metabolism. 
Flux of amino acids into the free pool comes from the diet 
(I) or from the breakdown of body proteins (B). Flux out 
of the free amino acid pool is via synthesis of body protein 
(S) or oxidation and excretion (E)v
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15When a continuous infusion of N-glycine is given at a rate d 
(mg isotope per hour) the specific activity (atom % excess N) in the 
excreted end-product (urea or ammonia) reaches a plateau S max. It is
assumed that in the steady state and at isotopic equilibrium the
proportion of isotope excreted in the chosen end-product of nitrogen 
metabolism (ammonia or urea) is the same as the proportion of the
nitrogen flux excreted in that same end product. This can be
expressed:
em Em
d Q
15where e = rate of excretion of N in the chosen end product, E m c r m
15= rate of excretion of the end product, d = rate of infusion of N 
and Q = the total nitrogen flux. Since in the steady state:
Em Smax
15Thus, during a constant infusion of N-glycine once plateau
enrichment has been achieved, by measurment of the atom % excess of
15 . . .
N m  urinary ammonia or urea, the rate of nitrogen flux m  the 
whole body can be calculated (Water low, Garlick and Millward,
1978).
Precursor method
With this method measurement of whole body protein turnover is
based on studying the kinetics of a single amino acid. A good example
13 14of this technique is when carboxyl-labelled G or C leucine is 
infused intravenously until the isotopic enrichment of the amino acid
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in the plasma reaches a constant value (Waterlow, Garlick and Millward,
1978; Matthews et al., 1980). This plateau value can then be used to
15calculate the flux in a way analagous to that for N-glycine. The 
rate of oxidation of the label can be calculated from the plateau 
isotopic enrichment of expired CC^ . A knowledge of the dietary intake 
of the amino acid then enables the rates of whole body protein 
synthesis and breakdown to be evaluated.
Rational for selection of end-product method
The end product technique (^N-glycine) was selected as the 
method of choice because:-
a) the method has been widely used (Picou and Taylor-Roberts,
1969; Fern et al., 1981; Jeevanandam et al., 1984), gives results
13 14similar to those obtained with C or C labelled leucine (Golden 
and Waterlow, 1977; Waterlow, Garlick and Millward 1978), and is 
sensitive to alterations in physiological states e.g. fasting (Rose 
et al., 1983).
b) By giving a primed, constant 24-hour infusion each patient 
study can be completed within 24 hours (Sim et al., 1980).
c) Sampling simply involves collection of urine and therefore 
disturbance to the patients and the need for nursing supervision is 
kept to a minimum.
15d) The cost of the labelled amino acid ( N-glycine: end
product method) and the instrumentation required to measure the
15enrichment of ammonia and urea with N (isotope ratio mass spectro-
13meter) is several times less than the cost of [1 - C] leucine 
(precursor method) and the gas chromatographic mass spectrometer
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required to measure the isotopic enrichment of blood leucine or 
oC -ketoisocaproate•
Details of end-product method
The protocol followed was that developed by Sim and coworkers
(1980) and Sim, Ward and Johnson, (1984). After an overnight fast and
during the 24h infusion the subject remained in bed and was allowed
free access to water but not to food. The baseline enrichment of
ammonia and urea was obtained from a urine sample taken at 08.00h. At
1509.00h a bolus of lOOmg N-glycine was given and immediately 
followed by a continuous 24h infusion at the rate of lOOmg 
15N-glycine/24h. The 15N-glycine (99% atom percent s
Amersham Int. Ltd., England) was dissolved in Na Cl (150mM) and 
sterilized by microfiltration. During the infusion, urine was collected 
in two consecutive 12 hour periods. A further sample was obtained at 
the end of the 24h infusion.
Urine collections were stored in the presence of 5ml of 6N HCl
and 2mg of Chlorhexidine gluconate (ICI Ltd., Macclesfield, Cheshire,
U.K.) in plastic containers. Urine samples were prepared for mass
spectrometry according to the method of Read and coworkers (1982). The
sodium/potassium form of the cationic ion exchange resin AG 50W - X8
(Biorad Laboratories Ltd., Watford, Hertfordshire, England) which
specifically binds ammonia in neutral solution was used to extract
ammonia from urine before and after treatment with urease (Type III,
Sigma Ltd., Poole, Dorset, England). The resin ammonia complex was
subsequently treated with alkaline hypobromite to liberate molecular 
15nitrogen and N-abundance measured with a double collector isotope 
ratio mass spectrometer (V.G. Micromass 602B, Cheshire, U.K.) with a
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precision of 0.0008 atom % excess. Total urinary nitrogen was measured 
by the micro-Kjeldhl method (Fleck and Munro, 1965).
Rates of whole body protein turnover (Q) were calculated from the 
isotopic enrichment of ammonia and urea using the equation described on 
page 45. Rates of protein synthesis and degradation were derived from 
Q using the equation described on page 44. Since the subject was 
fasted, nitrogen intake was zero and therefore rates of protein 
turnover and degradation were the same.
Reproducibility of end-product method
Since it was possible to make only one estimate of protein
* <
turnover rates in cancer patients it was necessary to establish the 
reliability of this measurement. A small study was therefore carried 
out in which the protein turnover rate was estimated in a healthy 
volunteer on three separate occasions.
15A primed, constant 24 hour infusion of N-glycine was 
administered to a healthy male volunteer (65Kg : 25yrs) on three
separate occasions. Rates of whole body protein turnover and synthesis 
were calculated from the isotopic enrichment of ammonia and urea 
obtained from a combined urine collection from the 12th - 24th hour of 
the infusion. The results are shown in Table 2.1.
The coefficient of variation of the rate of whole body protein 
turnover calculated from the isotopic enrichement of either ammonia or 
urea was less than 7%. The coefficient of variation of whole body 
protein synthesis with ammonia as the end product was 15.8% and with
INFUSION TURNOVER SYNTHESIS URINARY NITROGEN
(gProtein/Kg/<3) (gProtein/Kg/d) (gN/day)
Ammonia Urea Ammonia Urea
A 1.98 3.28 1.03 2.33 9.4
B 2.22 3.66 1.27 2.71 9.4
C 2.01 3.27 0.94 2.20 10.6
MEAN 2.07 3.4 1.08 2.41 9.8
C.V.* 6.3% 6.4% 15.8% 11.1% 7.1%
* Coefficient of variation
Table 2.1 Rates of whole body protein turnover and synthesis in a
fasted male volunteer following a primed, constant 24h 
15infusion of N-glycine. Results are from 3 infusions 
given at weekly intervals.
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urea was 11.1%. Since synthesis rates are calculated by subtracting 
the rate of nitrogen excretion from the rate of protein turnover (see 
page 44) the increased variability of the synthesis rates is probably 
accounted for by variation in daily urinary nitrogen excretion (Table 
2.1). These results clearly indicate that the end-product method is a 
reproducible and reliable method for the determination of rates of 
whole body protein kinetics in vivo.
Validation of the protocol used to measure whole body protein 
turnover by the end-product method.
The calculation of protein turnover from the isotopic enrichment
15of urinary ammonia or urea during a continuous infusion of N-
glycine requires the achievement of a plateau of isotope excretion (see
15page 44). If an unprimed infusion of N-glycine is administered
intravenously, isotopic equilibrium in the urea pool can be achieved
after about 48h (Picou and Taylor-Roberts, 1969). However, if at the
beginning of constant infusion the relatively large urea pool is primed 
15with a bolus of N-glycine it has been suggested that isotopic 
equilibrium can be achieved within 12 -18 h (Sim et al., 1980).
In order to confirm that plateau isotopic enrichment has been 
achieved, the rate of protein turnover is usually calculated from the 
mean isotope enrichment of several consecutive urine samples. However, 
a single urine collection over the second 12 hours of a 24h primed, 
constant infusion has been suggested as a method with which to avoid 
such multiple sampling (Sim, Ward and Johnson, 1984). This suggestion 
was confirmed by measuring the kinetics of isotope enrichment of 
ammonia and urea in a series of consecutive urine samples obtained from 
the same individual. This was done on three separate occasions. The 
results are shown in Table 2.2.
TIME INFUSION A INFUSION B INFUSION C
(atom % excess)
(h )* Ammonia Urea Ammonia Urea Ammonia Urea
0- 1 1.2529 0.0523 1.0003 0.0489 1.1121 0.0627
1- 2 0.2393 0.0367 0.2553 0.0388 0.2108 0.0442
2- 3 0.1468 0.0357 0.1504 0.0384 0.1407 0.0426
3- 4 0.1266 0.0427 0.1215 0.0298 0.1220 0.0447
4- 5 0.1005 0.0487 0.1216 0.0393 0.1078 0.0463
5- 6 0.0994 0.0483 0.1075 0.0408 0.1030 0.0457
6- 8 0.0911 0.0508 0.1062 0.0423 0.1047 0.0495
8-10 0.1169 0.0543 0.0880 0.0472 0.0898 0.0512
10-12 0.1177 0.0629 0.1045 0.0494 0.0868 0.0543
12-16 0.1157 0.0654 0.1018 0.0525 0.1064 0.0583
16-20 0.1046 0.0650 0.0898 0.0566 0.0992 0.0628
20-24 0.0939 0.0612 0.0764 0.0565 0.0932 0.0612
12-24 0.1003 0.0605 0.0894 0.0542 0.0990 0.0607
Mean** 0.1047 0.0639 0.0893 0.0552 0.0996 0.0668
CV** 10.4% 3.6% 14.2% 4.2% 6.6% 3.8%
15* : tune from start of N-glycine infusion
** : mean and coefficient of variation of end product enrichment in
urine collections taken from 12-16, 16-20 and 20-24 hours.
15Table 2.2 Kinetics of N enrichment of urinary ammonia and urea
15during a primed constant 24 hour infusion of N-glycme. 
The subject was fasted for 12 hours prior to the study. 
Results are from 3 infusions given at weekly intervals.
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Initially the isotope enrichment of urinary ammonia was very high 
but fell to a plateau within 4 hours of the start of the infusion. In 
contrast, the isotope enrichment of urea was only slightly elevated at 
first, fell to a trough level during the second hour of the infusion 
and then slowly increased to reach equilibrium which was maintained 
throughout the second twelve hours of the infusion. The coefficients 
of variation of isotope enrichment in ammonia and urea in the three 
urine samples from 12 to 24 hours were less than 15% and 5% respec­
tively. Thus a single urine collection obtained over the second 12
15hours of a 24 hour primed infusion of N-glycine appears to be a
15valid and reproducible method of assessing plateau N enrichment in 
both ammonia and urea.
Estimation of tissue specific rates of protein synthesis in mice.
The method used to measure rates of protein synthesis in the 
tissues of cachectic tumour bearing mice was that developed by Gar lick, 
MCNurlan and Preedy (1980)• Protein synthesis rates are estimated by 
determining the rate of incorporation of labelled phenylalanine into 
protein. All possible amino acid precursor pools for protein synthesis 
are flooded by intravenous administration of a very large dose of radio 
labelled amino acid such that all pools reach the same specific 
activity which is maintained at an almost constant level during the 
period of measurement. This enables an accurate rate of protein
synthesis to be calculated from measurements of the specific
radioactivity of free and protein bound phenylalanine in the tissues.
Ten minutes after a tail vein injection of 1ml of 150jun
3phenylalanine and 1 pCi per gram of L - [4 - H] phenylalanine the 
animals were lightly anaesthetised with diethyl ether and the liver,
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kidney, heart and skeletal muscle were excised, immediately frozen in 
liquid nitrogen and ground to a powder. Thereafter the free 
phenylalanine was extracted into ice cold perchloric acid and the bound 
phenylalanine released by hydrolysing the protein with 6M HC1 in a 
vacuum at 110°C for 24 hours.
3Determination of the specific radioactivity of [ H] phenylala­
nine involved its enzymatic conversion into B-phenylethylamine. This 
procedure was necessary because other amino acids (particularly tyro- 
sme) became labelled following an injection of [ H] phenylalanine. 
Phenylethylamine was extracted into an organic solvent and then into a 
dilute acid solution. An aliquot was removed for liquid scintillation 
counting and a further sample taken for estimation of the concentration 
of phenylethylamine. The measurement of phenylethylamine was based 
on the fluorescence enhancement of the amine with ninhydrin in the 
presence of the dipeptide leucylalanine. The fractional rate of 
protein synthesis (kg) was then calculated from the specific 
radioactivity of phenylalanine in protein (S_) at 10 minutes and the
13
mean specific radioactivity of free phenylalanine in the tissue (SA)
between 0 and 10 minutes. The value of was obtained by killing
animals at 2 and 10 minutes and assuming a linear fall in specific
activity between these two time points. The formula for calculating
K was : s
SB x 100
K =s ------------
S„ x t
where t is the incorporation time in days and the units of K are %O
per day.
Summary and Conclusions
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15A primed, constant, 24h infusion of N-glycine is a 
reproducible method of estimating whole body protein turnover in 
humans. This method is used in Chapter 6 to determine the rate of 
protein turnover and its relation to energy expenditure in patients 
with lung or colon cancer. The method is also used in Chapter 9 to 
determine the effect of systemic ketosis on the protein metabolism of 
of patients with cancer cachexia.
The flooding dose of phenylalanine method is used in Chapter 7 to 
examine the protein metabolism of a new murine model of cancer 
cachexia.
CHAPTER 3 53
Measurement of energy expenditure in vivo 
Introduction
In order to determine if weight loss in cancer cachexia is 
predominantly due to an increased energy expenditure rather than a 
decreased food intake, a method was required to measure energy 
expenditure in both humans and mice. There are two methods of 
measuring energy expenditure. Direct calorimetry relies upon 
measurement of the rate of heat exchange between the body and its 
environment. Indirect calorimetry estimates the rate of transformation 
of chemical energy into heat by oxidative metabolism. This is done by 
determining the rate of oxygen consumption and the rate of carbon 
dioxide production. Both methods rely upon the first law of thermo­
dynamics which states that energy is neither lost nor gained when it is 
transferred from one form to another (eg. chemical energy to heat). 
Indirect calorimetry is the easier of the two methods to adapt for 
clinical investigation and gives results which agree with those 
obtained by direct calorimetry (Dauncy, 1980)•
Measurement of resting energy expenditure in humans.
Resting energy expenditure was measured using an open circuit 
ventilated hood system housed in a temperature-controlled room. The 
subject*s head was enclosed in a perspex canopy (Kinney et al., 1964) 
and the system made airtight by a flexible adhesive neck seal. The 
canopy was ventilated with air at a rate of 35 - 40 1/min; total flow
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was measured by a wet gas meter (A. Wright Ltd., Tooting, London,
U.K.). The gas mixing time constant of the head canopy and connecting 
piping was measured to be 36s, giving approximately a 95% response to a 
gas concentration change in 1 minute. Oxygen concentration difference
across the canopy was measured by a dual-channel paramagnetic analyser 
(Servomex Ltd., Crowborough, Sussex, U.K.) and corrected to standard 
temperature and pressure. Carbon dioxide production was measured by an 
infra-red analyser (Sieger Ltd., Poole, Dorset, U.K.). The system 
provided measurements of v02 and vCC>2 for which the repeatability 
was + 5% (95% confidence limits). The equipment was calibrated 
frequently using oxygen free nitrogen, 0.8% carbon dioxide (B.O.C. 
Ltd., Polmadie, Glasgow, U.K.) and air of known barometric pressure. 
The sensitivity and accuracy of the calorimeter was checked 
periodically by burning butane gas in the canopy. The 80 estimates of 
vo2 and voo2 collected during each calorimetry run of 40 minutes 
were processed on line by a microprocessor and converted to mean energy 
production (Watts) and respiratory quotient (RQ) using the formulae of 
Wier (1949):
REE (kcal/d) = (3.9 v02 +1.1 v002) 1140 min/day
where kcal/d = watts x 10.65
vC>2 = oxygen consumption (1/min) 
vCX>2 = carbon dioxide production (3/min)
RQ = vCO^vOj
The patients had free access to water but not to food from 18.00h on 
the day prior to study. Each study began at 09.00h, patients having 
remained in bed since wakening. The 40 minute calorimeter run was
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preceeded by a 30 minute acclimatization run.
Resting energy expenditure was expressed in relation to the 
patient's lean body mass. Lean body mass was derived from the 
measurement of total body water. Tritiated saline (4MB^ ) was 
injected intravenously and serum samples were obtained 3 and 4 hours 
after injection. During the period of equilibrium all urine passed was 
collected to measure the loss of tritium in urine. Lean body mass was 
derived from the volume of body water assuming that lean tissue 
contains 73% water (Belcher and Vetter, 1971).
Measurement of daily energy expenditure of mice.
Levels of oxygen consumption and carbon dioxide production were 
obtained for each animal throughout the course of the investigation. 
Two animals were studied simultaneously using two glass metabolic cages 
(Minor Metabowl, H89/17/171, Jencons Scientific Ltd., Leighton Buzzard, 
Bedfordshire, England).
Ventilating room air was circulated through each cage at a small 
negative pressure (5mmHg) by pumps (Figure 3.1). Airflow was 
controlled and set within the range 275 to 325ml/min. The exhaust air 
from each cage was connected alternately to a wet gas meter (A. Wright 
Ltd., Tooting, London, U.K., England) for measurement of flow, then to 
gas analysers (Servomex QA150 Paramagnetic Analyser, LIRA Carbon 
Dioxide Analyser) to determine oxygen and carbon dioxide concen­
trations. This was accomplished by a timer which controlled two 
solenoid valves. Another solenoid valve (not shown in Figure 3.1) was
Cage 1
J S.V.* Timer
Cage 2
\
Pump
/ s.v.
* Flow meter
T
4
0 2 CO 2
Analysers
*S.V. = Solenoid Valve
Figure 3.1 Design of small animal indirect calorimeter.
Room air is circulated through each metabolism cage by a 
pump. A solenoid valve directs the air either to the air 
flow meter or to the gas analysers. Each solenoid valve 
is controlled by a timer (not shown) which alternates the 
position of the valve every 5 minutes so that when the rate 
of flow of air through cage 1 is measured, the concentration 
of 0^ and CC>2 in the air from cage 2 is analysed.
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energised for 5 minutes every 3 hours. This allowed room air to flow 
through reference and analysis cells of the oxygen analyser to measure 
baseline drift.
Prior to a runf both gas analysers were calibrated using oxygen 
free nitrogen as zero gas and a certificated reference stadard gas for 
the carbon dioxide analyser. Room air was used as the 'span' gas for 
the oxygen analyser.
As airflow was not measured when exhaust air was connected to the 
gas analysers, it was important that the resistance in the gas 
analysers* air circuit matched the resistance in the gas meter circuit. 
Thus at the beginning of each run, the air flow rate into each pump was 
measured with the solenoid valve in both positions and the two rates 
equated.
The wet gas meter has a multi-slotted disc from which electrical 
pulses proportional to flow rate can be obtained. A changeover relay 
controlled by the 5 minute timer was connected to the gas meter's 
electrical signal. Pulses from the gas meter were directed by this 
relay to one of two electromechanical counters so that the count 
accumulated by each counter was particular to a single channel. At the 
end of a run, the total count recorded by each counter was doubled and 
divided by the total run time to give the average flow rate.
In addition, an analogue signal of flow rate (derived from the gas 
meter's pulses) was recorded on one channel of a potentiometric
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recorder. The other channels were connected to the oxygen and carbon 
dioxide analysers.
Average values for oxygen consumption and carbon dioxide 
production over the 24hour run were obtained by planimetry of the 
traces. Estimates of vO^ and vCX^ were converted to energy 
production using the formulae of Weir (1949).
Summary and Conclusions
Indirect calorimetry can be adapted for both clinical and animal 
studies. These methods are used in Chapters 6 and 7 to estimate the 
energy expenditure of patients and mice with and without cancer in 
order to determine whether energy expenditure is increased in cancer 
cachexia.
CHAPTER 4
Determination of body conposition in vivo
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Introduction
The syndrome of cancer cachexia is characterized by severe weight 
loss, anorexia, early satiety, lethargy and anaemia (Caiman, 1982). 
However, these rather vague clinical descriptions provide little 
information concerning the alterations in nutritional status and the 
nature of tissue loss that occurs in patients with this condition. 
Body composition analysis is one of the most precise and accurate 
methods with which to determine nutritional status (Shizgal, 1985). 
Moreover, comparative measurements before and after weight loss allows 
the quantity and rate of tissue loss to be determined. This 
information can be used to assess the long term energy and nitrogen 
deficit which has been incurred by the patient.
In this chapter the various methods available to determine body 
composition in vivo are discussed, the rationale for the use of neutron 
activation body composition analysis and the basic principals 
concerning the technique are outlined. The model of body composition 
which was used to interpret the data provided by neutron activation 
analysis is also described.
Current methods used to determine body composition in vivo.
The body can be considered to consist of two compartments of 
relatively constant composition but which are distinctly different;
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the compartments are 1) the body fat, and 2) the fat free mass or lean 
body mass. Since total body weight represents the sum of body fat plus 
lean body mass, measurement of either of these compartments can be used 
to estimate the other.
The body fat compartment is anhydrous, contains no potassium, and
3 3has a fairly constant density of about 0.90 x 10 Kg/m . On the
other hand, the lean body mass compartment has a density of about 1.10 
3 3x 10 Kg/m (Durnin and Womersley, 1974), a fairly constant
potassium content (Boddy et al., 1972) and a water content of about
730g/Kg (Belcher and Vetter, 1971). Thus measurement of body density,
total body potassium, or total body water allows a calculation of the
relative proportion of fat and lean tissue in the normal individual.
Body density can be measured directly by underwater weighing (Durnin
and Rahaman, 1967) or indirectly by using the relationship between
skinfold thickness and body density as documented by Durnin and
Womersley (1974). Total body potassium can be analysed by measurement
of the gamma irradiation emitted from the naturally occurring radio-
40active isotope of potassium, K (Boddy et al., 1971). Total body 
water can be estimated by the standard tritiated water dilution 
technique as described by Vaughan and Bowling (1961). However, the 
accuracy of body composition analysis by these methods is limited by 
the variability of the composition and density of the lean body mass 
compartment in wasting disease (Moore et al., 1963).
Such variability is thought to arise because the lean body mass 
consists of two main components, namely, the cellular mass and the 
extracellular mass. In wasting disease it is recognised that the main
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losses are from the cellular mass leaving a higher proportion of
extracellular mass (James et al., 1984). Since tissues such as bone 
matrix make up the extracellular mass and have a low potassium and 
water content and also a high density this upsets the constancy of the 
lean body mass as a reference for density or compositional ratio.
Neutron activation body composition analysis.
One approach to the heterogeneity of the fat free mass is to 
measure directly the individual elements which make up the lean body 
mass. This can be done by application of the techniques of neutron
activation and whole body gamma spectrometry (Cohn et al., 1981a). In 
this technique total body nitrogen, sodium, chloride, calcium and 
phosphorous can be determined by counting the induced radioactivity 
(gamma rays) resulting from the interaction between fast neutrons and 
body tissues. The particular nuclear reactions and the corresponding 
energies of the gamma irradiation emitted as a consequence of these
reactions which are then used to calculate total body nitrogen, sodium, 
chloride, calcium and phosphorous are shown in Table 4.1. In addition,
total body potassium is measured in the same apparatus via the natural
. . .  40radioactivity emitted by K.
Details of neutron activation facility.
Patient and animal body composition studies were performed in the 
clinical facility at The Scottish Universities Research and Reactor
Element Reaction Gamma Ray Energy Yield Half life
(MeV) % (min)
NITROGEN 14 13 N(nr2n) N 0.511 200 9.97
SODIUM 23Na(n,*)24Na 1.37 100 901.8
CHLORINE 37Cl(n,tf)38Cl
2.75
1.6
100
38 37.18
CALCIUM 48 49 Ca(n,#) Ca
2.17
3.1
47
89 8.72
PHOSPHOROUS 31_. . 28 , P(n^ x) Al
4.1
1.78
10
100 2.243
Table 4.1 Principal neutron activation reactions in vivo.
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Centre, East Kilbride, Glasgow. At this centre induced and natural 
gamma irradiation is measured in a scanning bed counter (Boddy et al., 
1975). This consists of two 29cm diameter x 10cm thick sodium iodide 
detectors mounted above and below the bed on which the patient lies. 
The apparatus is contained within a 10cm thick lead shadow shield. 
Bilateral scanning irradiation is conducted in an adjoining facility 
which uses two 14MeV sealed tube neutron generators which each operate 
at 10*^ neutrons per second. The neutron generators are housed in a 
massive concrete shield. The patient lies on a couch which is driven 
through the tunnel and is irradiated during a single pass between the 
neutron generators (Williams et al., 1978).
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Patient procedure for neutron activation analysis
Before irradiation the subject is passed through the shadow
shield counter (30 scans taking about 20 minutes) in order to measure
total body potassium and the total background count rate arising from
the bodies' natural radioactivity. The subject is then transferred to
the irradiation facility. An average dose equivalent of lOmSv (1 rem),
principally due to fast neutrons but with about 5% due to gamma
radiation is delivered at the body surface during the irradiation. A
precise measurement of the neutron fluence to which the subject is
exposed is obtained from the activation of four copper bars (160g each)
62attached to the edge of the irradiation bed. The induced Cu 
activity is subsequently counted in a 7.5 x 7.5cm Sodium iodide Tl well 
counter.
After irradiation the subject is transferred back to the shadow 
shield whole body monitor and a further 30 scans are performed. This 
number of scans is used in order to obtain results with statistical 
counting errors of 3% or less for the average subject. Spectra obtained 
from the scans after irradiation are summed together in three groups: 
the first 5 scans; the next 10; and the last 15. The first 15 scans 
are made starting about 90s after the end of irradiation. The last 15 
scans are begun 30 minutes after the end of irradiation since these are 
used to determine the longer lived products (^Cl, ^Na) after 
decay of the shorter lived ones. In total, each study lasts about 90 
minutes.
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The gamma spectra are corrected for Compton contributions,
13detector activation, annihilation radiation scans other than N and 
interfering activities before computing the results. The precision of 
the method, represented by the average standard deviation of replicate 
phantom measurements, is + 2.9% (Williams et al., 1978)
Small animals (eg. rats) can also undergo neutron activation 
body composition analysis in vivo with the facilities at the Reactor 
Centre, East Kilbride. The modifications necessary to the shadow 
shield body monitor, irradiation facility and experimental protocol are 
described by Preston and coworkers (1985).
Compartmental model used in analysis of NAA data
Neutron activation analysis and gamma spectrometry in vivo can 
provide a precise and accurate measurement of total body N, P, Na, Cl, 
Ca and K. From the measurement of these elements it is possible to 
determine total body protein, water and minerals. Total body protein 
(g) is derived by multiplying total body nitrogen (g) by 6.25. 
Extracellular water (ECW) is derived from total body chloride (TBCl), 
the major extracellular anion, using the formula : ECW (1) =0.9 [TB Cl 
(mmol)/plasma Cl (mmol/1)] (Cohn, 1981c). Intracellular water (ICW) is 
derived from total body potassium (TBK), the major intracellular 
anion, using the formula: ICW(l) = TBK (mmol)/161 (McR. Russell et
al., 1983). Finally, body mineral content is calculated from the sum 
of total body Na, K, Cl, Ca, P and a predicted value for mineral oxygen 
(I.C.R.P., 1975). Since lean body mass is the sum of body protein
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water and minerals, body fat can then be calculated by subtracting
lean body mass (Kg) from total body weight (Kg).
The body protein mass can be further divided into muscle and non 
muscle protein due to the different ratio of potassium to nitrogen in 
these two compartments. The concentration of potassium in relation to 
that of nitrogen in muscle is more than twice that in other lean
tissues. Therefore a low proportion of muscle in the body will be
reflected in a low ratio of total body potassium to total body 
nitrogen. Burkinshaw, Hill and Morgan (1978) summarized the mean 
values for the concentration of nitrogen and potassium in muscle and 
non-muscle lean tissue and derived the equations which were used to 
calculate the mass and protein contents of muscle and non-muscle lean 
tissues from total body nitrogen and potassium.
Summary and Conclusions
Neutron activation analysis and whole body gamma spectrometry in 
vivo can provide a precise and accurate measurement of total body N, P, 
Na, Cl, Ca and K. This non-destructive method of body composition 
analysis can be used in animals ranging from small rodents to man. 
These methods are used in Chapters 5 and 7 to estimate the nature of 
tissue loss in humans and rodents with cancer cachexia.
CHAPTER 5 65
Changes in body composition associated with 
cancer cachexia in humans
Introduction
Patients with cancer cachexia suffer from extensive body wasting 
and this is thought to contribute to patient morbidity and mortality 
(Warrenf 1932? Inagaki, 1974). However, neither the cause, mechanism 
or nature of tissue loss in cachectic cancer patients is clearly 
established (Caiman, 1982). One method of determining the nature of 
tissue loss in wasting disease is to measure changes in whole body 
composition. Until recently, indirect measurement of body composition 
was the chief source of such information (Moore et al, 1963). However, 
neutron activation and whole body gamma spectrometry can now provide 
direct measurements of body elements and thereby detailed quantifi­
cation of body composition (Cohn et al, 1981c).
Previous body composition studies have generally examined cancer 
patients with a weight loss of only 5 - 15% (Warnold, Lundholm and 
Schersten, 1978? Burke, Bryson and Kark, 1980? Cohn et al, 1981b). 
However, this is not representative of the severe weight loss observed 
in cancer cachexia. Furthermore, these studies have examined hetero­
genous groups of patients with various types and stages of malignant 
disease many of whom have already undergone different forms of therapy. 
As discussed previously it is unlikely that cancer cachexia is a single 
phenomenon or that the mechanisms of weight loss are specific to a 
tumour type (Costa and Donaldson, 1979? see also Chapter 1) • It is, 
therefore, improbable that the documented changes accurately charac­
terise tumour specific alterations in body composition.
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The aim of this study was to determine the alterations in body 
composition which occur in non-small-cell lung cancer patients with 
severe weight loss (> 25% loss of pre-illness stable weight). Patients 
with this type .of tumour were chosen because of the high incidence of 
lung cancer in the general population and the fact that weight loss is 
the major predictive factor of poor survival in this disease (Lanzotti 
et al, 1977). Moreover, lung cancer does not primarily involve the 
gastrointestinal tract and many patients do not receive conventional 
therapy except for palliation of symptoms. Lung cancer patients, 
therefore, form an important, uniform group whose nutritional and 
metabolic status is primarily altered by direct tumour effects and not 
by gastrointestinal malfunction or antineoplastic therapy.
Probably the best method to study the effects of cancer cachexia on 
body composition would be to make sequential measurements on the same 
individuals throughout the natural course of their disease. 
Unfortunately, sequential measurements in cancer patients are difficult 
because it is impossible at present to predict who will lose weight 
and who will not. Moreover, the natural course of the disease is 
modified by the effects of surgery, chemotherapy or radiotherapy 
(Kokal, 1985), and patients are often lost to follow up due to a 
sudden deterioration in their condition. An alternative approach 
would be to compare the body composition of cancer patients who were 
already cachectic with that of weight stable controls who had been 
matched for the pre-illness weight of the cancer patients. 
Unfortunately, many patients do not know their usual stable weight. 
Therefore, the main error in this approach is the validity of the 
patients pre-illness stable weight.
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In this study the nature and extent of tissue loss in a group of 
six cachectic lung cancer patients was determined by comparing their 
body composition with that of a reference population who had been 
matched for the age, sex, height and pre-illness stable weight of the 
cancer patients. To ensure the validity of the cancer patient's 
pre-illness stable weight only patients who had been weight stable at 
their first clinic visit, had had their weight checked at that visit, 
and who had subsequently lost weight were included in the study. To 
improve the quality of the comparison, four control subjects were 
matched with each of the cancer patients. A six compartment model 
consisting of total body fat, muscle protein, non muscle protein, 
intracellular water, extracellular water and body minerals was 
constructed from measurements of total body nitrogen, sodium, chloride, 
calcium, phosphorous and potassium. These elements were measured by 
neutron activation and whole body gamma spectrometry.
Patients and methods
Cancer patients: The six cancer patients had histologicaly proven 
non-small-cell bronchial carcinoma. Disease staging included clinical 
examination, chest X-ray, full blood count and biochemical liver 
function tests. All patients had advanced metastatic disease (Stage 
III, WHO grading system). Two had small unilateral pleural effusions. 
None had overt ascites or ankle oedema. No patient had undergone 
surgery, radiotherapy or chemotherapy in the two months prior to study. 
The study was approved by the local hospital ethical committee. All 
patients gave written, informed consent.
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The clinical details of the patients are shown in Table 5.1. 
There were 5 males and 1 female. Their mean age was 55 years. The 
mean weight of the cancer patients was 44.9 + 3.4Kg (mean + S.E.M.) 
which was 29% less than their pre-illness stable weight (63.3 + 4.9Kg).
Control subjects: The 24 control subjects were selected from a 
group of over 1000 patients with mild to moderate hypertension. These 
individuals had undergone body composition analysis as part of a 
routine diagnostic protocol. Four control patients were matched for 
the age, sex, height and pre-illness stable weight of each of the 
cancer patients. The mean value of each group of 4 controls was then 
compared with that of each cancer patient.
The clinical details of the control patients are shown in Table 
5.2. There was no significant difference between the age, sex, height 
and pre-illness stable weight of the controls compared with the cancer 
patients.
Nutritional and dietary assessment Serum albumin was measured on 
a commercial multichannel autoanalyser and urinary creatinine 
concentration was determined according to the modified method of Folin- 
Wu (Hawk, Oser and Summerson, 1947) . Dietary protein and energy 
intakes were assessed by 24 hour dietary recall histories. At the time 
of body composition analysis patients were interviewed by an oncology 
dietician and their food intake noted for the previous 24 hours. The 
data was analysed by computer using a programme devised by Tayside 
Health Board which gave the protein, carbohydrate and fat contents of 
the diet. Desirable energy and protein intakes were obtained from 
standard tables (Documenta Giegy, Scientific Tables, 1962).
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Body composition analysis Total body sodium, nitrogen, chloride, 
calcium, phosphorous and potassium were determined by neutron 
activation and whole body gamma spectrometry as described in Chapter 4. 
Total body fat,: muscle protein, non-muscle protein, extracellular 
water, intracellular water, and body minerals were derived as described 
on page 63.
Statistical analysis: Student's paired T-test was used to compare 
patient and control data.
Results
Nutritional state and dietary intakes; The mean serum albumin 
concentration of the lung cancer patients was 35% lower than that of 
the weight stable controls (28 + 2 cf 43 + lg/1 : P < 0.01, Table 5.3). 
Furthermore, daily urinary creatinine excretion was 69% lower in the 
lung cancer patients when compared with the controls (3.9 + 0.3 cf 12.7 
+ 1.3imnol/d; P < 0.01) . The mean daily energy intake of the cancer 
patients was 5.0MJ/day which was 48% of their desirable intake 
(10.3MJ/day ; P < 0.01? Table 5.4). Their mean protein intake was 52g 
protein/day which was 75% of the desirable intake (75g protein/d : P < 
0.01). The food intake of the control patients was not measured.
Body composition of cancer patients and controls: The total body
nitrogen, sodium, chloride, calcium, phosphorous and potassium of the 
cancer patients and the controls are shown in Table 5.5. The mean 
total body nitrogen of the cancer patients was 20% less than that of 
the controls (1413 + 82 cf 1737 + 121gN : P < 0.01). Furthermore, 
total body potassium was reduced by 33% (81 + 6 cf 121 + lOgK : P < 
0.01). There was no significant difference in total body sodium (78 + 8
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cf 75 + 5gNa : P > 0.1). Total body chloride was slightly but not 
significantly greater in the cancer patients when compared with the 
controls (70 + 9  cf 60 + 3 gCl ; P > 0.1) Total body calcium was 17%
less in the cancer patients compared with the controls (830 + 71 cf 995 
+_ 54 gCa : P < 0.05). However, although total body phosphorous was 9% 
lower in the cancer patients, this difference was not statistically 
significant (499 + 43 cf 550 + 29gP : P > 0.1).
The mass (Kg) of total body fat, muscle protein, non-muscle 
protein, intracellular water, extracellular water and minerals derived 
from the chemical composition of the cancer patients and the controls 
are shown in Table 5.6 and Figure 5.1. The total body fat of the cancer 
patients was 80% less than that of the controls (3.1 + 2.0 cf 17.3 + 
1.7Kg : P <0.01). Furthermore, muscle protein was reduced by 76% (0.7 
+0.3 cf 2.9 + 0.3Kg : P < 0.01). There was no sty'ifificant difference 
between the non muscle protein mass of the cancer patients and that of 
the controls (8.1 + 0.5 cf 8.0 + 0.4Kg : P > 0.1). Intracellular water 
was 30% lower in the cancer patients (12.9 + 0.9 cf 19.2 + 1.5Kg : P < 
0.01) but there was no significant difference in the mass of extra­
cellular water of the two groups (17.5 + 1.9 cf 15.1 + 0.7Kg : P > 
0.1). The total mineral mass of the cancer patients was 13% less than 
that of the controls (2.6 + 0.2 cf 3.0 + 0.2Kg : P < 0.05). The lean 
body mass (body protein, water and mineral content) was also 13% lower 
in the cancer patients when compared with the controls (41.8 + 3.1 cf 
48.1 + 3.0Kg : P < 0.01).
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Controls Cancer
Kg
70
60
50
40
30
20
10
Fat 17.3
Non Muscle 
Protein
8.0
Muscle Protein 2.9
Intracellular
Water
19.2
Extracellular
Water
15.1
Minerals 3.0
LBM 
( < 0.02)
X n:6 )
Fat 3.1
Non Muscle 
Protein 8.1
Muscle Protein 0.7 |
Intracellular
Water
12.9
Extracellular
Water 17.5
Minerals 2.6
( n:6 )
Figure 5.1 Changes in body composition associated with 
development of cancer cachexia in a group of patients (n = 
6) with non-small cell bronchial carcinoma. Neutron 
activation body composition analysis was carried out on a 
group of cachectic lung cancer patients and these were 
compared with a group of healthy individuals who were 
matched for the age, sex and pre-illness stable weight of 
the cancer patients.
P
< 0.001
NS
<0.001
< 0.001
NS
< 0.02
Discussion 71
This study demonstrates clearly that the body composition of 
cachectic cancer patients is significantly different from that of 
healthy controls. There was a greater than 80% reduction of body fat 
and a 13% reduction of lean body mass in a group of cachectic lung
cancer patients who had lost 29% of their pre-illness stable weight.
Fat is the major energy reserve in the body. Under normal 
circumstances when there is an imbalance between energy intake and 
expenditure the principal body fuel used to correct the deficit is body 
fat. The fat mass of the cancer patients was 14.2Kg less than that of 
the weight stable controls (Table 5.6). The energy value of lKg of fat 
is approximately 38MJ. Therefore, to account for the loss of body fat, 
the total energy def icit of the cancer patients must have been in
excess of 532MJ. Since weight loss had occurred over a period of nine 
months this suggests an average energy deficit of 2MJ/day.
At the time of study the energy intake of the cancer patients was 5MJ 
less than predicted requirements (Table 5.4). As discussed elsewhere,
the measurement of food intake is at best an approximation (Chapter 7;
see also Acheson et al., 1980). Nevertheless, a food intake 50% 
less than predicted requirements would clearly be a major contributing 
factor to a negative energy balance and to weight loss. However, it 
cannot be determined whether this reduced food intake was the cause or 
the result of the cachectic process. The lethargy, depression, lack of 
mobility and metabolic abnormalities present in cachectic cancer 
patients may well contribute to anorexia (Caiman, 1982). However, the 
energy deficit of the cancer patients may have been due to an
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increased energy expenditure. This mechanism of weight loss is 
discussed further in Chapter 6.
The protein intake of the cancer patients was reduced by 25% 
whereas energy intake was reduced by 50% (Table 5.4). This relative 
preservation of protein intake has been observed in other studies of 
weight losing cancer patients (Cohn et al., 1981b; Burke, Bryson and 
Kark, 1980). Whether this contributes to the pattern of altered body 
composition in cachexia is not known.
The total body nitrogen of the cachectic cancer patients was 19% 
less than that of the weight stable controls (Table 5.5). In contrast, 
total body potassium was reduced by more than 33% (Table 5.5). Because 
muscle has a higher potassium concentration in relation to its protein 
content than other tissues of the lean body (Burkinshaw, Hill and 
Morgan, 1978) it is possible to explain this differential loss of 
potassium by a 76% reduction of muscle protein mass (Table 5.6). An 
alternative explanation is that there was a general reduction in 
intracellular potassium and that the overall reduction was not 
specifically related to loss of potassium rich muscle. However, normal 
intracellular concentrations of potassium have been demonstrated in the 
skeletal muscle of both wasted cancer (Symreng, Larrson and Moller, 
1985) and non cancer patients (King et al., 1978) and this would tend 
to suggest that body wasting is not associated with a generalised 
reduction of body potassium.
Another explanation for the differential loss of potassium is 
that the patients had lost protein predominantly from the cellular 
compartment, leaving a relatively high proportion of potassium free
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yet nitrogen rich extracellular collagen (James et al., 1984). 
However, 24h urinary creatinine has been shown to be closely related to 
body muscle mass (Heymsfield et al., 1983). Therefore, the 69% 
reduction of urinary creatinine excretion by the cancer patients (Table 
5.3) would support the suggestion that there had been a severe loss of 
muscle mass.
The cause of such muscle wasting in cancer cachexia is unknown. 
Clearly, the reduced energy and protein intake of the cancer patients 
(Table 5.4) may have contributed. However, it has been postulated that 
cancer may specifically reduce the rate of protein synthesis in the 
skeletal muscle of cachectic patients (Emery et al., 1984a). Whatever 
the cause, the clinical significance is more obvious. A loss of 75% of 
body muscle protein would account for the immobility of cachectic 
patients and would clearly contribute to reduced pulmonary ventilation 
and the development of fatal pneumonia.
In contrast to simple starvation the non-muscle protein mass of 
the cachectic patients was not significantly different from that of the 
healthy controls (Table 5.6). Moreover, the lean body mass was reduced 
by only 13% (Table 5.6). It has been suggested that the relative 
preservation of lean tissue (Watson and Sammon, 1980) or more particu­
larly of non-muscle lean tissue (Cohn et al., 1981c) in cancer cachexia 
may be due to an increased water content of the non-fat mass, the mass 
of the tumour, the failure of atrophy of visceral organs, or a 
combination of all three (Heymsfield and McManus, 1985). The results 
of this study show that the intracellular water space of the cancer 
patients was reduced whilst the extracellular water space was 
unchanged (Table 5.6). Furthermore, tumour weight rarely exceeds 1 -
2Kg (Heymsfield and McManus, 1985). Therefore, the most likely expla­
nation for preservation of non-muscle nitrogen would be maintenance of 
visceral organ mass. This has been documented repeatedly in animal 
models of cancer cachexia (Yeakel, 1948; Begg and Dickenson, 1951; 
Morgan and Cameron, 1973) and more recently has been confirmed in 
humans (Heymsfield and McManus, 1985). The reason for the maintenance 
of such organs as the liver or spleen are unknown. Increased hepatic 
protein synthesis has been described in tumour bearing animals and man 
and it may be that chronic immunological activation with hepatic 
synthesis of acute phase proteins is a contributory factor (Lundholm et 
al., 1978; Lundholm et al., 1979). This possibility is discussed 
further in Chapter 6.
The body mineral content of the cachectic cancer patients was 
reduced by about 10% (Table 5.6). This was principally due to a 17% 
reduction in total body calcium (Table 5.5). Since 99% of body calcium 
is contained in bone, this suggests a reduction of bone mineral mass. 
The reduced skeletal muscle mass of these patients may have contributed 
to bone loss since lack of mobility would lead to disuse atrophy.
Summary and Conclusions 75
A group of cachectic lung cancer patients who had lost 29% of 
their pre-illness stable weight were shown to have lost more than 80% 
of their body fat and 20% of body protein. The protein loss was 
accounted for by a 75% reduction of muscle protein mass. Non-muscle 
protein mass was not affected. This distinguishes cancer cachexia from 
simple starvation. The mobilization of body fat was sufficient to 
account for a mean daily negative energy balance of 2MJ/d and loss of 
body protein indicated a daily negative nitrogen balance of 1.2gN/d. At 
the time of study daily energy intake was 5MJ/d less than expected and 
daily nitrogen intake was 2.7gN/d less than expected. These results 
suggest that a reduced food intake may be a major contributary factor 
to the altered body composition of lung cancer patients.
CHAPTER 6 76
The relationship between protein turnover, resting energy
expenditure and weight loss in patients with and without
cancer
Introduction
Weight loss is most commonly due to a negative energy balance. 
In cancer patients this could be the result of a decreased food intake, 
an increased energy expenditure, or a combination of these two. In 
Chapter 5 it was shown that a reduced food intake was probably a major 
contributing factor to the continuing protein and energy deficit of 
cachectic lung cancer patients. This would tend to confirm that when 
anorexia is present a decreased food intake is probably the major cause 
of weight loss (Morrison, 1976). However, neither the incidence nor the 
possible mechanisms of an increased energy expenditure in cancer 
patients are known (Caiman, 1982).
Whole body protein turnover has been estimated to account for
between ten and twenty percent of basal energy expenditure in man 
(Reeds, Fuller and Nicholson, 1985). A reduction in the rate of 
protein turnover is thought to be one of the main methods of energy
conservation during periods of reduced food intake (Waterlow, 1981).
It has been suggested that this adaptive mechanism might be impaired in 
patients with malignant disease (Brennan, 1981) and this possibility is 
supported by observations that in some cancer patients the rate of 
.whole body protein turnover is elevated above normal (Heber et al., 
1982; Jeevanandam et al., 1984; Eden et al., 1984). Thus the energy 
expenditure of the cancer bearing host might be abnormally high; a 
situation which could either initiate or worsen a negative energy 
balance.
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Proteins play a crucial role in virtually all biological
processes such as enzymatic catalysis, transport and storage, 
mechanical support and the control of growth and differentiation 
(Stryer, 1975). In the body, proteins can undergo subtle changes and
as the ordered structure of these molecules is critical to their 
biological function, there is a persistent need for their resynthesis
(Reeds, Fuller and Nicholson, 1985).
The continual turnover of protein in the body has several
biological advantages. When protein is continually being broken down 
and resynthesized a small change in either the rate of synthesis or 
degradation can lead to a substantial change in the amount of that 
protein. If this protein is a rate limiting enzyme then such protein 
turnover provides a sensitive mechanism for metabolic regulation. 
Furthermore, rapid protein turnover enables a limited protein pool to 
be used with optimal efficiency.
However, protein synthesis is a process which requires energy and 
some energy may be used in the hydrolysis of peptide bonds when protein 
is broken down (Water low, Gar lick and Millward, 1978). Moreover, the 
reutilization of amino acids is not completely efficient (Waterlow and 
Stephen, 1966). Thus a state of dynamic protein flux is expensive in 
terms of energy and to a lesser extent, amino acids.
Not all workers have shown that whole body protein turnover is 
increased in patients with cancer (Glass, Fern and Garlick, 1983; Emery 
et al., 1984a). These contradictory results might be explained by the 
small size and heterogeneity of the groups of patients examined. In 
addition, few studies have described whole body protein turnover and 
resting energy expenditure measurments made in the same individuals.
78
One possible cause of an increased rate of whole body protein 
turnover in cancer patients might be the production of inflammatory 
mediators in response to neoplasia. The acute phase protein response 
is a characteristic alteration in the serum concentration of certain 
circulatory proteins which usually accompanies the body's inflammatory 
response to injury (Pepys and Baltz, 1983). Such an acute phase 
protein response can be demonstrated in the majority of individuals 
with progressive neoplasia (Cooper and Stone, 1979; Raynes and Cooper, 
1983). Furthermore, in patients with trauma or sepsis there is often 
a marked acute phase response (Pepys and Baltz, 1983) and this is 
associated with an increase in whole body protein turnover (Kinney and 
Elwin, 1983).
Thus, the aim of this study was to determine whether rates of whole 
bodt protein turnover are increased in patients with cancer and, if so 
whether they are associated with an increased resting energy expen­
diture and hence weight loss. Whole body protein turnover and resting 
energy expenditure were measured simultaneously in both weight stable 
and weight losing patients who had either colorectal cancer or non- 
small-cell bronchial cancer. These results were compared with those 
from both weight stable and weight losing non-cancer patients. In 
addition, rates of whole body protein turnover in cancer patents with 
an acute phase protein response were compared with those from patients 
not showing an acute phase response, in order to determine whether an 
abnormal protein metabolism in patients with cancer is associated with 
an inflammatory response.
Methods 79
The percentage weight change from pre-illness stable weight was 
used to divide patients into weight stable (< 5% weight loss) or weight 
losing groups (> 5% weight loss). This arbitrary division was used to 
separate those in energy balance from those with a negative energy 
balance.
Lung cancer patients: Twenty patients with histologically proven,
inoperable, non-small cell bronchial carcinoma who were either 
untreated or who had not undergone antineoplastic therapy within the 
previous two months underwent standard staging procedures. Investi­
gations included clinical examination, chest X-ray, bone scan, and 
hepatic ultrasound or isotope scan. Nine were shown to have stage 2 
disease and eleven stage 3 disease according to the WHO classification. 
Eight were weight stable and twelve were weight losing. Of the weight 
stable group five had stage 2 disease and three had stage 3 disease. 
In the weight losing group there were four with stage 2 disease and 
eight with stage 3 disease.
Colon cancer patients: Thirty eight patients with newly diagnosed
colorectal carcinoma were all studied prior to laparotomy when 
histological confirmation and staging according to Dukes' classi­
fication was carried out. Sixteen patients had stage B disease, 11 
stage C and 10 stage D. Seventeen were weight stable and 21 weight 
losing. Of the seventeen weight stable patients, 10 were stage B, 4 
stage C and 3 stage D. Of the 21 weight losing patients, 7 were stage 
B, 7 stage C and 7 stage D.
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Non-cancer patients; Twenty two patients with various non-neoplastic 
disease who had been admitted to a surgical ward for routine investi- 
gations were used as a control group. Eight were^stable, and 14 were 
weight losing. The diagnosis of the 8 weight stable individuals were 4 
benign polyp of the colon, 2 duodenal ulcer disease, 1 cholelithiasis 
and 1 benign stricture of the large intestine. The diagnosis of the 14 
weight losing individuals were 6 duodenal ulcer, 2 cholelithiasis, 2 
benign strictures of the small intestine, 2 spastic bowel syndrome, 2 
benign polyps of colon and 1 caecal diverticulum.
All patients were of performance status 2 or better (World Health 
Organization Performance Score), had normal adrenal and thyroid func­
tions tests, and were clinically judged to be free of other metabolic 
or endocrine disorders. None were pyrexial, had clinical or radio­
logical evidence of infection, were receiving steroids or were severely 
anaemic.
All patients had a normal serum urea and creatinine and although 
some patients with hepatic metastases had abnormal liver function 
tests, none had a bilirubin concentration outside the normal range (3 - 
18umol/l).
The study was approved by the local ethical committee. All 
patients were informed of the purpose and procedure of the study, and 
all gave informed consent.
Measurement of whole body protein turnover: Whole body protein turnover
was measured as described in Chapter 2. A primed continuous 24 hour 
15infusion of N-glycine was administered and the isotopic enrichment 
of urinary ammonia and urea was measured in urine collected during the 
second half of the infusion (12 - 24 hours).
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Enrichment of a sample taken at 24 hours was compared with that
from the 12 to 24 hour collection to ensure that isotopic equilibrium
had been achieved. No significant difference was detected between the 
15
N ennchement of the integrated 12 - 24 hour sample and that of the 
sample taken at 24 hours for either urea or ammonia.
Rates of whole body protein turnover, synthesis and breakdown 
were calculated using the stochastic model of Picou and Taylor Roberts 
(1969) as described in Chapter 2. Since this study was performed with 
patients in the fasting state the rate of protein turnover was equal to 
the rate of protein breakdown.
Measurement of resting energy expenditure: Measurements of resting
energy expenditure were made by indirect calorimetry as described in 
Chapter 3.
Experimental design; Whole body protein turnover and resting energy
expenditure were measured simulatenously. On the day prior to study
patients ate a standard hospital diet. After an overnight fast,
patients remained in bed from the time of wakening. The baseline 
15enrichment of N in ammonia and urea was obtained from a urine
sample taken at 0800 hours. At 0900 hours, a primed, constant 24 hour 
. 1 5infusion of N-glycine was commenced. At this time, the patient’s 
head was positioned in the canopy of the indirect calorimeter. 
Following a 30 minute acclimatisation run there was a 10 minute break.
A 40 minute calorimetry run was then undertaken.
During the 24 hour infusion patients were allowed free access to 
water, but not to food. The priming dose and rate of infusion of 
-^N-glycine were ag described on page 47. During the infusion the
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urine was collected in two consecutive 12 hour periods. A further 
sample was obtained at the end of the 24 hour infusion.
Assessment of acute phase protein status: Serum C-reactive protein was
measured in all patients as a marker for the presence of an acute phase 
protein response (Pepys and Baltz, 1983). Serum taken at the time of 
the protein turnover study was stored at -80°C until analysis. 
C-reactive protein was measured by a standard radial immuno-diffusion 
technique using antisera and standards obtained from Behringwerke AG 
(Marburg, Lahn, West Germany) • The limit of detection of this assay is 
a C-reactive protein concentration of 5mg/l or less. An undetectable 
concentration of C-reactive protein was considered to indicate that 
there was no acute phase protein. A concentration of > 10mg/l was 
designated as a positive acute phase response (Cooper and Stone, 1979; 
Raynes and Cooper, 1983).
Statistical analysis: Results were tested for significance by a one way 
analysis of'variance. Individual experimental groups were compared 
with non-cancer controls using the method described by Dunnett (1955).
Results
Of the weight losing patients, those with lung cancer had lost 
significantly more weight (21%, P < 0.05) than either the colon cancer 
patients (14%) or the non-cancer patients (14%) (Table 6.1). Hie mean 
duration of weight loss was similar for all groups. The serum albumin 
concentration was within the normal range for all patients except for 
the weight losing lung cancer patients where the concentration (32 + 
2g/l) was significantly less than that of the weight stable lung cancer 
patients (37 + lg/1 P < 0.05).
NON-CANCER 
WS* WL**
LUNG CANCER 
WS WL
COLON CANCER 
WS WL
Number 8 14 8 12 17 21
Age (yr) 59 + 4 58 + 5 62 + 4 58 + 4 65 + 2 64 + 3
Weight (Kg) 72 + 6 57 + 3 67 + 4 53 + 5 60 + 3 58 + 2
% weight loss 1 + 1 14 + 2 0 21 + 3 1 + 1 14 + 2
Duration of
weight loss (m) 1 + 1 6 + 1 0 7 ± 1 1 + 1 6 + 1
Albumin 40 + 1 38 + 1 37 + 2 32 + 2 38 + 2 37 + 1
* WS ; Weight Stable 
** WL : Weight Losing
Table 6.1 Clinical details of patients undergoing measurement of whole 
body protein turnover and resting energy expenditure.
Values are mean + SEM.
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Whole body protein synthesis rates; The rates of whole body protein 
synthesis and degradation of weight stable and weight losing lung 
cancer, colon cancer and non-cancer patients are shown in Table 
6.2. When the isotopic enrichment of urinary ammonia was used to 
calculate rates of protein synthesis the mean rate in all groups of 
cancer patients was at least 75% greater than that of weight stable 
non-cancer controls (P < 0.05). However, although the mean rate of 
protein synthesis in weight losing non-cancer patients was greater than 
that of weight stable controls this difference was not statistically 
significant (P > 0.05). Weight stable and weight losing lung cancer 
patients had slightly, but not significantly, higher mean rates of 
protein synthesis compared with weight stable and weight losing colon 
cancer patients (31% and 16% respectively). Protein synthesis rates 
based on the isotopic enrichment of urinary urea were between 25 and 
52% greater than those calculated from the isotopic enrichment of 
urinary ammonia. However, the overall pattern of results was-similar 
to that obtained with ammonia.
Whole body protein degradation rates: The rates of protein degradation 
(equivalent to protein turnover : for explanation see Materials and 
Methods) were all greater than the corresponding rates of protein 
synthesis since measurements were made with patients in the post 
absorptive state (Table 6.2). The mean rates of protein degradation, 
based on the isotopic enrichment of urinary ammonia, for all groups of 
cancer patients were more than 60% greater than those of the weight 
stable non-cancer controls (P < 0.05). However, although the mean rate 
of protein degradation in weight losing non-cancer patients was greater 
than that of weight stable controls this difference was not 
statistically significant (P > 0.05).
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Protein degradation was slightly, but not significantly, higher in 
weight stable and weight losing lung cancer patients compared with 
weight stable and weight losing colon patients (27% and 18% 
respectively). The mean rates of protein degradation were 16% - 30% 
higher when calculated from the isotopic enrichment of urinary urea, 
but the pattern of results was similar to that obtained with urinary 
ammonia.
Resting energy expenditure; Table 6.3 shows the rates of resting energy 
expenditure and whole body protein turnover expressed with reference to 
the patients* lean body mass. There were no significant differences 
between the rates of resting energy expenditure of the weight stable 
non-cancer controls and any of the groups examined. The mean rate of 
whole body protein turnover was significantly greater in lung cancer 
patients (P < 0.05) but not in colon cancer patients or weight losing 
non-cancer patients when compared with the weight stable controls. 
There was no correlation between individual rates of whole body protein 
turnover and rates of resting energy expenditure (Figure 6.1). More­
over, there was no correlation between individual rates of protein 
turnover and the severity of patients* weight loss (Figure 6.2) .
Acute phase protein response
An acute phase protein response was detected in the majority of 
cancer patients (41/58). However, there were no statistically signi­
ficant differences in the rates of whole body protein synthesis or 
turnover between those with or without an acute phase protein reaction 
(Table 6.4).
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Figure 6.1 Whole body protein turnover plotted against 
resting energy expenditure in cancer patients (weight stable 
: # , weight losing: O  )* and non-cancer patients (weight 
stable: ■ , weight losing: □ ). Whole body protein turn­
over was calculated from the isotopic enrichment of urinary 
urea and both variables are expressed with reference to the 
patients lean body mass.
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Figure 6.2 Whole body protein turnover of cancer and non­
cancer patients plotted against percentage weight loss (For 
key see Figure 6.1).
oo
Acute Phase Protein Response 
n
-ve (CRP<5mg/l) +ve (CRP>10mg/l)
17 41
Whole Body Protein
Synthesis (gP/Kg/d) 4,02+0.39 4.88+0.30
Whole Body Protein
Degradation (gP/Kg/d) 4.49+0.41 5.41+0.31
Table 6.4 Whole body protein kinetics of cancer patients with or
without an acute phase protein response. An acute phase 
protein response was defined as a concentration of 
C-reactive protein > 10mg/l in the patients serum.
Values are mean + SEM.
Discussion 85
The results of this study demonstrate clearly that patients with 
lung or colon cancer, whether weight stable or weight losing, tend to 
have an elevated rate of whole body protein turnover. When whole body 
protein turnover was expressed with reference to total body weight
patients with either lung or colorectal cancer had turnover rates which 
were 50 - 70% higher compared with weight stable non-cancer controls (P 
< 0.05). These elevated rates of whole body protein turnover were not 
related to altered body composition since the rate of turnover was
increased in both weight stable and weight losing cancer patients.
When whole body protein turnover was expressed with reference to lean 
body mass the mean rate in patients with lung cancer was significantly 
greater than that of weight stable non-cancer controls (P < 0.05).
However, although the mean rate in colon cancer patients was
approximately 50% higher than weight stable non-cancer controls, this
difference was not significant (0.1 < P > 0.05). This suggests that
there was a greater elevation of protein turnover in lung cancer
patients when compared with colon cancer patients. A higher rate of 
protein turnover in the lung cancer group might have been due to a 
greater proportion of lung cancer patients having advanced disease.
It has been suggested that elevated whole body protein turnover 
may increase the cancer patient*s energy expenditure and thus initiate 
or worsen a negative energy balance (Eden et al., 1984). In this study 
there was no difference between the rates of resting energy expenditure 
of cancer patients and that of the weight stable non-cancer controls 
(Table 6.3). Furthermore, there was no correlation between the rates'
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of whole body protein turnover and resting energy expenditure for any 
of the patient groups examined (Figure 6.1). Thus, although patients 
with malignant disease had an elevated rate of whole body protein 
turnover, this wa.s not associated with a detectable increase in their 
resting energy expenditure.
An elevated rate of whole body protein turnover was observed in 
all cancer patients, yet only a proportion lost weight. Therefore, the 
suggestion that cancer patients lose weight because of an increase rate 
of resting energy expenditure or whole body protein turnover 
(Jeevanadam et al., 1984) must be an oversimplification.
The weight stable cancer patients had significantly higher rates 
of whole body protein turnover than the weight stable non-cancer 
controls (Table 6.2). This increase occurred in the absence of trauma 
or sepsis, the two main pathological states normally associated with 
increased whole body protein flux (Kinney and Elwyn, 1983). The rate 
of protein synthesis in human tumours is approximately the same as that 
in the tissue of origin (Stein et al., 1982b), and human neoplasms 
rarely exceed 1% of body mass (Stein, 1982a). Thus, it is unlikely 
that protein synthesis within the tumour itself could have caused the 
observed increase in whole body protein turnover. It was decided, 
therefore, to investigate whether an inflammatory response by the host 
might be contributing to accelerated protein flux.
The majority of cancer patients in this study had a positive 
acute phase protein reaction (Table 6.4). Although the turnover rates 
in cancer patients with an acute phase protein response were 20%
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greater than in those with no response this difference was not 
significant. However, the possibility that the immune response of the 
host may participate in the production of some of the metabolic 
abnormalities of the cancer host is worthy of further investigation.
The rate of protein turnover has been shown to decrease during 
uncomplicated starvation (Jeevanandam, 1984; Rose et al., 1983) and it 
has been proposed that this may be a mechanism of energy conservation. 
Since anorexia and the associated decreased food intake is a major 
cause of weight loss in cancer patients (Morrison, 1976; see also 
Chapter 5) it might be expected that protein turnover should decrease 
with increasing weight loss. The results of this study indicate that 
in patients with either lung or colorectal cancer there is no corre­
lation between whole body protein turnover and weight loss (Figure
6.2). This emphasises the contrast between the metabolism of simple 
starvation and that of cancer cachexia.
It is possible that a small rise in resting energy expenditure 
did occur in the cancer patients, but that this was not detected by the 
methods that were used. From stoichiometry it can be estimated that 
the minimum energy required for the synthesis of a gram of protein is 
about 3.6KJ (Reeds, Fuller and Nicholson, 1985). Using the isotopic 
enrichment of urinary urea to calculate rates of protein synthesis, the 
mean rate of protein synthesis for all cancer patients was 4.6gP/Kg/d 
compared with 2.7gP/Kg/d for controls. This represents an increase of 
1.9gP/Kg/d. Since the weight of the patients was about 60Kg, the 
cancer patients were synthesising an extra 114g of protein per day. 
This extra protein synthesis would require the expenditure of 410KJ 
which represents less than 8% of the patients' mean resting energy 
expenditure. A change of this magnitude would be at the limit of
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detection of the method we used to measure resting energy expenditure 
(Chapter 3, page 51* ). Moreover, resting energy expenditure can vary 
between normal individuals by up to 50% (Garrow, 1985). Thus, if the 
above minumum estimates for the energy cost of protein synthesis are 
correct, we would probably not have detected the expected increase in 
resting energy expenditure. Nevertheless, an increase of energy 
expenditure of this amount lasting a period of months would be highly, 
significant in terms of a patient's cumulative energy deficit.
That the methods which were used were unable to detect a small 
rise in resting energy expenditure is one way to explain why the 
resting energy expenditure of the cancer patients was apparently not 
affected by an increased rate of whole body protein turnover. An 
alternative explanation could be that since resting energy expenditure 
is the sum of all energy dependent processes in the resting, post 
absorptive individual, other energy requiring processes were reduced to 
compensate for the energy cost of increased protein turnover. It is 
also possible that although the patients with cancer had an elevated 
rate of tracer flux, this might represent regional changes in protein 
turnover rather than a uniformly elevated rate of protein turnover in 
the whole body. It has been demonstrated that protein synthesis can be 
depressed in skeletal muscle and elevated in the liver of both patients 
and animals with cancer cachexia (Emery et al., 1984; Lundholm et al., 
1978). Furthermore, the efficiency of energy conservation and of 
protein synthesis may vary from one tissue to another. Thus, because 
whole body protein turnover and resting energy expenditure are 
measurements derived from all tissues of the body it would be wrong to 
assume that these two variables should necessarily change in parallel.
Summary and Conclusions 89
The hypothesis that cancer patients have an elevated rate of 
whole body protein turnover and that this leads to an increase in 
resting energy expenditure and to weight loss was examined. Rates of 
whole body protein turnover and resting energy expenditure were 
measured simultaneously in weight stable and weight losing patients 
with lung (n = 20) or colorectal cancer (n = 38) and these were 
compared with weight stable and weight losing non-cancer controls (n - 
22).
The cancer patients synthesised on average 1.9gP/Kg/d more 
protein than the weight stable controls. However, the resting energy 
expenditure of cancer patients was not significantly greater than that 
of the non-cancer controls. Moreover, there was no correlation between 
individual rates of whole body protein turnover and resting energy 
expenditure or weight loss.
Thus, although cancer patients had rates of whole body protein 
turnover which were 50 - 70% greater than controls, this was not 
associated with an increased energy expenditure, and it did not 
necessarily lead to weight loss. The assumption that elevation of whole 
body protein turnover or resting energy expenditure causes weight loss 
in cancer patients must be an over simplification. The nature of the 
negative energy balance in these patients remains to be determined.
CHAPTER 7 90
Mechanisms of weight loss in two contrasting rodent models of
cancer cachexia
Introduction
The mechanisms of weight loss in cancer cachexia are not clearly 
understood. For some patients the primary phenomenon is a lack of food 
intake (Morrison, 1976; see also Chapter 5). In contrast, other 
patients may have an adequate energy and protein supply with no
apparent intestinal malfunction and yet continue to lose weight (Heber, 
Byerly and Chlebowski, 1985). Certain abnormalities of protein, fat and 
carbohydrate metabolism and an increased energy expenditure have been 
proposed to account for such weight loss (Brennan , 1977; Lawson
et al., 1982). However, it is not known whether the metabolic 
abnormalities described in cachectic cancer patients are the cause or 
the result of their cachexia. Furthermore, accurate documentation of 
food intake in humans is extremely difficult (Acheson et al., 1980).
Thus, it is often impossible to determine what contribution any
metabolic abnormality has made to a patient's negative energy or 
protein balance. Numerous different factors may contribute to weight 
loss in each cancer patient and each of these factors may act 
to a variable degree from one patient to another. Thus, obtaining a 
uniform group of patients in which to evaluate a particular mechanism 
of weight loss is extremely difficult. Moreover, investigation of 
human cachexia is severely limited by ethical considerations.
These problems have prompted the search for an appropriate animal 
model of human cachexia. Unfortunately most models involve rodent 
tumours with doubling intervals between 12 - 48 hours, where signs of
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cachexia develop only when the tumour reaches 30 - 40% of total body 
weight (Begg and Dickinson, 1951; Recheigl, Grantham, and Greenfield, 
1961). In contrast, human tumours grow much more slowly and tumour 
burden rarely exceeds 5% of body weight (Heymsfield and McManus, 1985) • 
It is therefore not surprising that animal models have, as yet, proven 
to be of limited value in the investigation of human cachexia (Lundholm 
et al., 1978).
The Walker 256 carcinosarcoma has a doubling interval of about 36 
hours when grown in Sprague - Dawley rats and can reach 20% of host 
body weight before causing significant weight loss (Begg and Dickinson, 
1951). The lat&r stage of tumour growth is also associated with 
marked anorexia (Guaitani et al., 1982). Alternatively, the MAC-16 is 
a recently described, slow growing, transplantable adenocarcinoma of 
the colon which produces weight loss in syngeneic mice when tumour size 
is less than 3% of host weight (Tisdale, Brennan and Fearon, 1985). On 
this basis the MAC-16 tumour might be a more representative model of 
human cachexia. Moreover, the mechanisms of weight loss in this model 
might give valuable insight into that of humans with cancer.
The present study was undertaken to determine the mechanisms of 
weight loss in rats bearing the Walker 256 carcinosarcoma. These 
results are compared with those obtained from a similar study carried 
out on mice bearing the MAC-16 adenocarcinoma. Body composition 
analysis was performed in both models in order to determine the nature 
of host tissue loss and the contribution of the tumour mass itself to 
host wasting. This study is described in Part 1.
When tumour mass represented 10% of the host, the body 
composition and weight of rats bearing the Walker 256 tumour was
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unaltered except that there had been a transfer of protein and water
from the host to the tumour. However, in mice bearing the MAC-16
tumour neither the mass or composition of the tumour could account for 
host weight loss. This pattern resembles that observed in human
cachexia (see Chapter 5)• Therefore food intake and energy expenditure
were measured in mice bearing the MAC-16 tumour to determine whether a
decreased food intake, an increased energy expenditure or a combination
of the two was responsible for weight loss. As discussed in Chapter 6,
an elevated protein synthesis rate has been proposed to account for an
inappropriate energy expenditure in the cancer host. In order to
investigate this possibility rates of protein synthesis were determined
in the liver, kidney, heart and skeletal muscle of normal mice and mice
bearing the MAC-16 tumour. The results of these studies are presented
and discussed in Part 2.
Part 1. Changes in body composition of rats bearing the Walker 256 
tumour and of mice bearing the MAC-16 tumour.
Materials and Methods
Animals and Diet: Female Wistar rats and male NMRI mice aged between 8
- 10 weeks were maintained in conditions of controlled temperature and
lighting (21°C + 1°C, 12/12h light/dark cycle). Except where
stated in the text, animals were fed ad libitum on a standard diet (CRM 
diet, Labsure, Rank-Hovis-McDougal, Agricultural Division, Dorset, 
England). It contained 18.5% protein, 2.5% fat, 56% carbohydrate, 4.3% 
fibre, 2.4% minerals, 15.0% moisture and added vitamins and trace 
elements. The gross energy content of the diet was 14.8KJ/g.
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Tumours: The rapidly growing Walker 256 carcinosarcoma was obtained
from the Institute of Cancer Research, Sutton, Surrey and maintained by 
routine passage every 14 days in Wistar rats. The tumour arose 
spontaneously from the mammary pad of a pregnant female rat and has 
been passaged since 1928 in various non-syngeneic hosts (Fisher and 
Fisher, 1960)• The MAC-16 adenocarcinoma was obtained from Dr J. 
Double, Clinical Oncology Unit, University of Bradford. The tumour had 
been chemically induced in the colon of NMRI mice following prolonged 
administration of 1,2 dimethylhydrazine (Double and Ball, 1975). Viable 
tumour fragments (lOOmg) were transplanted subcutaneously into the 
right flank under aseptic conditions and light ether anaesthesia. The 
doubling time of the Walker tumour was 36 hours, whilst that of the 
MAC-16 tumour was 6 days.
Histology; Tissues for light microscopy were fixed in buffered 10% 
formalin and stained with haematoxylin and eosin. One mm cubes of 
tumour for electron microscopy were immediately fixed in a 2% solution 
of glutaraldehyde in Sarasens phosphate buffer. The samples were then 
treated with 2% osmium tetroxide and dehydrated with ethyl alcohol and 
propylene oxide. Tissues were embedded in araldite resin prior to 
sectioning for electron microscopy.
Body composition analysis: Total body nitrogen and phosphorous was
analysed by neutron activation analysis (See Chapter 4)• Induced 
radioactivity was measured in a modified clinical whole body monitor 
after bilateral iradiation with 14 MeV neutrons. The radiation dose 
equivalent was 116 mSv. This non-destructive procedure allows 
sequential measurements in vivo and compares well with chemical 
analysis (Preston et al., 1985). Total body water was measured by 
freeze-drying animal carcasses until constant weight. Water content 
was calculated from the difference between wet and dry weights.
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I^an body mass was assumed to consist of the sum of total body 
protein (N(g) x 6.25), water and minerals (P(g) x 6) (Preston et al., 
1985). Fat mass was obtained by subtraction of lean body mass (g) from 
total body weight (g).
Experimental Design
Walker 256 carcinosarcoma in rats: Body composition analysis was
performed in vivo on a group of rats (n = 6) immediately prior to 
implantation of the Walker 256 tumour. Fourteen days later animals 
were sacrificed, tumours were excised and weighed. Neutron activation 
analysis of both carcasses and tumours was then repeated. The water 
content of the carcasses and tumours was also measured.
MA.C-16 adenocarcinoma in mice: Two groups of NMRI mice were matched for 
body weight. One group (n = 6) underwent tumour inplantation and the 
other (n = 6) sham operation. Twenty four days later animals were 
sacrificed, tumours excised, weighed and body composition determined.
Statistical analysis: Where appropriate, Student’s T-test for paired or 
unpaired data was used to determine statistical significance.
Results
Histology
Walker 256 tumour: Light microscopy revealed the Walker 256 to be a 
very poorly differentiated tumour (plate 7.1). Large areas of 
haemorrhagic necrosis were associated with an inflammatory infiltrate. 
Cells were round or polygonal and were arranged in sheets. The nucleus
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to cytoplasm ratio was high and frequent mitotic figures, often with an 
abnormal configuration, were present.
Electron microscopy confirmed the loose arrangement of cells in 
sheets (Plate 7.2). Nuclei were large and frequently exhibited an 
irregular contour with invaginations. Nucleoli were large and often 
multiple. The cytoplasm contained relatively few organelles (Plate
7.3). Mitochondria were round or oval and had poorly organised cristae 
or were empty. The Golgi apparatus of the cells was not a praninant 
feature. Smooth and rough endoplasmic reticulum was scanty. Numerous 
cytoplasmic vacuoles were present. Apposition of cells appeared for 
the most part as a simple contact of cytoplasmic borders. No 
junctional complexes were observed.
MAC-16: Light microscopy revealed the MAC-16 to be a moderately well 
differentiated adenocarcinoma which developed a necrotic core as it 
enlarged (Plate 7.4). The tumour was associated with an intense 
inflammatory infiltrate which extended from the surrounding 
subcutaneous tissues into the necrotic core. Tumour cells were mostly 
arranged in acini (Plate 7.5), though in some areas little acinar 
differentiation was evident. Within an acinus, tumour cells had a 
columnar appearance. Large, round, vesicular nuclei with prom inant 
nucleoli were situated near the abluminal membrane. Numerous mitotic 
figures often with an abnormal configuration were present (Plate 7.5).
Electron microscopy again demonstrated the acinar arrangement of 
tumour cells (Plate 7.6). Nuclei were large and the nuclear chromatin 
was finely dispersed. Well developed nucleoli containing electron 
dense granules as well as vacuoles were present. The cytoplasm was 
densely packed with organelles (Plate 7.7). Mitochondria were round
Plate 7.1 Photomicrograph of Walker 256 tumour showing
pleomorphic tumour cells arranged in sheets. Poor 
cell to cell adhesion and extensive haemorrhage 
are features. (Magnification x 40).
Plate 7.2 Electronmicrograph of Walker 256 tumour showing 
loose arrangement of tumour cells, high nucleus 
to cytoplasm ratio and irregularity of nuclear 
membrane. (Magnification x 1820).
Plate 7.3 Electronmicrograph of Walker 256 tumour cell 
showing lack of intracellular organelles, 
numerous cytoplasmic vacuoles and poorly formed 
mitochondrial cristae. (Magnification x 6020).
• ' ■
Plate 7.4 Photomicrograph of MAC-16 tumour showing rim of 
viable tumour cells surrounding a necrotic core. 
An inflammatory infiltrate extends from the 
surrounding subcutaneous tissues into the 
necrotic core of the tumour. (Magnification x 4)
Plate 7. Photomicrograph of MAC-16 tumour showing acinar 
arrangement of columnar cells. Numerous mitotic 
figures are present. (Magnification x 40).
Plate 7.6 Electronmicrograph of MAC-16 tumour showing
acinar arrangement of tumour cells. The columnar 
shaped cells are closely apposed to each other and 
numerous junctional Complexes are present near the 
lumen of the acinus. (Magnification x 5040).
■>-.v  ■'
Plate 7.7 Electronmicrograph of MAC-16 tumour showing 
detail of mitochondria and Golgi apparatus. 
Mitochondria have well formed cristae. 
(Magnification x 17640).
Plate 7.8 Electronmicrograph of MAC-16 tumour showing the 
luminal surface of the tumour cells. The cells 
are joined by junctional complexes and on the 
luminal surface microvilli are present.
Numerous membrane bound vesicles are present 
just below the luminal surface. (Magnification 
x 28600).
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to ovoid and generally had * well formed cristae. However, in some 
sections the mitochondria were empty. Most cells had a well developed 
Golgi apparatus (Plate 7.7) and some rough endoplasmic reticulum. 
Numerous free ribosomes were scattered throughout the cytoplasm.
Each tumour cell was closely opposed to its neighbour and towards 
the lumen of the acinus cells were joined by junctional complexes (i.e. 
tight junctions and desmosomes ; Plate 7.8). Irregular microvilli were 
present on the luminal surface and, in some cells, numerous membrane 
bound vesicles were present in the subjacent cytoplasm (Plate 7.8).
Changes in body conposition of rats bearing the Walker 256 tumour: The
body composition of rats both before and 14 days after implantation of 
the Walker 256 tumour is shown in Figure 7.1. The total body weight 
(190.7 + 3.1 cf 190.5 + 6.1g : mean + s.e.m.), fat mass (21.8 + 0.9 cf
20.0 + 2.1g), mineral mass (8.3 + 0.2 cf 7.6 + 0.2g), protein mass 
(37.0 +0.6 cf 36.5 + 0.9g) and total body water (123.0 + 2.1 cf 126.4 
+3.9) before and after tumour growth were not significantly different. 
The tumour mass itself contained 3.3 + 0.2g protein, 18.5 + l.Og water 
and represented 10% of total body weight.
Changes in body composition of mice bearing the MAC-16 tumour: The body 
composition of mice bearing the MAC-16 tumour and of non-tumour bearing 
controls are shown in Figure 7.2. The mean weights of the two groups at 
the start of the study were not significantly different (35.5 +2.0 cf
36.0 + 1.2g). Twenty four days after tumour implantation, the tumour 
bearing mice had lost 13% of their total body weight and this was 
significantly reduced compared with controls (31.4 + 1.1 cf 36.3 + 2.0g 
: P < 0.02). Total body water (22.4 + 0.05 cf 24.1 + 0.5g) and mineral 
mass (1.0 + 0.1 cf 1.1 + O.lg) were not significantly decreased.
CONTROL TUMOUR BEARING
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Fat 2 1.8 Fat 2 0 . 0
Water (Tumour) l8 .5
Weight
(g>
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Figure 7.1 Changes in body composition of rats bearing the 
Walker 256 tumour. Neutron activation body composition 
analysis in vivo was performed before tumour implantation 
and repeated after 14 days when the animals were sacrificed.
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Figure 7.2 Changes in body composition of mice bearing the 
MAC-16 tumour. Two groups of six animals were matched for 
body weight. One group underwent tumour implantation and 
other sham operation. Twenty four days after tumour 
implantation both groups were sacrificed and body 
composition determined by neutron activation analysis.
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However, total body protein was reduced by 9% (6.0 + 0.1 cf 6.6 + 0.3g 
: P < 0.05). Tumour protein (0.35 + 0.05g) accounted for 5% of total 
body protein mass and total body fat was reduced by more than 55% (2.0 
+ 0.2 cf 4.6 + 0.4 : P < 0.01).
Discussion
The Walker 256 was a very poorly differentiated anaplastic 
tumour. There was no evidence of smooth muscle filaments, deposition of 
extracellular collagen or spindle cell formation. Therefore, the 
designation carcinosarcoma is probably invalid , and, as previously 
suggested (Fisher and Fisher, 1960), the tumour should be regarded as 
an epithelial malignancy. In contrast, the MAC-16 appeared to be
a well differentiated adenocarcinoma. The presence of junctional 
complexes confirmed the epithelial nature of the tumour. Furthermore, 
well developed mitochondria, a prominant Golgi apparatus and sublumenal 
membrane-bound vesicles confirmed the secterory nature of the cells.
The wasting associated with the early stages of growth of the 
Walker 256 tumour was almost entirely due to the transfer of nitrogen 
from the host to the tumour (Figure 7.1). This phenomenon has led 
previous investigators to suggest that the tumour acts as a 'nitrogen 
trap* for host amino acids (Mider, 1948). The mechanism whereby host 
protein is broken down to provide amino acids for tumour protein 
synthesis is unknown. However, in humans, cachexia can occur when the 
tumour is less than 1% of body weight (Morrison, 1976) and therefore 
'nitrogen trapping' by the tumour is unlikely to be an important 
mechanism of host weight loss. In contrast, the growth of the MAC-16 
tumour was associated with greater losses by the host than were gained 
by the tumour (Figure 7.2): a situation more in keeping with that
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observed in human cancer cachexia (see Chapter 5). The mechanisms of 
weight loss in this model might give a valuable insight into that of 
human cancer cachexia. Therefore, the food intake and energy and 
protein metabolism of mice bearing the MAC-16 tumour was studied to try 
and elucidate the mechanism of such excess weight loss.
Part 2: Energy balance and protein synthesis rates of mice bearing the
MAC-16 tumour.
Materials and Methods
Animals, diet and tumour: The MAC-16 tumour was implanted in male NMRI, 
mice as described on page 93. The diet of the animals was as described 
on page 92.
Estimation of daily Energy expenditure: Energy expenditure was
determined by indirect calorimetry. Rates of oxygen consumption and 
carbon dioxide production were measured in an open circuit, ventilated 
metabolism cage connected to a sensitive paramagnetic oxygen analyser 
and an infra-red carbon dioxide analyser. The system is described in 
detail in Chapter 3.
Estimation of protein synthesis rates in vivo: Mice were injected via a 
lateral tail vein with 1ml of phenylalanine (150mmol) which contained
L-[4- H]-phenylalalanine at a dose of lOOuCi/lOOg body weight. Ten 
minutes later animals were anaesthetised with diethyl ether and the
liver, heart, right kidney and right gastrocnemius muscle were
excised and rapidly frozen in liquid nitrogen. The fractional rate of 
protein synthesis was calculated from the ratio of the specific
radioactivities of free and protein-bound phenylalanine measured as
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described by Garlick and coworkers (1980) and outlined in Chapter 2. 
Tissue protein contents were estimated as the total ninhydrin positive 
material obtained after acid hydrolysis.
Experimental design
Energy expenditure and food intake of mice with MAC-16 tumour: Mice (n 
- 8) were housed individually in wire bottomed, perspex metabolism 
cages equipped with food and water resevoirs. Body weight was measured 
daily for one week to ensure a stable food intake and body weight 
before calorimetry. On the eighth day food intake, oxygen consumption 
and carbon dioxide production were measured over the following 24 
hours. Thereafter, tumours were implanted, the animals were maintained 
in the metabolism cages and on days 12, 19 and 26 measurements were 
repeated. Twenty seven days after tumour inplantation animals were 
sacrificed and tumours excised and weighed.
Protein synthesis rates in tissues of mice with MAC-16 tumour: Mice
were randomly assigned to two groups of 7 animals. One group underwent 
implantation of the MAC-16 tumour and the other sham operation. 
Twenty eight days later rates of protein synthesis rates were measured 
in the liver, kidney heart and gastrocnemius muscle of the animals. To 
compare the effect tumour growth with that of starvation a group of 
non-tumour bearing animals (n = 7) were deprived of food for 24 hours 
prior to measurement of protein synthesis.
Statistical analysis: Where appropriate, Student's T-test for paired 
or unpaired data was used to determine statistical significance.
Results 100
Weight loss, food intake and energy expenditure of mice bearing MAC-16 
tumour: The mean weights of mice before tumour implantation (day 0) and
at 12, 19 and 26 days thereafter are shown in Figure 7.3, The weight of
the mice was significantly reduced by the 12th day after tumour 
implantation (30.4+0.4 cf 31.0 + 0.5g : P < 0.001). Thereafter the 
weight of the mice decreased progressively until at 26 days it was
reduced by about 20% (24.8 + 0.4 cf 31.0 + 0.5g : P < 0.001). At 27
days the mice were sacrificed. Tumour weight was 2.6 + 0.4g which was 
10% of total body weight.
The food intake of the mice before and at 12, 19 and 26 days 
after tumour implantation are shown in Figure 7.4. Prior to tumour im­
plantation, the mean food intake of the mice was 4.6 + 0.3g/mouse/day. 
This was not significantly altered until the fourth week of the study 
when the mean daily food intake was reduced by 13% (4.0 + 0.3 cf 4.6 + 
0.3g; P < 0.02).
Rates of oxygen consumption, carbon dioxide production, the
respiratory quotient and energy expenditure before tumour implantation 
and at 12, 19 and 26 days thereafter are shown in Table 7.1. Compared
with the non tumour bearing state, oxygen consumption was the same
throughout the period of tumour growth (e.g. day 0 cf day 26 : 153 + 4 
cf 152 + 4 mmol C>2/mouse/24hr). There was a slight but not 
significant decrease in carbon dioxide production (145 + 4 cf 150 + 4 
mmol CO^/ mouse/24hr). Similarly, there was a trend towards a lower 
respiratory quotient (0.96+0.01 cf 0.98 + 0.01) but this difference 
was not statistically significant. There was no change in energy
expenditure associated with implantation and growth of the MAC-16 
tumour.
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Animal 
Weight
(g) 20
•P<0.001 I
§ Carcass
10
■j$r12 19
Time (days)
Figure 7.3 Effect of growth of MAC-16 tumour on body weight 
of male NMRI mice. Tumours were implanted on day 1.
Animals were killed and tumours excised and weighed on day 
26. Values are mean + SEM.
Food
Intake
(g/mouse) 4
Time (days)
Figure 7.4 Effect of growth of MAC-16 tumour on daily food 
intake of male NMRI mice. Tumours were implanted on day 1. 
Values are mean + SEM.
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Rates of Protein synthesis in tissues of mice bearing the MAG-16 
tumour: The fractional rate of protein synthesis in the liver, heart, 
skeletal muscle and kidney of normal and tumour bearing mice are shown 
in Table 7.2. There were no significant differences in rates of 
protein synthesis in the tissues of mice 28 days after tumour 
implantation compared with healthy controls. In contrast, after a 24h 
period of starvation rates of protein synthesis in non-tumour bearing 
mice were reduced in all tissues by 50%. The total protein content of 
the right gastrocnemius muscle was reduced by 33%, 28 days after 
inplantation of the MAC-16 tumour (97.3 + 9.6 cf 145.6 + 12.lpM/muscle 
n = 7: P < 0.01).
Discussion
Mice bearing the MAC-16 progressively lost weight so that 18 days 
after tumour implantation body weight was reduced by 10% (Figure 7.3). 
During this period, neither food intake (Figure 7.4) or energy 
expenditure (Table 7.1) changed measurably. If host weight loss had 
been entirely due to loss of adipose tissue (the most energy rich 
tissue of the body) the total energy deficit would have been 87KJ which 
would have required a daily energy deficit of -4.8KJ/d (= 7% of energy 
intake or expenditure). Since the coefficient of variation of daily 
food intake was 16% and that of daily energy expenditure was 8% it is 
possible that a sufficient change in either variable to account for the 
daily energy deficit could have occurred and would not have been 
detected. This would concur with the conclusions reached from the human 
data (see Chapter 6) • Alternatively, the efficiency of food digestion 
and intestinal absorption may have decreased so that the net energy 
available from food was reduced. Nevertheless, during the fourth week
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of tumour growth a negative energy balance was detected. This was due 
to a 13% reduction in food intake (Figure 7.4, P < 0.02) with no
alteration in energy expenditure (Table 7.1).
These results contrast with the findings of other studies on the 
nature of the negative energy balance in cachectic tumour bearing mice. 
Lindmark and coworkers (1983) demonstrated a fall in energy expenditure 
but an even greater fall in food intake in weight losing mice bearing a 
methylcholanthrene-induced transplantable sarcoma. In contrast, Brooks 
and colleagues (1981) demonstrated a rise in energy expenditure with no 
change in food intake in cachectic immune deprived mice bearing a human 
hypernephroma. It is therefore apparent that the nature of the 
imbalance between energy intake and expenditure varies from one model 
of cancer cachexia to another. Moreover, since the nature of this 
imbalance in humans is unknown and may, indeed, vary from one 
individual to another it is impossible to determine which system should 
be used to investigate the aetiology of human cancer cachexia.
In the present study the food intake of the tumour bearing mice 
decreased but energy expenditure remained at a constant level. This 
contrasts with the normal adaptive response to a moderate reduction of 
food intake where body composition is maintained by a compensatory 
reduction in energy expenditure (Cahill, 1970? Lindmark et al., 1984). 
Protein synthesis is an a energy dependent process which is thought to 
account for 10 - 20% of energy expenditure in rodents and in man 
(Reeds, Fuller and Nicholson, 1985). Moreover, a fall in protein 
turnover is thought to be one of the main mechanisms for energy 
conservation during starvation (Waterlow, 1981). Twenty eight days 
after implantation of the MAC-16, rates of protein synthesis in the 
liver, kidneys, heart and » skeletal muscle were the same in tumour
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bearing animals as in controls (Table 7.2). In contrast, non-tumour- 
bearing mice fasted for 24h showed a 50% reduction in protein synthesis 
in all tissues (Table 7.2). It is therefore possible that the failure 
to reduce energy expenditure in response to weight loss and a reduced 
food intake was due to the absence of an adaptive fall in rates of 
protein synthesis (see also Chapter 6).
Two previous studies have determined rates of protein synthesis 
in the tissues of cachectic tumour bearing mice by the same method as 
in the current investigation. Emery and coworkers (1984b) observed 
that immune deprived mice bearing the XKl human hypernephroma developed 
20% weight loss when the tumour reached 5% of host body weight. During 
weight loss, food intake was reduced by about 15% and rates of protein 
synthesis in skeletal muscle and liver were reduced by 70% and 40% 
respectively. In contrast, Pain and coworkers (1984) reported rates of 
protein synthesis to be unaltered in skeletal muscle but increased in 
the liver of mice bearing the Ehrlich ascites tumour. In the present 
study no change in protein synthesis rates were observed following 
tumour growth and the development of cachexia. Therefore, it is 
apparent that host protein metabolism shows a heterogeneous pattern of 
response to the development of cancer cachexia. Furthermore, that 
increased rates of protein synthesis are the major cause of an 
increased energy expenditure and negative energy balance in tumour 
bearing mice is clearly incorrect since in XKl tumour bearing mice 
energy expenditure is increased (Brooks et al., 1981) yet protein 
synthesis rates are markedly reduced (Emery et al., 1984).
Summary and Gonclusion 104
The mechanisms of weight loss were investigated in two rodent 
models of cancer cachexia. In rats bearing the Walker 256 tumour host 
weight loss wag entirely due to a transfer of protein and water from 
the host to the tumour. In contrast, mice bearing the MAC-16 
adenocarcinoma sustained greater protein and fat losses than were 
gained by the tumour.
The energy and protein metabolism of mice bearing the MAC-16 
tumour was studied to try and elucidate the mechanism of this excess 
weight loss. After 4 weeks of tumour growth a negative energy balance 
was detected due to a reduction in food intake with no change in energy 
expenditure. Rates of protein synthesis in the tissues of the mice 
were unchanged with tumour growth and weight loss. The failure of 
energy expenditure to adapt to a reduced food intake may have been due 
to the absence of an adaptive fall in rates of protein synthesis.
The pattern of changes in rates of food intake, energy 
expenditure and protein synthesis in mice bearing the MAC-16 tumour 
were different from those described in other murine models of cancer 
cachexia. This suggests a heterogenous mixture of metabolic 
abnormalities in cancer cachexia and may help to explain the difficulty 
in determining the causes of weight loss in humans with cancer 
cachexia.
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Effect of a host specific energy substrate on development of
cachexia in tumour bearing rats
Introduction
As discussed previously (Chapter 1) more than 80% of hospitalised 
cancer patients show evidence of protein-energy undernutrition (Nixon 
et al.f 1980) and cachexia is a major contributing factor to mortality 
in patients with malignant disease (Warren, 1932). Often, the side 
effects of ineffective antineoplastic therapy exacerbate the 
nutritional consequences of progressive tumour growth (Kokal, 1985). 
In an attempt to break this vicious circle, enteral and parenteral 
hyperalimentation have been extensively administered. The results of 
this approach have, however, been disappointing. Host reserves may 
only be partially restored (Nixon et al., 1981) and together with the 
dominance of progressive tumour growth this has meant that survival has 
not been prolonged (Brennan, 1981). This situation has encouraged the 
search for alternative methods with which to influence the host-tumour 
relationship.
One approach to this problem might be to maintain the host's 
energy supply in a form which cannot be used by the tumour. Tumour 
cells are known to have a high rate of glucose consumption, to show 
increased rates of anaerobic glycolysis, and to be susceptible to 
carbohydrate deprivation (see Demetrakopoulos & Brennan, 1982). 
Alternatively, many poorly differentiated tumours lack certain key 
mitochondrial enzymes and as a result have a greatly reduced ability to 
use fat or ketone bodies for energy production (Cederbaum & Rubin, 
1976? Tisdale & Brennan, 1983).
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Thus it has been proposed that ketone bodies might be administered as a 
"host specific" energy substrate (Tisdale & Brennan, 1983).
During starvation mobilization of free fatty acids from adipose 
tissue provides a source of energy for organs such as muscle or liver. 
Excess free fatty acids are converted to ketone bodies (acetoacetate 
and 3-hydroxybutyrate) in the liver and these serve as a source of 
energy for extrahepatic tissues including the brain (Owen et al., 
1969). This leads to a decrease in overall glucose requirement and 
hence a minimal requirement for gluconeogenesis from amino acids 
provided by breakdown of protein in skeletal muscle.
In contrast to starvation, humans with malignant disease 
demonstrate increased rates of gluconeogenesis (Waterhouse, Jean Petre 
and Keilson, 1979; Holroyde et al., 1975). This phenomenon may allow 
for continued tumour growth in the wasted host, and might account for 
accelerated weight loss in tumour bearing individuals (Gold, 1971). 
However, dietary induced systemic ketosis has been shown to reduce 
blood glucose concentration and glucose utilisation in man (Phinney et 
al., 1983). Moreover, the supply of glycerol and alanine as precursors 
for gluconeogenesis may be decreased in the ketotic state (see Robinson 
& Williamson, 1980). Thus, iatrogenic ketosis has been proposed as a 
method of regulating host metabolism such that host reserves are main­
tained and glucose supply to the tumour is reduced (Conyers et al., 
1979; Williams & Matthaei, 1981). A ketogenic diet has already been 
shown to reduce the growth rate of the tumour whilst maintaining that 
of the host in rats bearing a transplantable mammary cancer (Buzby et 
al., 1980).
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However, the feasibility of this approach in humans has not been 
tested. Indeed, it has been suggested that hepatic ketogenesis may be 
impaired in cachectic cancer patients (Conyers et al., 1979). Thus it 
might be difficult to induce a state of ketosis in order to examine its 
effects on tumour growth rate and host metabolism. It is also not 
established whether ketone bodies have a direct inhibitory effect on 
muscle proteolysis. Thus it is unknown whether ketosis would reduce 
muscle wasting or decrease the supply of amino acids for gluconeo­
genesis. Skeletal muscle is thought to account for approximately 50% 
of protein turnover in the whole body (Emery et al., 1984a). Therefore, 
one indirect method of assessing the effects of ketosis on host muscle 
protein metabolism would be to determine the effects of ketosis on 
total body nitrogen turnover and balance.
The ethical and practical considerations of keeping terminal 
cachectic cancer patients in hospital for a prolonged period of time 
precluded the elevation of ketosis as an inhibitor of tumour growth 
rate in humans. Therefore, this question was examined using an animal 
model of cancer cachexia. The Walker 256 tumour in rats grows 
reproducably enough to make this assessment possible with a relatively 
small number of animals. Moreover, the use of this animal model allows 
sequential body composition analysis to assess the effect of ketosis on 
long term whole body nitrogen balance.
The aim of the present study was to determine the effects of systemic 
ketosis oh tumour growth rate, host body composition changes and blood 
glucose concentration in rats bearing the Walker 256 carcinosarcoma. 
In addition, the activities of the three major enzymes responsible for 
the metabolism of ketone bodies were measured as an indication of the 
capacity of the tumour to utilize ketone bodies.
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Animals: Inbred female Wistar rats aged between 12 - 14 weeks and 
weighing 175-205g were housed individually. They were kept in 
conditions of controlled temperature and lighting (20°C + 2°Cf 
12/I2h light/dark cycle) and allowed free access to food (except where 
specified in text) and water.
Tumour: The rapidly growing Walker 256 carcinosarcoma was obtained from 
the Institute of Cancer Research, Sutton, Surrey and maintained by 
routine passage every 14 days in Wistar rats. Viable tumour fragments 
(lOOmg) were transplanted s.c. into the right flank under aseptic 
conditions and light ether anaesthesia. Tumour doubling time was about 
36h.
Diets:
Standard diet: The standard diet was CRM diet (Labsure, Rank- 
Hovis-McDougal, Agricultural Division, Dorset, U.K.). It contained 
18.5% protein, 2.5% fat, 56.0% carbohydrate, 4.3% fibre, 2.4% minerals, 
15.0% moisture and added vitamins and trace elements.
Ketogenic diet: Medium chain triglyceride (MCT, donated by Scientific 
Hospital Supplies Ltd., Liverpool, U.K.) was mixed with the standard 
diet and supplemented with protein powder (Maxipro: Scientific Hospital 
Supplies) so that the two diets contained the same quantity of protein 
per calorie. Vitamin supplements were also added. The MCT supplied 
70% of the total calories and this diet is referred to as the MCT diet.
Both diets were presented to the animals as a paste to minimise 
food scatter.
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Neutron activation analysis: Total body nitrogen was analysed by
neutron activation analysis as described in Chapter 4.
Determination of tumour enzyme activities: The activities of
3-hydroxybutyrate dehydrogenase, acetyl CoA acetyltransferase and 
3-ketoacid CoA transferase were determined spectrophotometrically as 
described by Tisdale & Brennan (1983). The tumour was surgically 
excised from the rat 8 days after implantation and homogenised at 4°C 
in 4 vol of ice cold Tris-HCL buffer, 10”^M pH 7.4, containing 
2-mercaptoethanol 10 M and sucrose 0.25M. The homogenate was then 
further dispersed by ultrasonic vibration for 30 sec. The homogenate 
was centrifuged at 30,000g for 20 min and the supernatant used for 
enzyme estimation. Activity, estimated in triplicate, is expressed as 
units/mg protein where one unit equals the amount of substrate 
converted in 1 min at 37°C.
Induction of ketosis: The Walker 256 carcinosarcoma was transplanted 
into 20 rats which were fed ad libitum on the MCT diet. Concurrently, 
another group of 20 tumour free rats were fed ad libitum on the MCT 
diet. After either 3, 6, 9, 12 or 15 days four animals from each group 
were killed and blood was taken for the estimation of the concentration 
of acetoacetate and 3-hydroxybutyrate.
Effects of ketosis on tumour weight and host body composition: Rats
were randomly assigned to four groups of 6 animals. Animals were fed 
on the paste diets, contained in glass beakers, for a period of 7 days. 
Food intakes were measured daily and all animals had attained a stable 
food intake by the seventh day. On the eighth day, total body nitrogen 
was determined by neutron activation analysis in vivo and this was 
followed by either tumour implantation (Groups A, B, C) or sham
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operation (Group D). Animals in Group A were subsequently fed ad 
libitum on the standard diet and those in Group B were fed ad libitum 
on the MCT diet. Since animals fed on the MCT diet ate slightly less 
than those on the standard diet, Groups C and D were included to act as 
controls for the reduced dietary intake. Each animal in Group C was
given a daily ration of the standard diet equivalent in energy and
nitrogen content, to that consumed on the previous day by its partner
animal in Group B. The tumour free animals (Group D) were fed on the
MCT diet and were similarly pair fed to Group B.
After 14 days all animals were killed and blood was taken for 
measurement of 3-hydroxybutyrate, acetoacetate and glucose concen­
trations. The tumours were then excised and weighed. Neutron 
activation analysis of both carcasses and tumours was then repeated.
Analysis of rat blood samples: Acetoacetate and 3-hydroxybutyrate were 
measured spectrophotometrically by the method of Williamson and 
Mellanby (1974). Glucose was measured spectrophotometrically by the 
method of Berger and Bernt (1974)•
Statistical analysis: Students t test for non-paired data was used.
Results
Enzyme activities estimated in the Walker 256 tumour: Table 8.1 shows
the activities of the three major enzymes responsible for the 
metabolism of ketone bodies, estimated in an homogenate of the Walker 
256 tumour. Significant activities of 3 hydroxybutyrate dehydrogenase 
and acetyl CoA acetyl-transferase were observed. However, no activity 
of the enzyme 3-ketoacid CoA transferase could be detected in the 
tumour homogenate (Table 8.1).
Enzyme
Enzyme activity 
units/mg protein
3-Hydroxybutyrate dehydrogenase 4.8
Acetyl CoA acetyltransferase 12.5
3-Ketoacid CoA transferase Nil
TABLE 8.1 Activity of 3-hydroxybutyrate dehydrogenase, acetyl CoA
acetyltransferase and 3-ketoacid CoA transferase in Walker 
256 carcinosarcoma. Values represent the mean of at least 
three observations. Units of enzyme activity are as 
defined in Materials and Methods
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Effects of the MCT diet on blood ketone body levels: Figure 8.1 shows
the total ketone body concentration in blood taken from rats fed ad 
libitum for various times on the MCT diet (open bars). A significant 
ketosis was observed in rats fed for only 3 days on the MCT diet and 
this level was maintained for at least 15 days. Also shown in Figure 
8.1 is the total ketone body concentration in blood taken from rats fed 
ad libitum on the MCT diet for various times after implantation of the 
Walker 256 tumour (hatched bars). The level of ketosis observed in the 
tumour-bearing rats was similar to that observed in the 
non-tumour-bearing rats.
Effects of the MCT diet on tumour growth rate and host body 
weight; Host body weight before (hatched bar) and 14 days after tumour 
implantation into rats fed ad libitum on the standard diet (stippled 
bars, Group A) is shown in Figure 8.2. There was a significant decrease 
(by 12.0%) in the body weight of the rats by the 14th day after tumour 
implantation (P < 0.01).
A similar decrease in body weight (by 14.6%) was observed in
*.2-
tumour bearing rats fed ad libitum on the MCT diet (FigureXGroup B). 
The daily energy intake of the tumour-bearing rats fed ad libitum on 
the MCT diet (38.2KJ/rat/day) was less than that of the tumour-bearing 
rats fed on the standard diet (43.3KJ/rat/day). When tumour bearing 
rats, fed on the standard diet, were pair fed to the tumour-bearing 
rats fed ad libitum on the MCT diet (Group B) , such that the mean 
intake of standard diet was 38.2KJ/rat/day, there was a slight, but not 
significant (P > 0.05), increase in the host body weight loss (Figure 
8.2, Group C cf Group A). Non-tumour-bearing rats restricted to a mean 
daily intake of 38. 2KJ/rat/day of the MCT diet also lost weight after 
14 days of this dietary regime (Figure 2, Group D). The weight loss of 
animals in Group D (12.1%) was similar to that of tumour bearing rats 
fed ad libitum on the MCT diet (Group B).
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Figure 8.1 Ketone body concentration estimated in blood 
from rats fed for various times on a 70% medium chain tri­
glyceride diet. Rats were either non-tumour-bearing (open 
bars) or underwent tumour implantation on day 0 (hatched 
bars). Values are mean + SEM (n = 4).
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Figure 8.2 Effects of systemic ketosis on host weight loss 
following growth of the Walker 256 tumour in rats. Body 
weight of rats before (hatched bars) and fourteen days after 
tumour implantation (stippled bars) is shown. Final tumour 
weight is also shown (open bars). Tumour bearing animals 
were fed either on the standard diet ad libitum (Group A) 
or on the MCT diet ad libitium (Group B). Animals in Group 
C were pair fed with standard diet to those in Group B. 
Animals in Group D were non tumour bearing and pair fed with 
MCT diet to those in Group B. Values are mean + SEM (n = 6). 
Mean daily energy intake of the animals is shown within the 
bars (Values are KJ/rat/day).
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The final tumour weight was similar for all three dietary regimes 
(Figure 8.2, open bars).
Effect of the MCT diet on the body composition of tumour-bearing 
rats; Figure 8.3 shows the total nitrogen content of rats both before 
(hatched bars) and 14 days after (stippled bars) tumour implantation. 
The final nitrogen content of the tumour is also shown (open bars). The 
rats were fed ad libitum on either the standard diet (group A) or the 
MCT diet (Group B). After 14 days the total nitrogen content of the 
rats had decreased and the decrease was similar for rats fed ad libitum 
on either the standard diet (0.63gN, Group A) or the MCT diet (0.78gN, 
Group B). The final nitrogen content of the tumour was slightly 
greater in rats fed ad libitum on the standard diet (0.55gN) than in 
rats fed ad libitum on the MCT diet (0.46gN) but this difference was 
not significant (P > 0.05). When the daily intake of the standard diet 
was restricted to that of the tumour-bearing rats fed ad libitum on the 
MCT diet (Group B) the final host nitrogen content and tumour nitrogen 
content was similar to that of the tumour bearing rats fed ad libitum 
on the MCT diet (Figure 8.3, Group C cf Group B). When non-tumour 
bearing rats were fed for 14 days on the MCT diet but restricted to a 
mean daily energy intake of 38.2KJ there was a slight, but not
significant (P > 0.05) decrease in the body nitrogen content (Figure 
8.3, Group D).
Blood glucose and ketone body concentrations of tumour-bearing 
rats on the various dietary regimens: Table 8.2 shows the final blood 
glucose concentration and total ketone body concentration of rats fed
ad libitum for 14 days on either the standard diet (group A) or the MCT
diet (group B). A significant ketosis was observed in tumour-bearing 
rats fed ad libitum for 14 days on the MCT diet and this was
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Figure 8.3 Effect of systemic ketosis on host body nitrogen 
following growth of the Walker 256 tumour in rats. Body 
nitrogen content of rats before (hatched bars) and after 
tumour growth (stippled bars) is shown: Final tumour nitrogen
content is also shown (open bars). Animal groups were as 
defined in Figure 8.2. Values are mean + SEM (n =6).
Group Total Blood 
Ketones (mM)
Blood Glucose 
(mM)
Control 0.14+0.07 6.5 + 0.3
A 0.25 + 0.09 6.2 +0.3
B 2.68 + 0.59 5.2 + 0.4
C 0.29+0.08 5.3 + 0.2
D 2.10 +0.22 3.4 + 0.4
Table 8.2 Total ketone body concentration (acetoacetate 
plus 3-hydroxybutyrate) and glucose concentration in blood 
from rats 14 days after tumour implantation (Groups A, B and 
C) and in non-tumour-bearing rats (Group D). Control values 
refer to non-tumour-bearing rats fed ad libitum on the 
standard diet. Animal groups were as defined in Figure 8.2. 
Values are mean + SEM (n = 6).
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accompanied by a significant (P < 0.02) reduction in the blood glucose 
concentration. When the daily energy intake of non-tumour-bearing rats 
on the MCT diet was restricted to that of the tumour-bearing rats fed 
on the MCT diet the blood ketone concentration was similar but the 
blood glucose concentration was significantly reduced (Table 8.2 Group 
D cf Group B: P < 0.01).
Discusssion
These results demonstrate clearly that induction of systemic 
ketosis following implantation of the Walker 256 carcinosarcoma in rats 
does not reduce the tumour growth rater nor does it prevent the 
subsequent decrease in host body weight. Furthermore, sequential body 
composition analysis of the rats indicated that the host nitrogen 
content decreased to a similar extent in tumour bearing animals fed on 
the MCT diet compared with those fed on the standard diet (Figure 8.3).
Two of the major enzymes responsible for the metabolism of ketone
bodies in the mitochondria, 3-hydroxybutyrate dehydrogenase and acetyl
CoA acetyltransferase, were shown to be present in significant amounts
in the Walker 256 tumour (Table 8.1). However, no activity of the
enzyme 3-ketoacid CoA transferase was detected. A similar distribution
of enzyme activities has been reported for other tumours of the
peripheral tissues (Tisdale and Brennan, 1983)• Since activity of the
enzyme 3-ketoacid CoA transferase determines the extent to which
3-hydroxybutyrate is used as a metabolic fuel (Williamson et al., 1971)
it might be expected that the Walker 256 carcinosarcoma would be unable
to metabolize ketone bodies. However, it has been shown previously that
14Walker 256 tumour cells grown m  vitro can form C02 from D(-)3- 
hydroxy 3-^c-butyrate, but only at a very low rate due to the
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presence of acetoacetyl CoA synthetase (Tisdale, 1984). Thus, although 
the tumour has a limited capacity for the metabolism of acetoacetate 
the low activity of acetoacetyl CoA synthetase and the absence of 
3-ketoacid CoA transferase indicates that ketone bodies cannot be a 
major energy source for this tumour.
The diet chosen for use in these studies produced a significant 
systemic ketosis when fed to rats for only 3 days; this ketosis was 
maintained in rats fed on the MCT diet for at least 15 days (Figure
8.1) . When non-tumour-bearing rats were fed on the MCT diet the
increased concentration of ketone bodies in the blood was accompanied 
by a significant decrease (P < 0.01) in the blood glucose concentration 
(Table 8.2). This is consistent with the observation that ketosis 
induced in humans by a diet containing 85% of calories as fat is 
associated with signficant reduction in the blood glucose concentration 
(Phinney et al., 1983). Similarly, the induction of a systemic ketosis 
by the infusion of 3-hydroxybutyrate into man (Sherwin et al., 1975), 
dogs (Binkiewicz et al., 1974) or sheep (Radcliffe et al., 1983) has 
been shown to produce a significant decrease in the blood glucsoe
concentration and is associated with a decrease in the rate of 
gluconeogenesis of both fed and fasted sheep (Radcliffe et al., 1983). 
However, although a similar degree of ketosis was induced in both 
tumour bearing and non-tumour-bearing rats fed on the MCT diet (Figure
8.1) the decrease in the blood glucose concentration of the tumour- 
bearing rats, though significant, was much less marked (Table 8.1). 
Furthermore, the limited decrease in blood glucose concentration of 
tumour-bearing rats fed ad libitum on the MCT diet could be accounted 
for by the decrease in their daily calorie intake since tumour-bearing
rats fed an equicaloric amount of the standard diet had a similar blood
glucose concentration (Table 8.2).
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In septic sheep systemic ketosis is not accompanied either by a 
decrease in the blood glucose concentration or by a decrease in the 
rate of glucose production by the liver (Radcliffe et al., 1983). This 
observation lends support to the suggestion that the metabolic 
abnormalities observed in the tumour-bearing host resemble some of 
those characteristic of semi-starvation but also some of those 
characteristic of sepsis and trauma (Brennan, 1977). The mechanism 
accounting for the failure of systemic ketosis to lower blood glucose 
in sepsis or cancer cachexia remains obscure. It may, however, be 
related to the insulin resistance characteristic of both metabolic 
states.
The failure of the ketogenic diet to restrict tumour growth may 
be, therefore, a result of the failure of ketosis to reduce the 
availability of glucose in tumour-bearing rats. It has already been 
shown that the growth rate of the Walker 256 tumour in rats can be 
decreased following administration of the glucose antimetabolite
2-deoxy-glucose (Ball et al., 1957) or following administration of 
hydrazine sulphate which inhibits gluconeogenesis (Gold, 1971). This 
suggests that the Walker 256 tumour is largely dependent upon glucose 
as an energy substrate. Thus, although the tumour cells are probably 
unable to use ketone bodies as a major energy source, the ketogenic 
diet did not restrict the supply of glucose to the tumour cells and 
thus failed to deprive the tumour of an important energy source.
The final tumour weight in rats fed ad libitum on the MCT diet was 
slightly, but not significantly (P > 0.05) less than that in rats fed 
ad libitum on the standard diet (Figure 8.2, Group B cf Group A). The 
slight decrease in tumour growth rate can be accounted for entirely by 
the reduced energy intake since a similar decrease in the final tumour 
size was observed in rats that had a daily allowance of the standard
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diet equal in energy content to that eaten by rats fed on the MCT diet 
(Figure 8.2, Group C cf Group B).
Although it cannot be concluded from this study that a host 
specific substrate does not restrict tumour growth, the results 
indicate the difficulty of such an approach to cancer treatment. The 
presence of metabolic abnormalities in cancer-bearing patients has been 
widely documented (Brennan, 1977; Heber, Byerly and Chlebowski, 1985) 
and these abnormalities may alter the host’s response to dietary 
modification. The effect of a ketogenic regimen on the metabolism of 
humans with cancer cachexia is described in Chapter 9.
Summary and Conclusions
The Walker 256 carcinosarcoma was shown to lack the enzyme 3-Keto Acid 
CoA transferase. This suggests that ketone bodies cannot be used as a 
major substrate for the energy metabolism of this tumour. Systemic 
ketosis (1 - 2mM acetoacetate plus 3-hydroxybutyrate) was induced both 
in tumour bearing and in non tumour bearing rats with a diet containing 
70% medium chain triglyceride. However, in rats bearing the Walker 256 
tumour, this dietary ketosis did not reduce the tumour growth rate nor 
did it prevent the subsequent decrease in host body weight. Host body 
nitrogen losses were similarly unaffected. The ketosis induced in 
tumour bearing rats was shown to be abnormal since the blood glucose 
concentration of ketotic tumour bearing rats was significantly higher 
compared with that of ketotic non-tumour bearing rats (5.2 + 0.4mM cf
3.4 + 0.6mM, P < 0.01). The failure of glucose metabolism to respond 
normally to ketosis may partly explain why systemic ketosis failed to 
alter the growth and cachexia induced by the Walker 256 tumour.
CHAPTER 9 117
Influence of systemic ketosis on substrate levels and nitrogen
metabolism in humans with cancer cachexia 
Introduction
It was concluded in Chapter 8 that induction of systemic ketosis 
in tumour-bearing rats does not reduce the tumour growth rate nor does 
it prevent host weight loss. The study was based on the assumption 
that the presence of ketone bodies would limit the supply of glucose to 
the tumour and thus restrict its growth rate. Since the host tissues 
can use ketone bodies as a substrate their energy metabolism should not 
be affected. However, in rats at least, induction of systemic ketosis 
did not restrict the supply of glucose to the tumour. This may be an 
indication of one of the many metabolic abnormalities induced in the 
host by the presence of a tumour. However, it may also be a charac­
teristic of the particular animal tumour model chosen for use in the 
study. Certainly induction of systemic ketosis in humans by a high fat 
diet results in a significant reduction in the blood glucose 
concentration (Phinney et al, 1983) as does infusion of 3-hydroxybuty­
rate (Sherwin et al., 1975).
One mechanism for the hypoglycaemic action of systemic ketosis in 
unstressed humans or rats (Phinney et al., 1983; Chapter 8) might be 
that ketone bodies directly inhibit protein breakdown in skeletal 
muscle. Thus the efflux of amino acids from skeletal muscle would be 
reduced and since gluconeogenesis is to some extent controlled by sub­
strate availability (Newsholme, 1976) this would reduce the rate of 
glucose synthesis de novo. However, as discussed in Chapter 8, ketone 
bodies may have no direct action on muscle proteolysis (Miles et al., 
1983). Although urinary nitrogen excretion falls after the intravenous
118
infusion of sodium 3-hydroxybutyrate (Sherwin, Hendler and Felig, 1975 
; Pawan and Semple, 1983) this effect can be reproduced by an equimolar 
infusion of bicarbonate (Miles and Haymond, 1983 ? Bartels and Sestoft, 
1983). Since the metabolism of salts of organic acids, such as 
3-hydroxybutyrate, results in an equimolar generation of bicarbonate 
ions, the administration of such salts probably reduces urinary 
nitrogen by decreasing the need for ammonium ion excretion by the 
kidney rather than by direct inhibition of muscle proteolysis (Bartels 
and Sestoft, 1983). If ketone bodies do not reduce muscle proteolysis 
this might explain why host nitrogen losses were not reduced in tumour 
bearing rats fed a ketogenic diet (see Chapter 8).
It has also been suggested that cancer patients exposed to a 
ketogenic regimen may not achieve the same level of ketosis as observed 
in normal individuals (Conyers et al., 1979). Thus a standard ketogenic 
diet in which endogenous ketogenesis is induced by carbohydrate 
restriction might not increase circulating ketone body concentrations 
to the extent that the metabolic effects of systemic ketosis in cancer 
cachexia could be determined. One approach to this problem would be to 
administer an exogenous source of ketone bodies at the same time as 
inducing hepatic ketogenesis by carbohydrate restriction. This type of 
diet was used in the current study.
Thus the aim of this study was to determine whether an adequate 
ketosis could be induced in cachectic cancer patients and if so, to 
determine the effects of this ketosis on the nitrogen metabolism, blood 
glucose concentration, and the concentration of various substrates of 
hepatic gluconeogenesis in these patients. Systemic ketosis was induced 
by feeding the patients a diet containing 70% medium chain triglyceride 
supplemented with arginine 3-hydroxybutyrate, 4mnol/Kg/day. The
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arginine salt was chosen in order to avoid the fluid retention which 
might be associated with a sodium load of 4mmol/Kg/d. Patients were fed 
on a normal diet for six days and this was followed by seven days on 
the ketogenic diet. Nitrogen retention has been shown to vary with 
energy intake (Elia, 1982). In general, increasing energy intake 
improves nitrogen balance at any given nitrogen input. Similarly, a 
rise in nitrogen input will improve nitrogen retention at any given 
energy intke. Therefore, in order to examine the effect of ketosis on 
nitrogen metabolism both diets were carefully balanced to be iso- 
nitrogenous and isocaloric. Blood samples were taken for estimation of 
blood glucose concentration and the concentration of various substrates 
of gluconeogenesis when the patients were on either regimen. Moreover, 
to determine the effect of systemic ketosis on host nitrogen metabolism 
daily nitrogen balance was measured throughout, and whole body protein 
turnover estimated on the last day of both the normal and ketogenic 
diets. The effect of ketosis on tumour growth rate was not assessed in 
this study.
Materials and Methods
Subjects: 5 patients, two male and three female with histologically
proven malignancy were entered into the study. Two had lung cancer, 
two gastric cancer and one ovarian cancer. Details of each patient’s 
weight, diagnosis, age, sex, height, weight and % weight loss are given 
in Table 9.1. Details of the patients* nutritional and haematological 
status at the start of the study are given in Table 9.2. Twenty four 
hour dietary recall histories obtained prior to the start of naso­
gastric feeding showed the mean daily energy intake of the patients to 
be 4.6MJ/d and the mean daily nitrogen intake to be 7.7gN/d. These 
values are 55% and 28% respectively below predicted normal intakes
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(Documenta Geigy, 1962). All patients gave informed, written, consent. 
The study was approved by the local hospital ethical committee.
Diets: For the first six days of the study, the subjects were given a
normal balanced regimen consisting of a lactose free commercial diet 
(Ensure, Ross Laboratories, USA). The diet provided 44 Kcal/kg/d and
1.5 g protein/kg/d and was supplemented with arginine 4mmol/kg/d. In 
the normal diet 55% of the total energy was supplied as carbohydrate 
and 31% as fat. From the seventh day of the study onwards, the 
patients were fed a ketogenic diet which supplied the same total 
energy and protein as the normal diet but in which 70% of the calories 
were supplied as medium chain triglyceride (Liquigen, Scientific 
Hospital Supplies Ltd, Liverpool, U.K.). This diet was supplemented 
with arginine D-3-hydroxybutyrate 4mmol/kg/d (a gift from Solvay Ltd, 
Brussels, Belgium). The protein source in the ketogenic was 
supplemented whey protein (Maxipro HBV, Scientific Hospital Supplies).
Both diets were administered at a constant rate over 24 hours 
using a fine bore nasogastric feeding tube connected to a peristaltic 
pump. The diets were well tolerated by the patients and there was no 
gastrointestinal upset.
Study Protocol: Patients received the normal diet on days 1 - 6  and the 
ketogenic diet on days 7-13. Twenty four hour urine collections for 
estimation of nitrogen balance were taken throughout the study. Blood 
samples for the estimation of urea and electrolytes were taken at 9 am 
on days 0, 5, 8, 10 and 13. Blood samples for the estimation of
substrate concentrations were taken at 9 am on days 5, 8, 10, 13 and
for insulin concentrations on days 5 and 13. Whole body protein 
turnover was measured on days 5-6 and 12-13.
121
Analysis of blood and urine samples; Blood for haemoglobinfwhite blood 
cell and differential counts, platelet counts, urea and electrolytes, 
and liver funtion tests was analysed by semiautomated techniques on the 
same day as sampling.Blood taken for 3-hydroxybutyrate, aceto-acetate, 
and pyruvate was immediately deproteinised with 30% ice cold perchloric 
acid and analysed within 3 hours of sampling. Plasma was separated 
from all other blood samples and frozen at -20°C until analysis. The 
glucose, lactate, and pyruvate assays were enzymatic determinations 
taken from the standard techniques of Bergmeyer (1971). 
3-Hydroxybutyrate and acetoacetate were measured by the method of 
Williamson and Mellanby (1974). Free fatty acids were measured enzyma­
tically (NEFAC kit, Wako Chemicals, West Germany). The amino acid 
profiles were determined by ion exchange HPLC on plasma which had been 
deproteinised with sulphasalicylic acid. Insulin concentration was 
measured by radioimmunoassay.
Serial 24-hour urine collections were stored in bottles at 4°C 
during the collection period. The volume was carefully measured after 
completion and aliquots stored at -20°C until analysis. Total 
urinary nitrogen was measured by the micro-Kjeldahl technique (Fleck 
and Munro, 1965). Urinary creatinine was measured according to the 
modified method of Folin-Wu (Hawk, Oser and Summerson, 1947).
Measurement of protein turnover and nitrogen balance: Rates of whole
body protein turnover, synthesis and degradation were calculated from
the plateau isotopic enrichment of urinary urea following a primed,
15constant 24-hr infusion of N-glycine as described in Chapter 2. 
Daily nitrogen balance was estimated by subtracting total urinary 
nitrogen plus 2gN (as an estimate of stool and skin nitrogen losses) 
from daily nitrogen intake.
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Statistical Analysis; Results are reported as means + standard error of 
the mean. Tests yielding results suitable for paired comparison were 
assessed by Student’s paired t-test.
Results
Effect of feeding on patient weight and performance status: The weight
and performance score of individual patients at the start of naso­
gastric feeding and after administration of the normal and ketogenic 
diets are shown in Table 9.3. The mean weight of the patients had not 
changed significantly after six days of normal diet (38.2 + 3.4 cf 38.6 
+ 3.8kg : P < 0.1). However, following seven days of the ketogenic diet 
the weight of the patients had increased by approximately 2kg (P<0.05). 
Similarly, the performance score (W.H.O. grading system) of the 
patients did not change during the period of the normal diet but had 
improved by one grade in all individuals by the end of the study.
Effect of ketogenic diet on various substrate concentrations 
in blood: The mean concentration of various substrates in the blood of 
patients whilst on the normal diet (day 5) and at several times whilst 
on the ketogenic diet are shown in Table 9.4. A significant ketosis 
(acetoacetate plus 3-hydroxybutyrate > 0.2 mmol/l) was observed in 
patients fed for only 24 hours on the ketogenic diet (total blood 
ketones concentration on day 8: 0.83 nmol/1) and this level increased 
to a total blood ketone concentration of 1.21 mmol/l after seven days. 
In contrast, there was a 14% decrease in the blood glucose concen­
tration by the seventh day of the ketogenic diet compared with the 
concentration observed when the patients were fed on the normal diet 
(5.7 + 0.5 cf 6.6 + 0.5 mmol/l : P < 0.05). Similarly, by the seventh 
day of the ketogenic diet the mean concentration of blood lactate had
Patient Start of Study End of Normal Diet End of Ketogenic Diet
Weight (kg) PS* Weight (kg) PS* Weight (kg) PS*
1 32.0 3 32.5 3 34.5 2
2 45.0 3 45.0 3 47.0 2
3 35.0 4 33.5 4 38.0 3
4 31.0 3 32.2 3 33.0 2
5 50.0 4 48.0 4 50.0 3
mean 38.6 38.2 40.5 .
(sem) (3.8)al (3.4)a2 (3.4)
PS* = perfonnance score (WHO system) 
b v a^ or a2 : P < 0.05.
TABLE 9.3 Weight and performance score of patients before start 
of nasogastric feeding, at the end of six days of 
normal diet and after 7 days of ketogenic diet.
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fallen by 46% (0.7 + 0.1 cf 1.3 + 0.2mmol/l : P < 0.01) and that of
pyruvate by 40% (0.06 +0.01 cf 0.10 + 0.01mmol/l : P < 0.05).
Although the mean concentration of blood alanine was decreased by 38% 
(0.18 +0.02 cf 0.29 + 0.05mnol/l) this difference was not statis­
tically significant. There was no change in the blood glutamine 
concentration (0.45+0.03 cf 0.41 + 0.03mmol/l). The mean free fatty 
acid concentration increased from 0.21mmol/l to 0.40mmol/l but again 
this difference not statistically significant.
Effect of ketogenic diet on blood insulin concentration: The mean
concentration of insulin in blood taken when the patients were on the
normal diet (day 5) was not significantly different for that when they 
were on the ketogenic regimen (day 13) (14.3 + 1.5 cf 15.3 + 5.1 uU/ml 
: P > 0.1)
Effect of systemic ketosis an urea, electrolytes and liver function 
tests: The mean concentration of urea and electrolytes before feeding
was started, and at the end of both the normal diet of the ketogenic 
diet are shown in Table 9.5. During the period of feeding with the 
normal diet the mean serum sodium concentration decreased (135 + 1  cf 
130 + 2mmol/l : P < 0.05) to below the normal range (N.R. 135 - 
144mmol/l) but increased again during the period of feeding with the 
ketogenic diet (130 + 2 cf 137 + 2irmol/l : P < 0.05). In contrast, the 
mean serum potassium concentration was within the normal range 
throughout the study. There was no significant change in the serum 
chloride concentration.
The mean concentration of serum bicarbonate remained within the 
normal range (N.R. 22 - 32mmol/l) throughout the study. However, the
concentration decreased significantly during the period of feeding
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with the normal diet (27 + 4 cf 22 + 2mmol/l ; P < 0.05), but returned 
to the initial concentration by the end of the ketogenic diet. There 
was no significant alteration in the serum concentration of urea and 
creatinine. The serum phosphate concentrations fell by 50% during the 
period of feeding with the normal diet (1.1 +0.1 cf 0.5 + O.lmnol/1 : 
P < 0.05) but returned to the initial concentration by the end of 
feeding with the ketogenic diet.
The liver function tests of patients before the start of nasogastric 
feeding and at the end of feeding with the normal and ketogenic diets 
are shown in Table 9.6. The mean concentrations of serum bilirubin, 
asparate aminostransferase (AST) and alanine aminotransferase (ALT) 
remained within the normal range throughout the study. Before the 
start of nasogastric feeding the mean serum albumin concentration was 
below the normal range (31 - 50g/l) and further decreased during the 
period of normal diet (31 + 2 cf 26 + 2g/l : P < 0.05). However, the 
concentration increased to 29 + 5g/l by the end of feeding with the 
ketogenic diet.
Effect of systemic ketosis on daily nitrogen balance and whole body 
protein turnover: Daily total urinary nitrogen excretion and calculated 
daily nitrogen balance throughout the periods of normal and ketogenic 
diets are shown in Table 9.7. The mean daily urinary nitrogen 
excretion when the patients were fed on the normal diet was 22% less 
than when the patients were fed on the ketogenic diet (9.5 + 0.7 cf
11.6 + 0.5gN.d : P >  0.1). Consequently, the mean daily nitrogen 
balance was slightly but not significantly more positive when the 
patients were fed on the normal diet as opposed to the ketogenic diet 
(+6.4 + 1.8 cf +4.3 + 1.2gN/d : P > 0.1).
Time Bilirubin AST ALT Albumin
(umol/1) (u/1) (u/1) (g/1)
(Normal, Range)________ (3-18) (10-35) (10-50) 36-50)
PRIOR TO STUDY 14 (5) 16.(2) 15 (2) 31 (2)a
NORMAL DIET 6 (1) 24 (4) 30 (8) 26 (2)b
KETOGENIC DIET 5 (1) 17 (5) 15 (5) 29 (5)
b v a : P < 0.05
TABLE 9.6 Liver function tests of patients before nasogastric
feeding and at the end of feeding with the normal diet 
(day 6) and the ketogenic diet (day 13). Results are 
mean (SEM), n = 5.
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Individual and mean rates of whole body protein turnover, 
synthesis and degradation on the last day of the normal diet and on the 
last day of the ketogenic diet are shown in Table 9.8. Although the 
rates of protein turnover, synthesis and degradation of some 
individuals changed by as much as 60% between the normal diet and the 
ketogenic diet, there was no overall trend up or down. Moreover, the 
mean rates of whole body protein turnover, synthesis and degradation 
when the patients were on Either the normal or the ketogenic diets were 
not significantly different.
Discussion
These results demonstrate clearly that a ketogenic diet 
containing 70% medium chain triglyceride and supplemented with 
4irmol/kg/d 3-D(-)-hydroxybutyrate (arginine salt) can induce a ketotic 
state in cachectic cancer patients and can maintain these individuals 
in a positive nitrogen balance.
Prior to the start of nasogastric feeding the patients had lost 
approximately 32% of their pre-illness stable weight and had been 
losing weight at the mean rate of 1.8Kg/month (Table 9.1). The 
patient's weight did not change significantly during the six days when 
they were given the normal diet but did increase by about 2Kg following 
the Ketogenic diet.(Table 9.3). The alterations in body composition 
which might account for this weight gain are not known. However, 
throughout the study the patients were in a positive nitrogen balance 
(Table 9.7). Since there was no significant alteration in the blood 
urea concentration (Table 9.5) this would suggest that at least a 
component of the weight gain was due to an increase in body protein 
mass. However, it cannot be established from this study to what extent 
the weight gain was specifically associated with ketogenic diet.
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The reduction in serum sodium and albumin concentrations (Tables
9.5 and 9.6 respectively) which occurred during the period of feeding 
with the normal diet were reversed during the period of feeding with 
the ketogenic diet. These effects could be explained by an initial 
gain and subsequent loss of water from the extracellular fluid space. 
It is noteworthy that the gain in body weight coincided with the rise 
in serum sodium and albumin concentrations suggesting that the 
dilutional effect observed in the initial phase of refeeding was due to 
a fluid shift from the intracellular space into the extracellular space 
rather than a net fluid retention. This was probably caused by the 
initiation of refeeding in very wasted patients rather than any effect 
specifically related to the normal or ketogenic diets. The fall in 
serum phosphate concentration during the normal diet probably reflects 
an initial uptake of phosphate into cells associated with the anabolic 
stimulus of refeeding.
Blood glucose lactate, and pyruvate concentrations decreased and 
there was a trend towards a reduced plasma alanine with the 
establishment of systemic ketosis (Table 9.4). The rate of hepatic 
gluconeogensis is, to some extent, controlled by the concentration of 
available substrates (Newsholme, 1976). Since lactate, pyruvate and 
alanine can act as substrates for glucneogenesis it is possible that 
the changes in substrate concentrations associated with systemic 
ketosis might reduce the rate at which glucose is supplied to the 
tumour. Moreover, the trend towards elevated blood levels of 
fat-derived energy substrates (free fatty acids and ketone bodies) and 
reduction in blood glucose concentration (Table 9.4) emphasise the 
potential of systemic ketosis in maintaining the supply of energy to 
the host whilst reducing glucose supply to the tumour. However, as 
discussed previously, a dietary induced ketosis did not reduce the 
blood glucose concentration in rats bearing the Walker 256 carcino­
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sarcoma (see Chapter 8). Thus the effects of systemic ketosis on blood 
substrate concentrations may depend on the individual characteristics 
of the tumour and host.
The mean nitrogen balance of the patients was positive throughout 
the study and was not significantly different when the patients were on 
the ketogenic diet compared with the normal diet. The observation that 
the patients were in a positive nitrogen balance whilst on both diets 
probably reflects that prior to the initiation of nasogastric feeding 
their food intake was markedly reduced. Thus, added dietary energy and 
protein were taken up by body tissues irrespective of the composition 
of the diet. The positive nitrogen balance of the cancer patients 
whilst on the ketogenic diet does, however, contrast with the findings 
of a recent study which examined the metabolic effects of dietary 
induced ketosis in young male volunteers (Phinney et al., 1983). The 
diet in the latter study provided 85% of calories as fat, 1.75g of 
protein per kilogram per day and less than 20g of carbohydrate per day. 
With this regimen the volunteers demonstrated a negative nitrogen 
balance during the first seven days of the ketogenic diet but achieved 
nitrogen balance thereafter. This initial negative balance was
probably due to this use of amino acids from muscle protein as sub­
strates for hepatic gluconeogenesis. Such de novo synthesis of glucose 
is required to support glucose dependent tissues such as the brain and 
red blood cells. It is only with the production of ketone bodies from 
fat and their use as energy substrates instead of glucose that this 
nitrogen efflux is reduced, as in compensated starvation (Robinson and 
Williamson, 1980). However, in this study, the patients remained in a
positive nitrogen balance throughout the induction of ketosis (Table
9.7). One explanation could be that the diet provided 30 - 40g of
carbohydrate per day and consequently the requirement for extra glucose
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production via gluconeogenesis was minimal. Alternatively, the infused
3-hydroxybutyrate may have been utilized as an alternative substrate to 
glucose in the interval between the time of glucose deprivation and the 
onset of adequate hepatic ketogenesis.
The mean rates of whole body protein turnover, synthesis, and
degradation were similar when patients received either the normal or 
the ketogenic diets (Table 9.8). Since the nitrogen balance of the
patients was similar during either regimen (Table 9.7), these findings 
suggest that in cancer cachexia, a dietary induced systemic ketosis 
does not influence either whole body nitrogen kinetics or the ability 
of the body to retain nitrogen. Whether the observed changes in energy 
substrate concentrations might lead to a reduction in tumour growth 
rate and thereby influence the development of cachexia in the long term 
remains to be determined.
Summary and Conclusions
The aim of this study was to determine whether a ketogenic diet
might improve host nitrogen balance whilst reducing the supply of
glucose for tumour energy metabolism in humans. Five patients with 
malignant disease and severe weight loss (mean 37%) were fed via a fine 
bore nasogastric tube. A normal diet was given for six days and this 
was followed by seven days of an isonitrogenous, isocaloric, ketogenic 
diet.
Both diets were well tolerated. At seven days the mean ketone 
body concentration in the blood of patients fed the ketogenic diet was 
1.21 + 0.33mM. This ketosis was associated with a significant
reduction of the concentration in blood glucose, lactate and pyruvate.
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There was, however, no significant alteration in host nitrogen balance 
or whole body protein synthesis, degradation or turnover rates when 
patients changed from the normal to the ketogenic diet.
Thus, although the ketogenic diet was well tolerated there was no 
beneficial effect on the nitrogen metabolism of the cachectic cancer 
patients. Whether the change from glucose to fat derived energy 
substrates might reduce tumour growth rates in the long term remains to 
be determined.
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Selective inhibition of tumour energy metabolism in vivo
Introduction
From Chapter 8 it would appear that control of tumour growth is a 
prerequisite for effective nutritional therapy in cancer cachexia and 
this has been suggested previously (Van Eys, 1982). Current cancer 
chemotherapy involves the use of cytotoxic agents to inhibit cell 
division within the tumour. These agents are non- selective since they 
also inhibit cell division within the tissues of the host. Their use 
is based upon the assumption that the rate of cell division within the 
tumour is greater than that of the majority of host tissues. Clearly 
this is not always a valid assumption (Caiman, Smyth and Tatter sail, 
1980) and such treatment is limited by host toxicity, some of which is 
manifest by a deterioration in the nutritional status of the patient 
(Kokal, 1985). In the cachectic cancer patient antineoplastic therapy 
has to be effective yet non-toxic. A more selective and thus less 
toxic approach to the treatment of cancer might be based on differences 
between tumour and host cells. One such difference is the altered 
energy metabolism of many tumour cells.
Mitochondria of normal cells: Every eukaryotic cell contains
mitochondria. The Greek words from which mitochondria get their name 
(mitos-thread; chondros-granule) characterise the appearance of these 
organelles.under the light microscope. However, under the electron 
microscope mitochondria have a highly organised structure. Two 
membranes surround the inner matrix. The smooth outer membrane is 
porous to molecules up to a molecular weight of 8,000 (Zalman, Nikaido 
and Kagawa, 1980). The inner membrane is plicated to form cristae and
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acts as a semipermeable membrane. The primary function of mitochondria 
is to couple the degradation of various organic compounds to the 
formation of ATP. Hence, they have been regarded as the 'power houses' 
of the cell. Mitochondria are also remarkable because they are in 
possession of their own genetic system (Kroon and Saccone, 1980) and 
replicate in a manner similar to that of the binary fission of 
bacteria. However, although mitochondria are able to synthesise some 
of their own constituent proteins (mainly those bound to the inner 
membrane) the nuclear genetic system is responsible for the majority of 
the proteins within these organelles.
Mitochondria contain numerous enzymes which provide the cell with 
reducing equivalents and metabolic intermediates. They contain a 
system for the oxidative degradation of fatty acids, the B oxidation 
pathway (Greville and Tubbs, 1968), and also possess enzymes for the 
oxidative decarboxylation of some amino acids. In addition, 
mitochondria contain the Krebs cycle enzymes (Lowestein, 1969) which 
degrade acetyl-CoA. Acetyl CoA is formed as a result of the oxidative 
degradation of lipids, some amino acids and carbohydrates. The 
processing of these substrates along such catabolic pathways leads to 
the production of reducing equivalents in the form of NADH and reduced 
flavins. The availability of reducing equivalents is required for the 
formation of ATP during oxidative phosphorylation.
The respiratory chain is a multienzyme system which is firmly 
embedded in the inner mitochondrial membrane. The chain is composed of 
flavoproteins, iron-sulphur proteins, ubiquinone and several 
cytochromes. Reducing equivalents, formed during various oxidation 
reactions occurring inside as well as outside the mitochondria, are 
transferred along this chain to molecular oxygen. The hydrogen atoms,
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or the electrons, are thus passed from the negative redox potential of 
their initial acceptors to the positive potential of oxygen. This fall 
of free energy of electrons is the primary force for ATP synthesis 
(oxidative phosphorylation).
Mitochondria of tumour cells: Almost 60 years ago Warburg hypothesised
that damage to respiration, that is a deficiency in the respiratory 
chain, causes the transformation of normal cells into tumour cells 
(Warburg, 1930). However, tumour mitochondria generally contain normal, 
funtional respiratory chains. It is possible to quantify the 
efficiency of ATP synthesis by mitochondria. If a known amount of ADP 
is added to isolated mitochondria, the amount of oxygen consumed in 
order to convert the ADP to ATP can be determined and is known as the 
P/O ratio. Carefully isolated tumour mitochondria show normal P/O 
ratios and normal respiratory control indices (Pederson, 1978). A 
general disorder of tumour mitochondria is therefore unlikely to be the 
major underlying factor in the neoplastic transformation process 
(Weinhouse, 1982). Nonetheless, an extensive literature has accumulated 
to show that tumour cell mitochondria have aberrations of one kind or 
another. These include deficiencies of enzymes involved in the 
metabolism of ketone bodies (Tisdale and Brennan, 1983; see also 
Chapter 8), alterations in inner membrane components particularly 
phospholipids (Reitz, Thomson and Morris, 1977) abnormal adenine 
nucleotide translocation (Lau and Chan, 1984), and alteration of 
respiratory chain components (Nelson et al., 1984).
Whatever the significance of these mitochondrial alterations in 
terms of carcinogenesis, it is clear that in a great many cancers the 
organelle is defective. From the viewpoint of cancer chemotherapy, 
this would seem to be a weak spot in cancer cells and could be the
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focal point of therapy using antimitochondrial agents. Indeed various 
anticancer drugs have been shown to inhibit mitochondrial function 
(Gonsalvez et al., 1976? Bernal, Shapiro and Chen, 1982) and several 
inhibitors of mitochondrial function have been demonstrated to have 
selective antineoplastic effects (Wilkie, 1979). However, as yet the 
use of such agents to inhibit selectively mitochondrial function and 
thereby reduce tumour growth rate has received little or no attention 
in clinical cancer chemotherapy.
High glycolytic capacity of tumour cells: An increased rate of
anaerobic and aerobic glycolysis has been demonstrated repeatedly in 
rapidly growing tumours (Warburg, 1930? Weber et al., 1961). Moreover 
many tumours have been shown to have a high rate of glucose consumption 
and to be susceptible to carbohydrate deprivation (Demetrakopoulos, 
Linn and Amos, 1978). The increased glycolysis of some tumours has 
been linked to enhanced levels of glycolytic-enzymes (Weber and Morris, 
1963). These appear largely as fetal-like isoenzymes (Ibsen, 1977? 
Weber, 1977) which are less prone to product inhibition (Bustamante and 
Pederson, 1977).
The increased glycolysis of tumour cells has prompted several 
attempts to reduce carbohydrate availability or utilization in the hope 
that such intervention might preferentially impair malignant cells. 
The glucose antimetabolite 2-deoxyglucose has been shown to reduce the 
growth rate of various rodent tumours in vivo (Ball, Wick and Sanders, 
1957? Sokoloff et al., 1955) and in tumour bearing rats inhibition of 
gluconeogenesis with hydrazine sulphate has been shown to have 
antineoplastic activity (Gold, 1971). Furthermore, hydrazine sulphate 
can enhance the efficacy of conventional cytotoxic therapy (Gold, 
1975). However, although both 2-deoxyglucose (Landau et al., 1958) and
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hydrazine sulphate (Lerner and Regelson, 1976) have been administered 
to cancer patients, clinical efficacy has not been demonstrated 
conclusively.
A series of experiments involving the mitochondrial dye Rhodamine 
1,2,3 has recently given new impetus to the use of tumour energy 
metabolism as a target for systemic therapy in cancer. Rhodamine 1,2,3 
and Rhodamine 6G are two related compounds which have been shown to be 
cytotoxic in vitro (Zigman and Gilman, 1980;, Johnson, Summerhayes and 
Chen, 1982; Wilie and Fearon, 1985). They belong to a series of 
permeant cationic fluorochome dyes with a high negative reduction 
potential which inhibit both protein and DNA synthesis in intact cells 
and also delay mitosis (Zigman and Coilman, 1980). Both agents are 
potent inhibitors of mitochondrial oxidative phosphorylation (Higuti et 
al., 1980; Lampidis et al., 1983) and it has been suggested that their 
cytotoxic activity is related to an inhibition of fcATP production 
(Darzynkiewicz et al., 1982).
Rhodamine 1,2,3 is taken up into the mitochondria of both normal 
and tumour cells but is retained for much longer in those of the tumour 
cells. This retention is associated with the cytotxic action of the 
dye. In addition, Rhodamine 1,2,3 has been shown to be selectively 
cytotoxic against numerous malignant cell lines (Lampidis et al.,
1983). This selectivity is thought to be related to a transformation 
dependent abnormality of mitochondrial membrane potential 
(Nadakavukaren, Nadakavukaren and Chan, 1985). If the glucose 
antimetabolite 2-deoxyglucose, is administered simultaneously, the two 
agents have been shown to have synergistic anti-tumour activities both 
in vitro (Lampidis et al., 1983) and in vivo (Bernel et al., 1983). 
Thus it would appear that much greater efficacy can be achieved if both 
glycolysis and oxidative phosphorylation, the two main intracellular 
sources of ATP, are inhibited simultaneously.
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An alternative method of reducing glycolysis would be to induce a 
state of hypoglycaemia. This can be achieved by inhibiting 
gluconeogenesis in the fasting state. The present investigation was 
undertaken to examine the effects of an antimitochondrial agent, an 
inhibitor of gluconeogenesis, and the combination of the two on the 
growth rate of the Walker 256 carcinosarcoma in rats. Rhodamine 6G is 
a fluorochrome mitochondrial dye (Higuti et al., 1980) and has been 
shown to be a more potent inhibitor of tumour cell growth in vitro than 
Rhodamine 1, 2, 3 (Wilkie and Fearon, 1985). Hypoglycaemia was induced 
with 3-mercaptopicolinic acid. This compound blocks the synthesis of 
glucose de novo by inhibiting phosphoenolpyruvate carboxykinase 
(E.C.4.1.1.32) (Di Tullio et al., 1974) and has been shown to induce 
marked hyopglycaemia in both fasted rats (Di Tulli© et al., 1974) and 
man (Burt et al., 1985).
Materials and Methods
Chemicals: 3-Mercaptopicolinic acid was a gift from Dr N.W. Di Tullio, 
Smith, Klyne and French Ltd, Philadelphia, USA. Rhodamine 6G was 
obtained from BDH Chemicals Ltd, Poole, Dorset, England.
Animals: Inbred female Wistar rats, aged between 12 -16 weeks and
weighing 180 - 220g were allowed free access to food (SDS diet, SDS
Ltd., Witham, Essex) and water except where stated. Animals were kept 
in conditions of controlled temperature and lighting (20°C + 2°C, 
12h/12h light/dark cycle).
Tumour: The rapidly growing Walker 256 carcinosarcoma described in 
Chapter 7 was used. Viable tumour fragments (lOOmg) were transplanted 
subcutaneously into the right flank of rats under aseptic conditions
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and light ether anaesthesia. The tumour doubling time was about 36h.
Cannulation of rats for serial measurement of blood glucose
concentration: The right common carotid artery was cannulated 24 hours 
prior to drug administration under aseptic conditions and 
halothane/nitrous oxide anaesthesia. The cannula (1mm external 
diameter Portex polythene tubing, Portex Ltd, Hythe, Kent, England) was 
heparinised (5000u/ml) and then externalised onto the dorsal aspect of 
the animals neck via a subcutaneous tunnel. Once outside the animal, 
the cannula was protected by a tightly coiled stainless steel spring. 
The spring and cannula were suspended from a pulley system which 
allowed the animal to move freely within a wire bottomed, perspex 
metabolism cage.
Serial blood samples (lOOul) were obtained via the cannula and 
the total blood volume of the rats was maintained by replacing each 
blood sample with an equal volume of isotonic saline (0.9% W/V Na Cl) •
Measurement of blood glucose concentration: The concentration of
glucose in blood was determined by an enzymatic method (GOD - Per id, 
Boehringer Mannheim, Lewes, Sussex, England). lOOul blood samples were 
immediately deproteinised with 1ml of uranyl acetate solution 
(Boehringer Mannheim) and then centrifuged. The supernatant was stored
at 4°C and assayed on the same day.
Drug Administration Animals underwent tumour implantation 48h 
prior to i.p. drug administration. The hypoglycaemic effect of 3MPA 
was only observed in the fasted state, therefore except where stated 
rats were fasted for 24h prior to drug administration. The animals 
were then fasted for a further 8h before being allowed access to food.
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Statistical analysis Overall statistical significance was 
determined by an analysis of variance. Dunnett's test (1955) was used 
when multiple comparisons were made within each group.
Results
Effect of 3MPA and R6G on blood glucose concentration of starved normal 
rats: The blood glucose concentration of control rats fasted for 24
hours was approximately 3.5mmol/l and remained constant throughout the 
seven hour sampling period (Figure 10.1). Administration of 3MPA 
(70mg/kg) to rats fasted for 24h resulted in a signficant decrease in 
the blood glucose concentration (P < 0.01) within 15 minutes. This 
decrease continued and reached a minimum level of 1.4mmol/l after 180 
minutes. Thereafter, there was a gradual increase in blood glucose 
concentration until normal fasting values were achieved 360 minutes 
after drug administration (Figure 10.1).
Rats given both 3MPA (70mg/kg) and R6G (0.8mg/kg) had 
significantly lower mean blood glucose concentrations at 120 and 180 
minutes compared with rats given 3MPA (70mg/kg) alone (Figure 10.2 cf 
Figure 10.1, P < 0.01). However, this decrease was irreversible. The 
combination of a lower dose of 3MPA (40mg/kg) and the same dose of R6G 
(0.8mg/kg) induced a reversible period of hypoglycaemia lasting 
approximately 240 minutes with a trough blood glucose concentration of 
2.2mmol/l at 180 minutes (Figure 10.2).
Effect of 3MPA and R6G on blood glucose concentration of fed and 
starved tumour bearing rats: The mean blood glucose concentration of 
24h fasted tumour bearing rats was 2.3 + 0.3irmol/l (Figure 10.3) 180 
minutes after injection of 3MPA (40mg/kg) plus R6G (0.8mg/kg) • In
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Figure 10.1 Effect of 3MPA on blood glucose concentration 
of starved non-tumour-bearing rats. Rats (8 per group) were 
starved for 24h prior to, and for 8h after administration 
i.p. of saline (solid circles) or 3MPA at a dose of 70mg/Kg 
(open circles). Repeated blood samples were obtained from 
an indwelling arterial cannula at the times indicated. Values 
are mean + SEM.
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Figure 10.2 Effect of combination of 3MPA plus R6G on blood 
glucose concentration of starved non-tumour-bearing rats. 
Rats (8 per group) were starved for 24h prior to, and for 8h 
after administration i.p. of 3MPA (40mg/Kg) (solid circles) 
or 3MPA (70mg/Kg) plus R6G (0.8mg/Kg) (open circles). 
Repeated blood samples were obtained from an indwelling 
arterial cannula at the times indicated. Values are mean 
+ SEM.
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Figure 10.3 Effect of 3MPA plus R6G on blood glucose 
concentration of non-tumour-bearing rats fed ad libitum 
or starved for 24h. 180 minutes after drug administration
i.p. rats were lightly anaesthetised and blood was obtained 
by cardiac puncture for estimation of blood glucose 
concentration. Values are mean + SEM.
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contrast, the mean blood glucose concentration of rats fed ad libitum 
and given 3MPA (40mg/kg) plus R6G (0.8mg/kg) was 6.7 + 0.3irmol/l 
(Figure 10.3). This was not significantly different from controls fed 
ad libitum (6.6 ± 0.3mnol/l, Figure 10.3).
The fasting blood glucose concentration of tumour bearing rats 
was not significantly different from that of 24h starved non-tumour 
bearing rats (Figure 10.4). Moreover, the blood glucose concentration 
in fasted tumour bearing rats 180 minutes after administration of 3MPA 
(70mg/kg) or 3MPA (40mg/kg) plus R6G (0.8mg/kg) was not significantly
different from that of non-tumour bearing rats given the same drug
regimen (Figure 10.4).
Effect of R6G on growth rate of Walker 256 tumour in rats: The effect 
of R6G administration 48h after tumour implantation on tumour weight 5 
days after drug administration are shown in Figure 10.5. Host weight 
loss and mortality in each group is also shown. Administration of R6G 
(0.8mg/kg) led to a small but not significant reduction of tumour 
weight (5.6 + 0.5 cf 7.1 + 0.7, P > 0.05). This dose was associated 
with a weight loss of 5% compared with 1.5% in the controls. When the 
dose of R6G was increased to 1.6mg/kg tumour weight was reduced by 30% 
but again this decrease was not significant (5.0+0.5 cf 7.1+0.7, P 
> 0.05). Host weight loss increased to 9.2% but there was no
mortality. At a dose of 2.4mg/kg tumour weight was reduced by 75% (1.8 
+0.5 cf 7.1 + 0.7, P < 0.01) but one out of seven animals died. At a
dose of 3.0mg/kg 3 out of 7 animals died and at 4.0mg/kg all the
animals died within 3 days.
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Figure 10.4 Effect of 3MPA alone or 3MPA plus R6G on blood 
glucose concentration of starved tumour-bearing and non­
tumour-bearing rats. Rats (7 per group) were starved for 
24h prior to, and for 3h after administration i.p. of 
either saline, 3MPA (70mg/Kg) or 3MPA (40mg/Kg) plus R6G 
(0.8mg/Kg). Tumour bearing rats (hatched columns) had 
undergone implantation of the Walker 256 tumour 48h prior 
to drug administration. Non-tumour-bearing rats (open 
columns) had undergone sham operation. 180 minutes after 
drug administration, all groups of rats were lightly 
anaesthetised and blood was obtained by cardiac puncture 
for estimation of blood glucose concentration. Values are 
mean + SEM.
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Figure 10.5 Effect of increasing doses of R6G on growth 
rate of Walker 256 tumour in rats. R6G was administered 
i.p. at the doses shown 48h after tumour implantation. 
Five days after drug administration the animals were 
sacrificed and the tumours were excised and weighed. 
Values are mean + SEM. The percentage weight loss of the 
animals over the seven days of the study is shown within 
the columns.
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Effect of 3MPA plus R6G on growth rate of Walker 256 tumour in fed and
fasted rats: When the combination of 3MPA (40mg/kg) and R6G (0.8mg/kg) 
was administered 48h after tumour implantation, to rats starved for 24h 
the mean tumour weight 5 days after drug administration was 49% less 
than that of controls (3.6 + 0.3 cf 7.1 + 0.7g, P < 0.05). Host weight 
loss was only 3% in rats receiving combination therapy and was 
comparable to that in control tumour bearing animals (2%) (Figure 10.6) 
However, when the combination of 3MPA (40mg/kg) plus R6G (0.8mg/kg) was 
administered 48h after tumour implantation to rats fed ad libitum the 
mean tumour weight was not significantly different from that of 
untreated tumour bearing animals (6.2 + 0.5 cf 7.3 + 0.6g, P > 0.1,
Figure 10.6).
Starvation for a period of 32h commencing 48h after tumour 
implantation had no effect on tumour weight 7 days after tumour 
implantation (7.3 + 0.6 cf 7.1+ 0.7g, P >  0.1). Similarly,
administration of 3MPA (70mg/kg) 48h after tumour implantation to rats 
starved for 24h prior to and for 8h after drug administration had no 
effect on tumour weight 7 days after implantation (7.4 + 0.5 cf 7.1 + 
0.7g, P >  0.1, Figure 10.6). Administration of R6G (0.8mg/kg) 48h 
after tumour implantation to rats starved for 24h prior to and 8h after 
drug administration resulted in a slight but not significant reduction 
in tumour weight 7 days after implantation (5.6 + 0.5 cf 71 + 0.7g, P > 
0.05, Figure 10.6).
Discussion
This study demonstrates clearly that the growth rate of the 
Walker 256 in rats is reduced significantly when R6G is administered 
during a period of hypoglycaemia. Neither hypoglycaemia or R6G alone
to
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Figure 10,6 Effect of 3MPA plus R6G on growth rate of the 
Walker 256 tumour in rats fed ad libitum or starved for 
24h prior to and for 8h after drug administration i.p. The 
drug regimens were as shown. Tumours were implanted 48h 
prior to drug administration and animals were killed 5 days 
thereafter. Values are mean + SEM (n=7 per group). The 
percentage weight loss of the animals over the seven days 
of the study is shown within the columns.
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caused a significant inhibition of tumour growth. The combined regimen 
was well tolerated and reduced tumour growth rate with minimal host 
toxicity.
When 2-deoxyglucose (an inhibitor of glycolysis) is administered 
at the same time as Rhodamine 1, 2, 3 the combination has synergistic 
antitumour activity both in vitro (Lampidus et al., 1983) and in vivo 
(Bernal et al., 1983). This suggests that when combined with selective 
inhibition of mitochondrial function a reduction in glycolysis may have 
a potent antitumour effect. In this study increasing doses of 
Rhodamine 6G were associated with decreased rates of tumour growth. 
Unfortunately such high doses of R6G were also associated with 
increasing host weight loss and mortality (Figure 10.5). However, when 
the circulating concentration of glucose was reduced with 3MPA (Figure 
10.6), tumour growth rate was inhibited by a dose of R6G which was not 
toxic to the host (Figure 10.6).
The hypoglycaemic effect of 3MPA is due to the inhibition of 
glucose synthesis de novo (Di Tullio et al., 1974). Thus hypoglycaemia 
is only observed in the fasting state because if the animals have free 
access to food there is usually an adequate supply of glucose from the 
diet to maintain blood glucose levels. It might be argued that it was 
not the hypoglycaemic effect of 3MPA which was important in making the 
R6G/3MPA combination effective. However, the blood glucose 
concentration of tumour bearing rats starved for 24h and given 3MPA 
(40mg/kg) plus R6G (0.8mg/kg) was signficantly reduced compared with 
fasted controls (Figure 10.4) In contrast, there was no reduction of 
blood glucose concentration (Figure 10.3) or of tumour growth rate 
(Figure 10 ;6) in rats given the same combination but fed ad libitum.
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Thus, a reduction in blood glucose concentration would appear to have 
been necessary for the combination to be effective.
The effects of starvation on tumour growth rate in vivo appear to 
vary from one animal model to another. Previous animal studies have 
demonstrated either no change (Goodgame et al., 1979) or a slight 
reduction of tumour growth rate (Giovanella et al., 1982) following 
variable periods and degrees of caloric restriction. In this study, a 
period of starvation lasting 32h had no effect on final tumour weight 
(Figure 10.6). Moreover, the administration of 3MPA (40mg/kg) or R6G 
(0.8mg/kg) to tumour bearing rats starved for 24h before drug 
administration and for 8h thereafter did not reduce final tumour weight 
(Figure 10.6). However, when the combination of R6G plus 3MPA was 
administered to rats starved for a total of 32h final tumour weight was 
reduced by nearly 50% (Figure 10.6). This supports the conclusion that 
is was the combination of drugs administered in the fasting state which 
was important in reducing tumour growth rate.
Several malignant or transformed cell types, when deprived of a 
glucose source, suffer a dramatic lowering of ATP levels within the 
first hour of starvation (Demetrakopoulos, Linn and Anlos, 1978). 
However, normal cells are able to maintain their ATP content for 12 to 
24h at levels essentially similar to those of cells grown in the 
presence of glucose. This differential effect probably arises from the 
requirement of malignant cells for glucose as an energy source.
Previously it has been demonstrated that the growth rate of the 
Walker 256 tumour in rats can be reduced by administration of the 
glucose antimetabolite 2-deoxyglucose (Ball, Wick and Sanders, 1957) or 
by administration of hydrazine sulphate which inhibits gluconeogenesis 
(Gold, 1971). This suggests that the Walker 256 tumour is largely
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dependent on glucose as an energy substrate. Walker 256 cells have 
also been shown to possess few mitochondria and those that are present 
have abnormal morphology and a reduced complement of enzymes (Pedersen, 
1978, see also Chapter 8). It is possible that the synergy between R6G 
and hypoglycaemia was the result of R6G inhibiting an already 
restricted capacity for ATP production via oxidative phosphorylation. 
Thus, the tumour would be even more dependent on glycolysis for energy 
production. In this situation even a small decrease in the substrate 
available for glycolysis might lead to a substantial reduction in 
intracellular ATP concentration, thereby reducing cell viability.
Under normal circumstances when 1 mole of glucose is fully 
oxidized to carbon dioxide and water, 2 moles of ATP are produced via 
glycolysis and 36 moles are produced from oxidative phosphorylation. 
Therefore, in terms of ATP production it is much more efficient if 
glucose is fully oxidized via oxidative phosphorylation rather than 
partially oxidized to lactate via glycolysis. The AS-30D hepatoma is 
similar to the Walker 256 tumour in that it is a rapidly growing rodent 
tumour which is known to exhibit high rates of aerobic glycolysis and 
lactate production in vitro (Pedersen, 1978). It has been demonstrated 
that when glucose is supplied to AS-30D cells as the exogenous energy 
source 60% of total ATP production is derived from glycolysis and only 
40% from oxidative phosphorylation (Nakashima, Paggi and Pederson, 
1984). However, in the absence of added glucose, glutamine alone can 
maintain the same ATP production rates. Thus although these hepatoma 
cells rely predominantly on the inefficient glycolytic mode for energy 
production in vitro, in the absence of glucose other subtrates which 
enter the Krebs cycle directly are able to maintain ATP production.
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In the present study, a selective antineoplastic effect was 
demonstrated by administration of an inhibitor of oxidative 
phosphorylation (R6G) during a period of hypoglycaemia. Neither 
treatment was effective on its own. This suggests that for the Walker 
256 tumour in vivo, both glycolysis and oxidative phosphorylation are 
important in the maintenance of cellular ATP levels. Furthermore, 
cancer cell lines exhibit a broad spectrum of aerobic glycolytic 
activity. Slow growing, well differentiated tumours resemble normal 
cells in that they exhibit low rates of glycolysis and high rates of 
oxidative metabolism for energy production (Pedersen, 1978? Weinhouse, 
1982). Previous attempts to use tumour energy metabolism as a target 
for antineoplastic therapy have used single agents aimed at inhibiting 
either glycolysis or oxidative phosphorylation (Ball, Wick and Sanders, 
1957? Wilkie, 1979). Since most tumour cells use both pathways for 
energy production this approach is unlikely to succeed. The results of 
this and of other studies (Lamipidis et al., 1983? Bernal et al., 1983) 
indicate that simultaneous manipulation of both sourses of intra­
cellular ATP may be used to a achieve more selective control of tumour 
growth.
Summary and Conclusions
The administration of an inhibitor of oxidative phosphorylation 
(Rhodamine 6G) during a period of hypoglycaemia was shown to reduce 
significantly the growth rate of the Walker 256 in rats? minimal host 
toxicity was-observed. Neither Rhodamine 6G nor the period of hypogly­
caemia alone significantly reduced tumour growth rate. Thus greater 
antineoplastic activity was achieved by manipulating both oxidative 
phosphorylation and glycolysis simultaneously. This relatively 
non-toxic approach may prove useful in the control of tumour growth 
particularly in the already compromised cachectic cancer patient.
CHAPTER 11 
General Discussion and Conclusions
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The aims of this thesis have, on the whole, been achieved. The 
results extend previous studies on the mechanisms of weight loss in 
cancer cachexia. Studies of the body composition and protein 
metabolism of cancer patients demonstrate that cachexia is not entirely 
consistant with semistarvation. However, the apparent lack of an 
effect of the tumour on host energy expenditure means that the 
1 metabolic component1 of cachexia has yet to be identified. A method 
of selectively feeding the host but not the tumour was evaluated as a 
new form of therapy for cachexia. The failure of this approach 
confirms the conclusion that the best way to cure cachexia is to cure 
the cancer. Therefore, the most promising finding of this study is a 
novel form of anticancer therapy. This is based on differences between 
host and tumour energy metabolism and is shown to be both effective and 
non-toxic in tumour bearing rats.
The results have been discussed in detail in each Chapter and 
only the main points will be discussed in this final Chapter.
Clearly an investigation of weight loss must first determine 
which of the body compartments are reduced. In this study a group of 
cachectic lung cancer patients who had lost nearly 30% of their usual 
body weight were shown to have sustained an 80% loss of body fat and a 
20% loss of body protein (Chapter 5, Figure 5.1) Since there is no 
specific store of protein in the body, loss of protein implies loss of 
structural and functional components of the body. The vital importance 
of protein is illustrated by the observation that a greater than 30% 
reduction of body protein is incompatible with survival (Cahill, 1970).
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The marked loss of body fat may have been well tolerated but implies 
that the patients had been in a prolonged negative energy balance. The 
severe loss of body protein is probably the basic reason for the 
morbidity and mortality associated with the cachexia of cancer (Warren, 
1932; Inagaki, Rodriguez and Bodey, 1974).
Weight loss is most commonly due to a reduced food intake, an 
increased energy expenditure or a combination of the two. The 
cachectic patients whose body conposition was studied had a markedly 
reduced food intake (Table 5.4). This would support the observation 
that in many respects the cachectic cancer patient is suffering from 
semistarvation (Walsh, Bowman and Jackson, 1983). However, it could 
not be determined whether a reduced food intake had been present 
throughout the period of weight loss.
Several studies have examined the dietary intake of weight losing 
cancer patients at an early stage in the development of cachexia and 
have failed to demonstrate a significant reduction in food intake 
(Costa et al., 1981; Burk, Bryson and Kark, 1980; Warnold, Lundholm and 
Scherston, 1978). It might be argued that failure to detecta 
difference was simply due to substantial interindividual variation 
(Acheson et al., 1980). Nevertheless, if a reduced food intake were 
the only cause of weight loss, then supplemental nutritional support 
should completely reverse cachexia. Yet even enteral or parenteral 
hyperalimentation is unable to totally reverse the altered body 
composition of cachectic cancer patients (Nixon et al., 1981; Cohn et 
al., 1982). Furthermore, the cachectic lung cancer patients had lost 
protein almost entirely from the skeletal muscle protein mass (Figure 
5.1). If they had lost weight simply due to starvation, protein would 
also have been lost from the non-muscle protein compartment (Heymsfield 
and McManus, 1985).
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An alternative explanation to account for a negative energy 
balance and weight loss might be that the energy expenditure of cancer 
patients is increased. It has been suggested that in cancer patients 
whole body protein turnover is elevated and that the energy cost of 
this leads to a rise in host energy expenditure (Jeevanandam et al., 
1984; Eden et al., 1984). Several investigators have measured either 
whole body protein turnover or resting energy expenditure in small 
heterogeneous groups of cancer patients. However, the results have 
been conflicting showing that whole body protein turnover may be normal 
(Glass, Fernand Garlick, 1983; Emery et al., 1984a) or increased 
(Heber et al., 1982; Jeevanandam et al., 1984) and that resting energy 
expenditure can be decreased, normal or increased (Knox et al., 1983). 
One aim of this study was to determine, in large homogenous groups of 
patients, whether rates of whole body protein turnover are increased 
and, if so, whether they are associated with an increased resting 
energy expenditure and hence with weight loss (See Chapter 6).
Rates of protein turnover were increased in patients with either 
lung or colon cancer (Chapter 6, Table 6.2.). However, there was no 
correlation between individual rates of whole body protein turnover and 
either rates of resting energy expenditure (Figure 6.1) or weight loss 
(Figure 6.2). Thus although whole body protein turnover would appear 
to be elevated in the cancer host, the energy cost of this is not 
sufficient to increase resting energy expenditure, nor is it necessa­
rily associated with weight loss. It might be argued that the energy 
expenditure of the cancer patients had increased but that the methods 
which were used were unable to detect this small increment. However, 
the fact that weight stable cancer patients had elevated rates of whole 
body protein turnover indicates that for at least a proportion of 
cancer patients the added burden of elevated whole body protein turn­
over is within the limits at which energy balance can be maintained.
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One of the main problems in determining which metabolic
abnormalities might lead to an elevated energy expenditure is that an 
individuals resting energy expenditure is a composite measurement of 
all energy dependent metabolic processes. Thus, there are numerous 
variables apart from the one under study which might affect energy 
expenditure. Moreover, since inter-individual variation can be more 
than 50% (Garrow, 1985) it is unlikely that even in homogenous groups 
of patients a metabolic change which increases energy expenditure by 5 
- 10% would be detected. Yet over a period of months a change of this 
magnitude would be highly significant in terms of a cumulative energy 
deficit and thereby weight loss.
In an attempt to overcome the problems of heterogeneity and
interindividual variation two animal models of cachexia were studied 
(see Chapter 7). Body composition analysis showed clearly that in the 
case of the Walker 256 tumour model weight loss is due to a transfer of 
protein from the host to the tumour (Figure 7.1). However, in the
MAC-16 tumour model the tumour is small and does not act simply as a
nitrogen trap. Mice bearing the MAC-16 sustained a greater protein loss 
than was gained by the tumour (Figure 7.2). Moreover, carcass fat was 
reduced by about 50%. This suggests that the presence of the tumour 
had induced both a negative energy and protein balance. One explanation 
which might account for these changes could be that the energy 
expenditure of tumour bearing mice had increased. However, throughout 
the period of weight loss there was no change in the daily energy 
expenditure of the mice (Table 7.1). An alternative explanation could 
be that the food intake of the mice had decreased. However, a reduction 
of food intake was demonstrated only when the mice had already lost 20% 
of their body weight (Figure 7.4). There was no evidence that either 
the tumour or the development of cachexia had altered the rate of
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protein synthesis in the tissues of the mice (Table 7.2).
Although the results of this study were inconclusive and thus 
disappointing they did raise an important factor which must be 
considered in future studies. The duration of weight loss is such that 
a small change in any process involved in the overall energy balance of 
the body could account for the severe weight loss observed. Thus it 
might be that the sensitivity of the techniques available is not 
sufficient to be able to detect these changes. Clearly it is necessary 
optimise the accuracy and precision of measurements of food intake and 
energy expenditure. More accurate documentation of food intake in 
animal experiments will principally involve keeping food scatter to a 
minimum. For humans, rather than a subjective recall of dietary 
intake, direct observation and meal portioning by a trained dietician 
is probably necessary. One approach to minimise intra-individual 
variation in daily energy expenditure would be to measure energy 
expenditure over several days or weeks. Recent developments in stable 
isotope methodology means that it is now possible to measure the energy 
expenditure of humans or small animals over a period of several days or 
weeks (Prentice et al., 1985). Since patients or animals will not be 
restricted by the techniques of indirect calorimetry this may well give 
a more accurate reflection of the natural history of the development of 
their negative energy balance. Moreover, the limited participation of 
the patients required for this technique may allow sequential studies 
on the same individuals and thereby cut down inter- individual 
variation.
Nutritional support has been tested extensively as a method of 
reversing the nutritional problems of cancer patients. It was hoped
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that this might improve patients tolerance to conventional antineo­
plastic therapy and also prolong survival (Copeland, Daly and Dudrick, 
1977). However, standard enteral or parenteral hyperalimentation is 
unable to reverse completely the abnormal body composition of cachectic 
cancer patients. In particular, replenishment of the patients protein 
mass is difficult to achieve (Cohn et al., 1982). One explanation for 
this might be that nutritional support leads to an acceleration of 
tumour growth rate. Certainly, an increased rate of tumour growth has 
been demonstrated in parenterally fed tumour-bearing rats (Popp, 
Morrison and Brennan, 1981; Cameron, 1981). Furthermore, it is now 
evident that partial repletion of host tissues will not improve the 
outcome of only partially effective chemotherapy or radiotherapy 
(Brennan, 1981). One of the aims of this thesis was to evaluate two 
novel approaches which might be used to reverse the host-tumour 
imbalance in cachexia.
Systemic ketosis was evaluated as a therapy in cancer cachexia 
because several tumour cell lines have been shown to be unable to use 
fat or ketone bodies as energy substrates (Tisdale and Brennan, 1983) 
and rely predominantly on glucose for energy production (see 
Demetrakopoulos and Brennan, 1982). Thus ketone bodies might act as a 
*host specific* energy substrate (Tisdale and Brennan, 1983). In 
addition, the limited supply of glucose in the semistarving cancer host 
is thought to be augmented by its synthesis de novo from amino acids 
derived from the breakdown of muscle protein (Gold, 1968)• It has been 
proposed that ketone bodies might directly inhibit muscle proteolysis 
(Sherwin, Hendler and Felig, 1975) and thereby might reduce the supply 
of amino acids for accelerated gluconeogenesis in the cachectic cancer 
host (Williams and Matthaeis, 1981). Thus, host muscle would be 
preserved and glucose supply to the tumour might be reduced. Moreover,
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since ketone bodies would not be available as energy substrates for the 
tumour there should be no stimulation of tumour growth on refeeding. 
This hypothesis was tested by examining tumour growth rate and host 
nitrogen losses in rats bearing the Walker 256 tumour fed either a 
normal or ketogenic diet (see Chapter 8). The effects of systemic 
ketosis on the nitrogen metabolism of cachectic patients was also 
evaluated (see Chapter 9).
It was shown that the Walker 256 tumour could probably not 
utilize ketone bodies as a major energy substrate since the latter 
lacked one of the key mitochondrial enzymes required for the metabolism 
of either acetoacetate or 3-hydroxybutyrate (Table 8.1). However, 
systemic ketosis had no effect on tumour growth rate or host nitrogen 
losses. Moreover, the reduction in blood glucose concentration observed 
in ketotic non-tumour bearing rats was not observed in the tumour- 
bearing rats (Table 8.2). This lack of effect of systonic ketosis on 
blood glucose concentration may partly explain why ketosis did not 
inhibit either tumour growth rate or the development of cachexia.
Although the blood glucose concentration of patients with cancer 
cachexia was slightly reduced following the induction of ketosis (Table 
9.4) there was no effect on either whole body protein turnover (Table 
9.8) or nitrogen balance (Table 9.7). This agrees with the findings of 
several recent studies which have shown no direct effect of infused 
3-hydroxybutyrate on the protein metabolism of humans (Miles et al., 
1983; Takala, Peltola and Kirvela, 1985). Thus, although systemic 
ketosis might be used as a method of providing extra energy to the host 
whilst not increasing glucose supply to the tumour, the lack of effect 
on host protein metabolism or tumour growth rate suggests that ketosis
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on its own would not markedly change the host-tumour imbalance of 
cachexia.
The final aim of this thesis was to determine whether tumour 
energy metabolism could be used as a target for selective and therefore 
non-toxic systemic anticancer therapy (See Chapter 10). The successful 
elimination of the tumour is probably the most promising approach to 
the treatment of cachexia. Ever since the original observations of 
Warburg (1932) evidence has been accumulating which suggests that the 
energy metabolism of tumour cells is different from that of normal 
cells (see Pedersen, 1978). However, not all tumour cells have the same 
abnormalities and there is a broad spectrum of aberrations (Weber, 
1977). Various isolated attempts have been made to make use of these 
abnormalities to selectively inhibit either oxidative phosphorylation 
or glycolysis within tumour cells (see Demetrakopoulos and Brennan, 
1982). However, it has been shown that some tumour cells in vitro 
obtain as much ATP from glycolysis as from the much more efficient 
process of oxidative phosphorylation (Nakashoma, Paggi and Pedersen,
1984). Thus inhibiting only one process may not reduce intracellular 
ATP levels to the extent that tumour cell viability is compromised.
In an attempt to selectively kill tumour cells in vivo Rhodamine 
6G (a potent inhibitor of oxidative phosphorylation) was administered
to fasted tumour bearing rats at the same time as hypoglycaemia was
induced with 3-mercaptopicolinic acid. The latter compound inhibits 
phosphoenolpyruvate carboxykinase which is a key enzyme in the
gluconeogenic pathway. Neither Rhodamine 6G or the period of
hypoglycaemia reduced tumour growth rate. However, the combination 
which was designed to inhibit both glycolysis and oxidative 
phosphorylation reduced final tumour weight by 50% and was non toxic to 
the host (Figure 10.5).
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It is therefore apparent that tumour energy metabolism may be a 
useful target for non-toxic anticancer therapy. In particular, 
simultaneous manipulation of both glycolysis and oxidative phosphory­
lation may enhance anti-tumour selectivity. Future work should 
evaluate the ability of various inhibitors of glycolysis and oxidative 
phosphorylation to selectively inhibit these processes within tumour 
cells. In addition, further knowledge about the particular nutritional 
requirements of both normal and neoplastic tissues will help in the 
design of nutritional perturbations which might be selectively 
antineoplastic.
Clearly the best way to cure cachexia is to cure the cancer. 
Thus, selective manipulation of the tumour energy metabolism may be a 
method of significantly improving the survival of cachectic cancer 
patients. Meanwhile, continuing the investigation into the mechanisms 
of weight loss and the mediators of these effects in cancer patients 
may provide the means to redress more effectively their nutritional 
problems and thereby reduce the morbidity and mortality resulting from 
neoplastic disease.
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